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Summary in Norwegian 
Utfordringer i primærforebygging av allergisk sykdom 
Barneallergistudien i Trondheim  
 
Det har vært en betydelig økning i forekomsten av allergiske sykdommer som astma, 
høysnue og eksem blant barn de siste 30-40 år. Forekomsten av luftveisplager og atopi 
blant barn i Aberdeen har blitt undersøkt med spørreskjema gjennom 35 år. Fra 1964 til 
1999 økte forekomsten av astma (noen gang) fra 4% til 24%, for eksem økte 
forekomsten av eksem (noen gang) fra 5% til 21% og for høysnue økte forekomsten fra 
3,2% til 15% for skolebarn(Devenny et al. BMJ  2004;329:489-490). 
Stortingsmelding nr. 118-1993-94 omhandlet denne økningen og forebygging av 
allergiske sykdommer ble et forskningsmessig satsningsområde. På bakgrunn av dette 
tok Trondheim kommune i samarbeid med SINTEF Unimed i 1997 initiativet til et 
prosjekt for primærforebygging av allergiske sykdommer, Barneallergistudien i 
Trondheim. Under forutsetning av at prosjektet var gjennomførbart og hadde nasjonal 
overføringsverdi ga Sosial- og Helsedirektoratet økonomisk støtte til prosjektet. NTNU 
ved Institutt for samfunnsmedisin fikk i oppdrag å gjennomføre evaluering av 
effektiviteten og effekten av intervensjonstiltakene. 
Hovedhensikten med PACT-studien var å studere hvor effektivt (endret deltakerne 
atferd) det er å intervenere på tre antatte risikofaktorer for allergisk sykdom i en 
uselektert populasjon av gravide kvinner og små barn. Videre å se om endret 
risikoatferd fører til endret forekomst av astma og allergisk sykdom ved:  
• Økt inntak av Omega-3-fettsyrer og fet fisk  
• Redusert eksponering for tobakksrøyk under svangerskapet og barnets 2 første 
leveår 
• Redusert fukt i inneklima under svangerskapet og barnets 2 første leveår. 
 
Mål 
Det er mange utfordringer knyttet til gjennomføring og evaluering av et slikt prosjekt 
og målsettingen med denne avhandlingen var å studere om: 
• Intervensjon mot risikofaktorer for allergisk sykdom hos små barn, innenfor 
rammen av ordinær primærhelsetjeneste, førte til endring i atferd og dermed 
eksponering. 
• Intervensjon mot røyking under svangerskapet hadde effekt på røykeatferd.  
• Spørsmålene brukt til å bestemme forekomsten av allergisk sykdom hos små 
barn var pålitelige. 
• Inntak av tran og fet fisk under svangerskapet og i barnets første leveår 
forebygget foreldrerapportert eksem og legediagnostisert astma hos toåringer. 
 
Metode 
For å gjennomføre evalueringen ble det opprettet en hovedstudie med en kontrollkohort 
av gravide og barn som fikk den vanlige oppfølging og datidens råd i 
primærhelsetjenesten og en intervensjonskohort (tiltaksgruppe) som fikk den nye 
systematiserte veiledningen. Inklusjon til intervensjonskohorten startet juni 2002 og 
alle gravide og småbarnsforeldre i Trondheim kommune skulle får den samme 
rettledningen enten de deltok i studien eller ikke. Kontrollkohorten ble etablert i 
perioden fra høsten 2000 til mai 2002. 
Formålet med kontrollkohorten var å følge utvikling av prevalens av risikofaktorer og 
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insidens av allergisk sykdom. Deltakerne besvarte spørreskjema under svangerskapet, 6 
uker etter fødselen og når barnet var 1 og 2 år gammelt.  
 
Resultat 
Diettintervensjonen lyktes, inntaket av tran og fet fisk økte både under svangerskapet 
og i barnets 2 første leveår i intervensjonskohorten sammenliknet med 
kontrollkohorten, mens vi ikke fant noen forskjell mellom kohortene i matslag vi ikke 
intervenerte på. Vi observerte en betydelig redusert nedgang i røyking i 
intervensjonskohorten sammenliknet med kontrollkohorten. Tidstrenden for røykeslutt i 
studieperioden gikk i samme retning i begge kohorter, og nedgangen i røykeforekomst 
kunne derfor ikke tilskrives intervensjonen. Vi fant heller ingen effekt av 
røykeintervensjonen under svangerskapet på de kvinner som fortsatt røykte ved 
inklusjon i studien. Vi observerte imidlertid en betydelig høyere spontan røykeslutt ved 
svangerskapets start i Trondheim sammenliknet med Bergen og hele Norge når vi 
sammenliknet tall fra Medisinsk fødselsregister.  
Spørsmålene vi brukte til å bestemme forekomsten av allergisk sykdom blant 2 åringer 
var pålitelige, og ingen av spørsmålene overestimerte forekomsten av allergisk sykdom. 
Inntak av tran og fet fisk under svangerskapet viste ingen sammenheng med rapportert 
eksem eller legediagnostisert astma ved 2 års alder. Inntak av tran første leveår viste 
heller ikke sammenheng med allergisk sykdom ved 2 års alder. Inntak av fisk derimot, 
og spesielt inntak av feit fisk ved 1 års alder en gang i uken eller mer sammenliknet 
med de som spiste fikk mindre enn en gang i uken viste en sterk beskyttende på 
rapportert eksem ved 2 års alder.  
 
Konklusjon 
Intervensjonstiltak for å endre atferd for å redusere risikofaktorer for allergisk sykdom i 
primærhelsetjenesten lar seg gjennomføre, men det er noen begrensinger. 
Risikofaktorer helsearbeiderne var vant til å arbeide med, som kost lot seg endre, mens 
et ukjent tema som fukt i boliger ikke lot seg endre. Røykeslutt ved svangerskapets start 
var svært vanlig, og de som ikke sluttet spontant lot seg ikke påvirke av våre 
intervensjonstiltak. For å få de som ikke slutter spontant å røyke ved svangerskapets 
start, ser det ut til at det må utvikles nye røykesluttstrategier. Røykeintervensjonen i 
PACT studien kan på makroplan ha bidratt til at en høyere andel av gravide sluttet å 
røyke i Trondheim sammenliknet med Bergen, muligens ved at studien har forsterket de 
nasjonale røykesluttkampanjene. Spørreskjemaet vi utviklet for å måle forekomst av 
allergiske sykdommer var pålitelig. Fisk, men ikke tran gitt det første leveår beskytter 
mot eksem ved 2 års alder. Vår hypotese er at det kan være andre allergibeskyttende 
faktorer i fisk enn omega-3 fettsyrer, som enten virker alene eller sammen med 
fettsyrene med hensyn til å beskytte mot eksem, og våre funn rettferdiggjør søken etter 
slike faktorer.         
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Why did I as a GP start researching, and why did I choose allergic disease? 
 
In my work as a general practitioner, working at a health care centre for small children 
and as a doctor for school children from 1986, a large proportion of my patients have 
been children. During the first decade of my practice as a GP, from 1986 to 1996, 
allergic diseases increased dramatically in prevalence. Children with allergic rhinitis, 
dermatitis and asthma were a common challenge in my daily practice, and over the 
years the interest in this field flourished. 
 
I took part in several drug trials, in some of them as principal investigator. During this 
work the first sparks were lit for this research. When the daughter of a good friend of 
mine developed very severe asthma I even became more interested in this field. I 
became active in arranging postgraduate courses for colleagues and also took part in a 
project regarding patient education for asthmatics. 
 
When the Prevention of Allergy among Children in Trondheim (PACT) study was 
initiated, as a joint venture between the Municipality of Trondheim and SINTEF 
Unimed, I was invited to participate in the planning of the study. During this process I 
faced the challenge of taking part in the evaluation of the project. I did not want to 
leave my work as a GP; I wanted to combine general practice and academic work. 
However, the planned intervention study was very large, comprising 3000 pregnant 
women and some 17 000 controls, so this was not a part-time job. Subsequently I 
approached my esteemed colleague, Ola Storrø, and together we applied for a 
university scholarship and the ball started rolling...     
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Introduction – the history of PACT 
 
The Municipality of Trondheim has shown a considerable interest towards and 
motivation to invest in prophylactic measures for the benefit of children and youth in 
general. Both on a political and administrative level, the attitude of the local authority 
was positive to a major scientific investigation on allergic diseases such as asthma, 
eczema and allergic rhinoconjunctivitis (ARC). Without the investment in 
infrastructure made by the municipality of Trondheim, a project like the PACT study 
would have been difficult to accomplish. 
 
In spring 1997, representatives from the Municipality of Trondheim and SINTEF 
Unimed had a meeting with the Social and Health Ministry in Norway, exploring the 
possibility of establishing an action plan for primary prevention on allergic and indoor-
climate diseases among children in Trondheim. The Ministry supported the planning 
and establishment of this project from 1997 to 1999. The Ministry concluded that the 
project had the potential to reach results of general national value, and pronounced an 
intention to support the accomplishment of the project with funding of the project’s 
organisation.  
 
From autumn 1998 the project was organised by an interdisciplinary working party and 
a steering committee with representatives from the research group and the city council. 
It soon became evident that evaluating changes in prevalence and incidence of allergic 
diseases demanded interventions directed towards pregnant women and children up to 2 
years of age. 
 
The Municipality considered it important for the project to have a solid political 
affiliation. From 1998 an “ad hoc” municipal committee worked on this, concluding 
with a “Health Promoting Plan for Children and Youth in Trondheim”. This plan 
received general political acceptance, and made it possible to find financial support for 
projects within the scope of this plan. The PACT study was one of the first specific 
projects to fall within the framework of this enterprise.  
 
The Municipality of Trondheim was already giving advice and information to parents 
on risk factors for developing asthma and allergy and this was already one of the high 
priority topics. Some maternity clinics had started smoking cessation groups, but had to 
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terminate these due to the small number of participants. The community considered the 
PACT study a good opportunity to develop the contents of existing guidelines to 
improve ongoing interventions on assumed risk factors for allergic diseases. In the 
process of developing methods and the new guidelines, there was a close collaboration 
between the maternity clinics, primary physicians, midwifes, SINTEF Unimed and 
NTNU using a Delphi technique[1]. The guidelines should at best be evidence based. A 
multi-behavioural intervention programme was developed targeting reduced tobacco 
exposure, increased intake of oily fish and n-3 polyunsaturated fatty acids (n-3 PUFAs) 
and reduced housing dampness during pregnancy and infancy. There was sparse 
documentation on the effectiveness of specific strategies for implementing life-style 
interventions in ordinary primary health care. When new guidelines regarding 
prophylaxis and treatment of disease are considered, a preceding investigation and 
evaluation of the implementation programme and how it may change behaviour in a 
real-life setting provides important knowledge to health professionals, decision-makers 
and politicians. Thus a research group from the Department of Public Health and 
General Practice was set to evaluate the efficacy of the new intervention programme. 
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1 Background 
 
General 
To understand the substantial increase in asthma, allergy and atopic eczema among 
children in the industrialised world, studies considering both genetic and environmental 
factors influencing the risk of atopy combined with investigations on underlying 
mechanisms are needed[2,3].  
 
The increase has been most evident among children without a former known genetic 
predisposition for atopic disease[4]. The observed substantial difference in prevalence 
between populations of equal age and ethnicity in many parts of the world indicates the 
importance of environment and living conditions. It is reasonable to assume that either 
new environmental factors that provoke atopic sensitisation have emerged, or 
potentially protective factors have been lost[2,5]. Besides, there are obvious 
associations between age, exposure and disease penetration, hinting at different 
vulnerability for the same exposure depending on the actual living conditions when the 
child is exposed[6]. 
 
The ISAAC study (see below, 6.3.5) has documented evident variation in disease 
prevalence between east and west, rural and urban areas, the poor and the rich[5,7]. The 
risk factors investigated so far do not have a geographic or socio-economic presence to 
explain these differences in allergy prevalence. This necessitates a search for new or 
lost environmental factors, distributed in a way that can explain these variations in 
disease prevalence[2,5,8,9]. An increased understanding of the immunological basis for 
allergic disease has formed a basis for investigating several new environmental 
factors[10]. In addition to the fact that environmental factors have an impact on 
incidence changes in individuals with different predisposition for allergic disease, the 
morbidity depends on the age of the individual when the exposure takes place[11].  
In the PACT study three separate environmental factors that have been assumed to be 
causally related to allergy incidence are investigated:  
• Second-hand smoke (SHS)  
• Dietary intake of n-3 PUFAs and oily fish 
• Indoor dampness.  
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A literature search was conducted for the validity and reliability of questionnaires on 
atopy and allergy among children (Medline and Cochrane search). Most of the existing 
literature was concerned with variations of ISAAC. However, ISAAC was constructed 
for and applies to older children, not children at aged 2 years. To evaluate the 
effectiveness of the intervention, existing questionnaires from the ISAAC protocol[12]  
had to be revised for the actual age group. 
 
The rest of this section will address; the definitions, prevalence, and risk factors for 
allergic diseases, the rationale and the association between the three environmental 
factors and allergic disease, and finally different strategies in preventing disease. 
1.1 Allergic diseases; definitions, prevalence and risk factors 
1.1.1 Atopy 
When the study was planned in 1999 the word atopy was used in the title.  A position 
statement from the European Academy of Allergy and Clinical Immunology (EAACI) 
Nomenclature Task Force proposed in 2004 that the definition of atopy should be as 
follows: 
Atopy is a personal or familial tendency to produce IgE antibodies in 
response to low doses of allergens, usually proteins, and to develop typical 
symptoms such as asthma, rhinoconjunctivitis, or eczema/dermatitis. 
 
EAACI proposed that the terms atopy and atopic should be reserved to describe this 
clinical trait and predisposition, and not be used to describe diseases. The first 
manifestations of atopy in a child are often “allergic” symptoms, such as diarrhoea, 
wheezing, and skin rashes, and only later can the responsible IgE antibody be detected. 
The term atopy should be used with caution until IgE sensitisation can be documented. 
Therefore allergy has replaced atopy in the title, as the term allergic diseases best 
describes what we are studying. 
1.1.2 Allergy  
Allergy is a hypersensitivity reaction initiated by immunologic mechanisms. Allergy 
can be antibody- or cell-mediated. In most patients, the antibody typically responsible 
for an allergic reaction belongs to the IgE isotype and these patients may be said to 
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suffer from IgE-mediated allergy. It must be noted that not all IgE-associated allergic 
reactions occur in atopic subjects. Allergy can also be cell-mediated, as in allergic 
contact dermatitis, in which immunologically sensitised lymphocytes play a major role. 
Similar immunological mechanisms seem to be important in non-IgE-associated “atopic 
dermatitis/eczema” (see below). 
1.1.2.1 The role of exposure level in allergy sensitisation 
A cross-sectional survey that was part of the ISAAC multi-centre study describes the 
prevalence of atopic diseases in Icelandic schoolchildren[13] and concludes that the 
prevalence of atopic diseases and wheezing in Icelandic children was high and 
comparable to that in other countries in Europe. These findings are of interest, because 
the allergen load in Iceland is very low. The pollen count is very low compared with 
other European countries, pet ownership is low and house dust mites are absent. Iceland 
has had an affluent lifestyle for a considerable time, but the absence of dust mites, low 
pet ownership and relatively low pollen counts in the country raise doubts about the 
role of exposure levels in the development of sensitisation and atopic diseases. 
1.1.3 Asthma 
Asthma is a disorder defined by its clinical, physiological, and pathological 
characteristics. The predominant feature of the clinical history is episodic shortness of 
breath, particularly at night, often accompanied by cough. Wheezing appreciated on 
auscultation of the chest is the most common physical finding. The main physiological 
feature of asthma is episodic airway obstruction characterised by expiratory airflow 
limitation. The dominant pathological feature is airway inflammation, sometimes 
associated with airway structural changes. Asthma has significant genetic and 
environmental components, but since its pathogenesis is not clear, much of its 
definition is descriptive. Based on the functional consequences of airway inflammation, 
an operational description of asthma is:  
Asthma is a chronic inflammatory disorder of the airways in which many 
cells and cellular elements play a role. The chronic inflammation is 
associated with airway hyper responsiveness that leads to recurrent 
episodes of wheezing, breathlessness, chest tightness, and coughing, 
particularly at night or in the early morning. These episodes are usually 
associated with widespread, but variable, airflow obstruction within the 
lung that is often reversible either spontaneously or with treatment[14].  
 22
 
Because there is no clear definition of the asthma phenotype, researchers studying the 
development of this complex disease turn to characteristics that can be measured 
objectively, such as atopy (manifested as the presence of positive skin-prick tests, 
production of specific IgE, or the clinical response to common environmental allergens), 
airway hyper responsiveness (the tendency of airways to narrow excessively in 
response to triggers that have little or no effect in normal individuals), and other 
measures of allergic sensitisation. Although the association between asthma and atopy 
is well established, the precise links between these two conditions have not been clearly 
and comprehensively defined. Asthma was formerly classified according to the severity 
of the disease before commencing treatment. This classification has little predictive 
value regarding what treatment will be required and what the response to that treatment 
might be. There is now good evidence that the clinical manifestations of asthma 
symptoms – sleep disturbances, limitations of daily activity, impairment of lung 
function, and use of rescue medications – can be controlled with appropriate treatment. 
When asthma is controlled, there should be no more than occasional recurrence of 
symptoms and severe exacerbations should be rare. Therefore the Global Initiative for 
Asthma (GINA) in 2006 proposed a new classification based on level of asthma 
control[14]. According to the new classification, asthma is classified as controlled, 
partly controlled or uncontrolled.  
 
In a study from British Columbia, Canada, the incident rate for asthma among children 
diagnosed at 2–3 years was 2.72 per hundred person years of follow-up[15]. In a 
Norwegian study, where use of anti-asthmatic medications was used as a proxy for 
prevalence of asthma in children, the highest asthma prevalence for both genders was 
found among children at about 2 years of age (7% of girls and 10.1% of boys)[16].  
   
From the ISAAC study phase III, the prevalence of atopic wheeze (defined as current 
wheeze plus skin prick-test reactivity) among 8–12 year old children and non-atopic 
wheeze varied widely between centres. Atopic wheeze was least prevalent in Pichincha, 
Ecuador (0.2%), and most prevalent in Hawkes Bay, New Zealand (13.4%). In Tromsø 
and Østersund, 9.1% and 6.2% of the children reported atopic wheeze, respectively. In 
the UK 6.5% reported atopic wheeze[17].  The mechanisms initiating non-allergic 
asthma are not well defined, although similar inflammatory changes occur in both 
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forms of asthma. Several studies have shown that the patterns of risk factors for atopic 
versus non-atopic wheeze may differ between affluent and non-affluent countries[18-
21]. Findings in phase III of the ISAAC protocol indicate that in most high prevalence 
countries (i.e., Western countries and English-speaking countries) the prevalence has 
peaked and is now decreasing, particularly in the 13–14 year age group. In regions 
where prevalence was previously low, increases in prevalence are found. Although the 
global differences in asthma prevalence are lessening, the global burden of asthma may 
continue to rise[22].    
1.1.4 Eczema   
In the broadest sense, dermatitis – inflammation of the dermis and epidermis – is a 
component of many skin diseases. The inflammatory process is primary and the signs 
and symptoms are typical. Erythema, scaling and usually pruritus occur in well-
recognised patterns depending on the type of dermatitis. Usually dermatitis can be 
diagnosed visually, excluding other skin disorders[23]. One way to categorise 
dermatitis is by location on the body, with seborrheic, atopic, and stasis dermatitis all 
having a typical distribution. Another aid in classification is the presence of a personal 
or family history of underlying conditions as we see in individuals with atopic 
dermatitis.  
 In the revised nomenclature for allergy for global use[24], the term eczema was 
proposed to replace the term atopic eczema/dermatitis syndrome (AEDS) used in the 
previous version[25]. Since the work of the EAACI Nomenclature Task Force started, 
there has been increased acceptance of the basis for a term describing an aggregation of 
several skin diseases with certain clinical characteristics in common involving a 
genetically-determined skin barrier defect[26]. There is substantial evidence in support 
of a strong genetic component in the aetiology of atopic eczema. Twin studies show 
that an identical twin has an 80% chance of developing eczema if their twin is affected, 
whereas a fraternal twin has an approximately 20% chance of developing eczema if 
their twin is affected[27]. Eczema and other atopic disorders show clustering within 
families[28] and children whose parents have atopic eczema have a greater risk of 
developing eczema than children whose parents have asthma or hay fever[29]. These 
observations suggest that the genetic risk of eczema may be mediated through 
polymorphisms in genes encoding proteins important in the structure and function of 
 24
the skin, rather than through systemic immune or “atopy” risk genes. There is a 
growing understanding of the importance of epithelial barrier dysfunction in atopic 
eczema[30]. In 2006 it was reported that two common polymorphisms in the filaggrin 
gene (filament-aggregating protein) are strong predisposing factors for atopic 
eczema[31]. Filaggrin aggregates keratin within the keratinocytes, helping to bring 
about their compaction into cell death and squame shape during cornification. In this 
way the cornified cells replace the keratinocyte cell membrane, which forms an 
important permeability barrier to water, microbes and allergens and provides 
mechanical defence by maintaining skin integrity.  
 
As long as the immunological mechanism of eczema is unclear, the disease should be 
referred to as eczema. Eczema without any signs of an atopic constitution is common in 
preschool children[32]. Non-atopic children with eczema have been reported to have 
less risk of developing asthma as adolescents than atopic children with eczema[32,33]. 
However, non-atopic eczema in children may evolve into atopic eczema. The 
differentiation of atopic eczema from eczema in general seems to be of significant 
prognostic importance for the long-term prognosis and it is therefore important to know 
that the risk of the development of an IgE-mediated respiratory disease is much lower 
in the case of non-atopic eczema[34]. 
1.1.5 Allergic rhinitis 
A novel classification of allergic rhinitis according to duration and severity of 
symptoms was suggested by the World Health Organization initiative, “Allergic 
Rhinitis and Its Impact on Asthma” (ARIA)[35]. Rhinitis is defined as an inflammation 
of the lining of the nose and is characterised by nasal symptoms including anterior or 
posterior rhinorrhoea, sneezing, nasal blockage and/or itching of the nose. These 
symptoms occur during two or more consecutive days for more than one hour on most 
days. Allergic rhinitis is the most common form of non-infectious rhinitis and is 
associated with an IgE-mediated immune response against allergens. It is often 
associated with ocular symptoms. Several non-allergic conditions can cause similar 
symptoms; infections, hormonal imbalance, physical agents, anatomical anomalies and 
the use of certain drugs. Symptoms of allergic rhinitis include rhinorrhoea, nasal 
obstruction[36], nasal itching and sneezing which are reversible spontaneously or with 
treatment. Postnasal drip mainly occurs either with profuse anterior rhinorrhoea in 
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allergic rhinitis or without significant anterior rhinorrhoea in chronic rhino sinusitis. 
Preschool children may just have nasal obstruction. However, when nasal obstruction is 
the only symptom, it is very rarely associated with allergy. Patients with non-allergic 
rhinitis may have similar symptoms[37]. Allergic rhinitis is subdivided into intermittent 
or persistent disease. The severity of allergic rhinitis can be classified as mild or 
moderate/severe. Thus, intermittent and persistent describe duration, and mild and 
moderate-severe define effect of symptoms on sleep, work, and other activities. 
 
The clinical definition of rhinitis is difficult to use in the epidemiological settings of 
large populations where it is impossible to examine everybody or to obtain the 
laboratory evidence of an immune response. So far there has been no standardisation of 
the definition of rhinitis in epidemiological studies, and thus comparison of prevalence 
between studies is difficult[35].  
1.2 The risk factors studied and their association to allergic diseases 
1.2.1 The role of second-hand smoke in allergic disease 
Passive smoking during or after pregnancy has been shown to be a risk factor for the 
development of both allergic sensitisation and obstructive respiratory disease in 
children[38]. 
1.2.1.1 Second-hand smoke and allergic sensitisation 
The association between exposure to tobacco smoke in childhood and risk of atopic 
sensitisation has been extensively studied but the data is inconclusive[39-42]. In a 
comprehensive review in 1998, it was concluded that parental smoking is unlikely to 
increase the risk of IgE sensitisation in children[41]. This review, however, primarily 
dealt with studies of relatively small size and none was a birth cohort study. Subsequent 
larger birth cohort studies still do not provide a consistent picture. Thus in the German 
Multicentre Allergy Study, no association was demonstrated between prenatal or 
postnatal exposure to tobacco smoke and IgE sensitisation to inhalant allergens at the 
three-year follow up, whereas an association was found for sensitisation to food 
allergens[39]. In “The National Asthma Campaign in Manchester”, little or no effect of 
second-hand smoke was found on the development of atopy[40].  
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A recent published study from Sweden[42] found no evident increase in the risk of any 
sensitisation (i.e., inhalant and/or food allergens) if the mother had smoked during any 
of the trimesters (adjusted odds ratio (aOR) 1.00 (95% CI 0.61 to 1.66)) but not 
thereafter.  On the other hand, exposure to SHS at 2 months of age, without previous in-
utero exposure, tended to be associated with sensitisation (aOR 1.26 (95% CI 0.95 to 
1.68)) and there was no clear evidence of interaction between in-utero and postnatal 
exposure. For postnatal SHS exposure, with or without exposure in utero, the adjusted 
ORs for sensitisation to inhalant allergens were 1.12 (95% CI 0.84 to 1.48), for food 
allergens 1.46 (95% CI 1.11 to 1.93) and for any sensitisation 1.28 (95% CI 1.01 to 
1.62). In conclusion, data from the Swedish study indicates that SHS exposure in early 
infancy increases the risk of sensitisation to indoor inhalant and food allergens. 
1.2.1.2 Second-hand smoke and asthma 
Strachan and Cook presented a complex picture of the associations of parental smoking 
with asthma incidence, prognosis, prevalence, and severity[43]. In their review they 
found that illness in early life was increased if there was smoking in the household, 
particularly by the mother[44], whereas the incidence of asthma during the school years 
was less strongly affected by parental smoking. A similar age-related decline in the 
strength of the passive smoking effect was found in cross-sectional studies[45]. They 
concluded that this may simply reflect the diminishing level of exposure to SHS from 
household sources as children grow up[46]. Alternatively or additionally, parental 
smoking may have differential effects on the incidence of various forms of wheezing 
illness[47], with a stronger influence on viral-associated wheezing (common in early 
childhood) and a weaker relationship with atopic wheezing (often of later onset). Three 
studies comparing wheezing in atopic and non-atopic children lend support to the latter 
hypothesis[48-50].   
1.2.1.3 Exposure to SHS and early lung function 
Several studies concerning the effects of exposure to SHS and lung function in 
newborns and early life have been published. In the first studies published concerning 
the relationship between exposure to SHS and reduced lung function in infants, lung 
function was measured from 4 to 5 weeks of age[51]. Small numbers were exposed 
exclusively at the prenatal or postnatal stage, so one cannot exclude the possibility that 
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postnatal exposure might influence the results. It was important to measure lung 
function in newborn babies to exclude a possible effect of postnatal exposure to SHS. 
From a birth cohort, the Environmental Childhood Asthma study in Oslo, more than 
800 newborn infants had their lung function measured on their second to fifth day of 
life by tidal flow–volume loops and passive respiratory mechanics[52]. Reduced lung 
function was demonstrated in the newborn infants of smoking mothers in a dose–
response pattern. A significant relationship was found both for the ratio of time to peak 
flow/total expiratory time and for compliance of the total respiratory system[52]. 
Similar results for compliance of the total respiratory system were found in a British 
study of 189 newborn children whose mother had smoked during pregnancy, who were 
compared with 100 newborn children of non-smoking mothers, but the differences were 
significant only for boys[53]. Another study from Australia confirmed the finding of a 
reduction in the ratio of time to peak flow/total expiratory time in the newborn infants 
of smoking mothers[54].  
How early does the reduction in lung growth start in the infants of smoking mothers? In 
a study of prematurely born infants in England, similar findings to those cited above,          
of a reduction in the ratio of time to peak flow/total expiratory time and compliance of 
the total respiratory system, were found in 40 out of 108 infants at a mean of 33 weeks’ 
pregnancy[55]. This suggests that the effects of maternal smoking on development of 
the lungs may start early during pregnancy. 
1.2.2 The role of diet in allergic diseases 
In a review article from 2000, Fogarty and Britten[56] stated that several nutrients such 
as magnesium, vitamin C, vitamin E, pyridoxine, manganese, copper, potassium, 
selenium and fatty acids may be involved in the aetiology of asthma. Overall, they 
stated, there was a general consistency in the evidence that an unhealthy diet seemed to 
be associated with an increased risk of asthma.  
1.2.2.1 N-3 fatty acids and allergic diseases 
An increase in allergic diseases has been preceded and paralleled with changes in 
dietary intake of polyunsaturated fatty acids[57]. A shift towards increased 
consumption of n-6 polyunsaturated acids (n-6 PUFAs) and decreased consumption of 
n-3 pol yunsaturated acids (n-3 PUFAs) and oily fish has been observed[58]. A diet rich 
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in n-3 PUFAs during pregnancy may decrease the risk of allergic diseases in the 
offspring[59]. Since the 1990s there has been a growing interest in the role n-3 PUFAs 
might play in primary prevention of allergic diseases, and several studies have 
examined the association between n-3 PUFA supplementation, either during pregnancy 
or during infancy. A diet rich in n-3 PUFAs during pregnancy may decrease the risk of 
allergic diseases in the offspring[59]. A randomised controlled trial confirmed that 
maternal fish-oil supplementation during pregnancy significantly changed the 
composition of fatty acids in neonatal erythrocyte membranes, and also changed the 
cytokine profile of leucocytes in response to allergen exposure[60]. A potential 
reduction in subsequent infant allergy after maternal fish oil supplementation was 
suggested, but the study was not designed to assess clinical effects. A Cochrane review 
on dietary marine fatty acids for asthma in adults and children concluded that there is 
little e vidence to recommend that people with asthma should supplement or modify 
their dietary intake of n-3 PUFAs in order to improve their asthma control[61]. Blümer 
and Renz concluded in their review that there is evidence that a perinatal n-3 PUFA 
supplementation has anti-allergic effects on disease-related symptoms like allergic 
rhinitis, wheeze or atopic cough[62]. The body of evidence according to the review is 
not conclusive. Accordingly, a large randomised controlled trial to test modification of 
n-6/n-3 dietary intake in the first 5 years of life of children with a family history of 
asthma was successful regarding change in plasma n-6/n-3 ratio, but no effect on the 
prevalence of asthma, wheezing, eczema or atopy was found[63].   
1.2.2.2 Fish and allergic diseases 
Frequent intake of fish during pregnancy may counteract the development of allergic 
sensitisation for food allergens in the offspring of mothers without atopic disease[64]. 
Observational studies have suggested a protective effect of at least two fish meals a 
week on bronchial hyper responsiveness in 7–11 year old children and of eating oily 
fish on the prevalence of asthma[65].  Frequent intake of fish during pregnancy may 
contrast the development of skin-prick sensitisations for food allergens in offspring of 
mothers without atopic disease[64]. Sausenthaler et al., who found that a diet rich in n-3 
PUFAs during pregnancy may decrease the risk of allergic diseases in the offspring, 
found no correlation between maternal consumption frequency of fish and time for 
introduction of fish during the first year of life[59]. Salam et al. found that maternal 
oily fish intake during pregnancy may protect offspring from asthma; however, eating 
 29
fish sticks (which are rich in trans fats) during pregnancy may increase asthma risk in 
children[66]. This study did not account for the children’s diet during the first year of 
life.  
 
Hodge et al.[65] showed, in a cross-sectional study of 9 year old children, that regular 
consumption of fresh, oily fish was associated with a reduced risk of current asthma. 
This reduced risk remained significant after adjustment for other known risk factors for 
asthma. 
 
In a study of 4300 young adults (20–44 yrs) on the west coast of Norway[67], fish 
consumption was not significantly associated with self-reported respiratory symptoms. 
The intake of fish was high, and the prevalence of asthma low, thus a minor protective 
effect of fish consumption on respiratory symptoms could not be ruled out. A large 
cross-sectional study from Japan showed a higher prevalence of asthma among children 
aged 6–16 years who ate fish one to two times a week than among those who ate fish 
one to two times a month. A dose response relationship was found. The first study to 
find an association between ordinary dietary fish intake and lung function in an 
epidemiological context was a cross-sectional sample of 2526 adult subjects aged 30–
70 yrs from the First National Health and Nutritional Examination Survey (NHANES 
I). A difference of 115 ml in FEV1 between those eating fish less than once a week, and 
those eating fish more than once a week was found. There were few asthmatics in this 
population (2.6%), so the impact of eating fish on asthma could not be established[68]. 
Two Scandinavian studies have investigated the association between consumption of 
fish during the first year of life and asthma and allergic diseases at 4 years of 
age[69,70]. Both studies showed a protective effect of early introduction of fish on 
allergic diseases at 4 years of age. Controlling for disease-related modification of 
exposure in the Swedish study did not change the association[70]. Neither of the studies 
had information on maternal intake of fish or n-3 PUFAs during pregnancy.   
1.2.2.3 Margarine and allergic diseases 
Margarine is the only food factor to date that has been associated with allergic disease 
without provoking any allergic reaction and this positive association between margarine 
and allergic diseases has been shown in more than 10 studies. There have been different 
explanations for these phenomena. One is that margarine alters the n-6 PUFA /n-3 
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PUFA ratio and thereby a modulation of the synthesis of IgE and inflammatory 
mediators[71,72]. Another explanation is that margarine has been enriched with 
vitamin D3 in many countries for several decades. Due to experimental and 
epidemiological findings on the immunological action of vitamin D3 and its 
metabolites, some hypothesise that vitamin D3 supplement may be responsible for the 
observed effect of vitamin D3-enriched margarine[73].  
1.2.2.4 Fruit and vegetables 
Fruit and vegetables contain many potentially important vitamins and antioxidants. 
Reactive oxygen species have been associated with airway inflammation. Among 
children, consumption of fresh fruit, particularly fruit high in vitamin C, has been 
related to a lower prevalence of asthma symptoms and higher lung function[74]. Low 
intake of vegetables and fruit has been associated with respiratory symptoms as cough 
and wheeze[75], whereas a Mediterranean diet, rich in fresh fruit and vegetables, during 
childhood had a beneficial effect on symptoms of asthma and rhinitis  in a study from 
Crete[71]. The Mediterranean diet is characterised by elevated intake of plant foods 
such as fruits and vegetables, bread and cereals, legumes and nuts. All these are 
important sources of dietary antioxidants.    
A high adherence to a Mediterranean diet during pregnancy  was found to be protective 
against persistent wheeze, atopic wheeze and atopy at age 6.5 years after adjusting for 
potential confounders[76]. In a Norwegian study it was shown that daily consumption 
of fresh fruit or vegetables during the first year of life was associated with less asthma 
at 12 years of age, whereas intake of fruit and vegetables less than daily had no 
protective impact. It was also shown that extra vitamin supplements were not associated 
with later asthma development[77]. 
1.2.3 The role of indoor dampness and allergic diseases 
1.2.3.1 Indoor dampness and allergy 
A high level of indoor dampness provides optimal conditions for the growth of mites. 
Several studies have indicated a positive correlation between allergy prevalence and 
indoor dampness[78,79].  
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1.2.3.2 Indoor dampness and asthma and wheeze 
Living in a damp home is considered a risk factor for asthma in infants. In 
schoolchildren and in a meta-analysis, Fisk et al. found that  building dampness and 
mould were associated with an approximately 30–50% increase in a variety of 
respiratory and asthma-related health outcomes[80]. Dampness is considered a risk 
factor for bronchial obstruction in young children[81]. In homes with dampness and 
low air exchange, the risk of bronchial obstruction was increased with a threefold[82]. 
Dampness is considered a risk factor for respiratory symptoms in newborns and in 
schoolchildren[83]. Dampness in itself is probably not the causal agent, but dampness 
or moisture are known to promote the growth and proliferation of dust mites, mould, 
and bacteria, exposure to which can result in allergic or infectious health outcomes. 
Dampness also promotes the degradation of some building materials and furnishings 
and can increase and alter their emissions.  
1.2.3.3 Indoor dampness and eczema 
A number of studies have suggested an association between house dust mite and atopic 
eczema. House dust mites thrive in damp conditions, and housing dampness may 
therefore be an indicator of house dust mite. In a study from Nottingham, a statistically 
significant association was shown between atopic eczema symptoms and dampness in 
the child’s home[84]. The population attributable risk was estimated to be 4% for 
housing dampness. The suggested explanation was an indirect effect of dampness 
through house dust mite. Later studies have questioned the link between house dust 
mite and atopic eczema[85,86].  No clear linear association between early exposure to 
house dust mites was found. The risk of eczema appeared to increase for the three 
lowest quintiles of house dust mite allergen exposure[87]. 
1.3 Prevention strategies; definitions and key concepts 
In medicine, prevention is any activity that reduces the burden of mortality or morbidity 
from disease by measures taken to prevent illness or injury, rather than curing them. 
This type of care can be exemplified by hand washing and immunisation. It can be 
contrasted not only with curative medicine, but also with public health methods (which 
work at the level of population health rather than individual health). Rose’s Theorem 
states that “a large number of people at small risk may give rise to more cases of 
disease than a small number who are at high risk”[88]. In the PACT study several types 
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of prevention strategies have been used to accomplish the primary objective of the 
study; reduced incidence of allergic diseases among children. The smoking intervention 
in PACT used a “high-risk” strategy[89], i.e., female smokers were identified and 
offered a structured smoking cessation programme[90]. This “high-risk” strategy led to 
an intervention that was appropriate to the pregnant women smokers and their partners. 
Regarding the dietary intervention, we used a population strategy, i.e., we tried to 
change the risk factor level for the whole population of pregnant women and their 
offspring regarding the intake of cod liver oil and oily fish. When it comes to the 
housing dampness intervention, we used a combined approach, a “high-risk” strategy 
was used to identify houses with dampness problems, and advice was given to improve 
the situation. A population strategy was used to lower housing dampness for the whole 
population as all participants were given advice on how to reduce housing dampness, 
both written and verbally, regardless of whether they participated in the intervention or 
not. Prevention can be applied at primary, secondary and tertiary prevention 
levels[88,89].   
1.3.1 Primary prevention  
Primary intervention occurs at a systems level to reduce the number of new cases 
(incidence) of a potential problem (e.g. in the PACT study, reducing incidence of 
allergic diseases among children by reducing assumed risk factors for allergic disease). 
1.3.2 Secondary prevention 
Secondary intervention is concerned with reducing the number of existing cases 
(prevalence) of an already identified condition or problem. Secondary prevention 
involves the promotion of compensatory skills and behaviours (e.g. in the PACT study 
extra effort was focused on parental smoking cessation and preventing smoking relapse 
in those who stopped smoking). 
1.3.3 Tertiary prevention 
Tertiary interventions are concerned with reducing the complications associated with an 
existing and identified problem or condition and were not the scope of this thesis. 
1.3.4 Environmental prevention  
Environmental prevention approaches are typically managed at the regulatory or 
community level, and focus on interventions to deter drug consumption. Prohibition 
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and bans (e.g. workplace smoking bans, alcohol advertising bans) may be viewed as the 
ultimate environmental restriction. Norway has had a governmental agency working for 
tobacco control since 1971. The Tobacco Control Department in the Norwegian 
Directorate of Health has the main responsibility for governmental tobacco control 
initiatives and implementation, as well as being the supervisory authority for certain 
provisions in Norwegian tobacco control legislation. Milestones of the Norwegian 
tobacco legislation are shown in Table 1. 
 
Table 1 
 
1.3.5 Individual intervention 
Intervention can be given individually or in groups. In the PACT study we offered 
intervention individually at consultations with GPs, midwives and health nurses and in 
groups at two selected maternity care centres, where we offered smoking cessation 
support in groups. 
1965 
The Norwegian Parliament appoints an interdisciplinary committee to investigate 
what measures could be implemented to combat the health problems caused by 
tobacco use. 
1971 The National Council on Tobacco and Health (a governmental office for tobacco 
control) is established.  
1973 The Act relating to Restrictive Measures for the Marketing of Tobacco Products (the 
Tobacco Act) is sanctioned. 
1975 The Tobacco Act comes into force (advertising ban, 16 years age limit, labelling). 
1988 The Clean Air Act is adopted. It provides for smoke-free air in public localities and 
means of transportation. 
1993 Restrictions on smoking in public restaurants, bars, cafés, pubs and discotheques. 
Smoking was allowed in 2/3 of the establishment’s premises. 
1998 Further restrictions on smoking in public restaurants, bars, cafes, pubs, discotheques. 
Smoking was only allowed in 50% of the establishment (as opposed to 2/3). 
2002 
Amendments to the Tobacco Act are passed. These include a ban on misleading 
descriptors such as “light” and “mild”. A legal basis for demanding disclosure of 
ingredients in tobacco is also enacted. 
2003 
The bill concerning a total ban on smoking in bars, restaurants, cafés etc. is passed 
by Parliament. The first national comprehensive mass media campaign on tobacco 
and health.  
For many years a public health campaign is run in Norway, adapted from the 
Australian campaign “Every cigarette is doing you damage”. 
2004 Total ban on smoking in restaurants and bars takes effect on 1 June 2004. 
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1.3.6 Legislation 
Another level of intervention is legislation. Norway has a history of more than 40 years 
of regulation of tobacco advertising and tobacco smoking in public. During the study 
period, a total ban on smoking in restaurants and bars took effect on 1 June 2004 (Table 
1).   
1.3.7 Mass media campaigns  
Anti-tobacco media campaigns, often called counter-advertising campaigns, were 
originally aimed at countering the effects of tobacco advertising by cigarette 
manufacturers. Their focus was generally to change individual behaviour by 
discouraging smoking. Campaigns have also attempted to decrease smoking rates by 
changing social norms through generating public support for various tobacco control 
policies, such as new tax initiatives or clean indoor air laws[91], or by scaring people 
from smoking, as in the national televised anti-smoking campaign in Australia[92,93],  
which proved to be very cost effective[94]. 
 
Norway has recently focused more on mass media campaigns. In January 2003, a 
campaign was based on the Australian campaign, “Every cigarette is doing you 
damage”. Survey evaluations have shown several positive trends, but not statistically 
significant results. A decline in the consumption of cigarettes of 4.5% during the first 
five months of 2003, compared with the first five months of 2002, was registered. 
 
The PACT study was initiated with inclusion of a control cohort in September 2000. 
After having developed the guidelines, the interventional programme started in a 
consecutive cohort in July 2002, and is still in progress. Amongst the many challenges 
in conducting a study on primary prevention of allergic diseases was the selection of 
applicable intervention topics that were associated with allergic diseases, were easy to 
implement in primary health care, and eventually, were measurable with reliable and 
valid tools. 
 
The primary objectives of the PACT study were to investigate the effectiveness of the 
risk-factor intervention on behavioural changes among parents, secondly to investigate 
the efficacy on the incidence of allergic diseases in the offspring from increasing n-3 
fatty-acid intake and reducing second-hand smoke exposure and indoor dampness. 
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2 Objectives 
 
The aims of the thesis were to answer the questions:  
 
1. Does primary intervention of allergic disease among small children, in the frame 
of ordinary primary care, lead to change in exposure?      
 
2. Does intervention against smoking during pregnancy have any impact on 
smoking behaviour when conducted locally in a real life primary care setting? 
 
3. Were the questions constructed to assess allergic disease among 2 year olds 
reliable?  
 
4. Do consumption of cod liver oil and oily fish during pregnancy and in infancy 
prevent parent-reported eczema and doctor-diagnosed asthma in 2 year olds?   
 
The questions will be addressed through four papers:  
Paper I 
A primary health-care intervention on pre- and postnatal risk factor behavior to prevent 
childhood allergy. The Prevention of Allergy among Children in Trondheim (PACT) 
study. 
 
Paper II 
The impact of a minimal smoking cessation intervention for pregnant women and their 
partners on perinatal smoking behaviour in primary health care: A real-life controlled 
study. 
 
Paper III 
Assessing atopic disease in children two to six years old: Reliability of a revised 
questionnaire.  
 
Paper IV 
Do early intake of fish and fish oil protect against eczema and doctor-diagnosed asthma 
at 2 years of age?  A cohort study. 
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3 Material and Methods 
3.1 PACT study 
The PACT study is an ongoing cohort study in primary health care in the city of 
Trondheim, the capital city of central Norway, with 165 000 inhabitants and 
approximately 2100 births  per year. In all, 32 of 35 general practices (104 general 
practitioners), all seven community-based midwives and all 20 maternity health centres 
in Trondheim agreed to participate. The three practices that refused to participate were 
all single practices. Additionally, four group practices withdrew from including women 
to the intervention cohort.   
 
The main purpose of the control cohort was to supply cross sectional data to monitor 
potential changes in lifestyle and diet habits and trends in incidence of allergic diseases 
during the study period (Paper I). Secondly, participants in the control cohort who 
answered more than one questionnaire could be followed in a prospective design (Paper 
II and IV).   
Admission to the control cohort started in September 2000 and ended December 2004.  
All pregnant women and children at 6 weeks, 1 year, and 2 years after birth were 
eligible to participate and included at ordinary scheduled consultations with GPs, 
midwifes or by health visitors. Inclusion to the control cohort ended when the 
intervention started for the actual age group (Figure 1).  All women who had children in 
these birth-cohorts, who received an invitation and were willing and able to complete a 
self-reported questionnaire in Norwegian, after giving written informed consent to 
participate, were included in the study with no further selection criteria. Recruitment to 
the intervention cohort started in July 2002, and all participants were included by GPs 
and midwives during pregnancy. The inclusion ended in June 2006, and collection of 
questionnaires at two years after delivery continued until March 2009 (Figure 1). 
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3.2 Figure 1 (Flow-chart) 
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The interventional program was developed in collaboration between community 
midwives, maternity care nurses, GPs and parents and should be implemented as a part 
of ordinary antenatal and postnatal care at scheduled consultations. The officially 
recommended schedule for primary care antenatal and postnatal consultations in 
Norway was followed for both cohorts. This programme is accessible and 
recommended for all women, free of charge, and with a nationwide attendance rate of 
nearly 100% in both urban and rural areas. Interventions should be repeated at 
scheduled consultations throughout pregnancy until two years postpartum. The 
schedule constitutes of 8 to 10 antenatal consultations with a GP or midwife from the 
eighth–tenth week in pregnancy, followed by 10 postnatal consultations with public 
health nurses at maternity care centres during the child’s first year of life. The 
interventions could be simultaneous or sequential, but repeated at least five times for 
each topic, both pre- and postnatal, within the recommended maternity care schedule 
and without extra expenditure of time. The interventional programme should be 
implemented without extra costs to the participants or the primary health care system. 
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4 Interventional strategies 
4.1 The n-3 PUFA intervention 
In Norway a daily supplement of cod liver oil is very common and is already 
recommended for children and adults alike. In the intervention programme we aimed 
for: 
• Increased dietary intake of n-3 PUFAs by intake of at least two meals of oily 
fish a week and 5 ml cod-liver oil a day during pregnancy (5 ml cod liver oil = 
1.2 g n-3 PUFA).   
• Cod liver oil to be introduced to children’s diet from 4 to 6 weeks of age, 
increasing to 5 ml/ day, and oily fish at least twice a week from 6 months of age 
as part of a meal or spread on a sandwich. 
4.2 The smoking cessation and SHS intervention 
The smoking intervention programme was a brief office intervention[95-97]. The 
intervention was adapted from the United States Department of Health and Human 
Services Public Health Service (USHPS) guideline “Treating Tobacco Use and 
Dependence. Clinical Practice Guideline”[90]. 
4.3 The indoor dampness intervention 
To detect and reduce home dampness the interventional strategy was to provide advice 
on how to detect water and dampness damage in domestic housing, and advice on how 
to reduce risk factors for home dampness and its consequences.  
 
4.4 The non-participants study 
To investigate if there was a selection bias in the PACT study we conducted an 
additional non-participants study, where 391 parents who consecutively visited 
maternal postnatal care were asked to complete a short and anonymous questionnaire 
on age, education, familial allergic disease and smoking behaviour, regardless of 
whether they participated in the PACT study or not (Paper I, II and IV). 
4.5 Medical Birth Registry of Norway 
Aggregated data from the Medical Birth Registry of Norway (MBR) were used to 
illustrate smoking cessation in Norway and the two comparable cities of Bergen and 
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Trondheim from 1999 to 2004. Smoking data from the MBR were available from 1999 
to 2004. These data are collected as a mandatory procedure at discharge from any 
maternity ward in Norway, a procedure that has existed since 1967. Since 1999, 
registration of smoking habits during pregnancy has been included in the standardised 
notification form and reported to the MBR. Forms are completed in an interview with a 
midwife or physician and by using the hospital medical records. The women are asked 
if they smoked at the beginning or end of pregnancy, and they can answer “no”, 
“occasionally” or “yes”. Smoking is coded as a dichotomous variable, “occasionally” 
and “yes” are coded as smokers, “no” as non-smokers. Data were available for 
approximately 90% of the women who gave birth during the period from 1999 to 2004, 
according to information from the MBR.  
4.6 Study variables 
4.6.1 Exposure 
The risk factors and life-style were monitored by questionnaires completed by the 
mothers during pregnancy, and when the child was 6 weeks, 1 and 2 years of age 
(Appendix 1–4). Validated questionnaires for the actual age-group were not available at 
the time, and questions were adapted from various sources[12,98-100]. The topics 
covered in all questionnaires were; number of siblings, parietal status, birth weight, 
vaccinations, marital status, heredity for allergic disease, pregnancy conditions, housing 
conditions and indoor environment, semi-quantitative food frequency data for mother 
and child, parental smoking behaviour and information on child care[101-103]. 
Exposure variables subject for intervention will be described more in detail.  
4.6.1.1 Housing conditions 
Housing conditions and indoor dampness was assessed by asking for eight different 
indicators on indoor dampness, such as mould or musty smell, moist cardboard and 
newspapers after storage, dew on windows, moist spots on ceilings, walls or 
wallpapers, leakage detected on water pipes or taps, leakage from roof or ground, or 
moisture in floors.  If “yes” to any question, the follow-up question was whether the 
problem was repaired.  Alternatively, the answer could be “no” to all.  
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4.6.1.2 Diet 
Information regarding age for introduction of a variety of food products, including 
different kinds of porridge, bread, vegetables, fruit, commercially-produced baby food, 
homemade baby food, fish, cows’ milk, and eggs, were obtained when the children 
were 1 year of age. Duration of breastfeeding, time for introduction and type of infant 
formula, vitamins and cod liver oil, information on consumption of vegetables, cod 
liver oil, lean fish (cod and coalfish) and oily fish (redfish, halibut, salmon, trout, 
herring and mackerel) as meals and sandwich spread were collected by using a set of 
validated semi-quantitative food frequency questions with six categories; never, less 
than once a week, once a week, twice a week, three times a week and four times a week 
or more, and re-categorised later in the analyses[101,102]. Lean and oily fish as a meal 
was separately dichotomised, merging never and less than once a week into category 
zero, and the remaining four values into category one. Fish as sandwich spread was set 
to category zero if consumption was two slices or fewer per week. Eating more than 
two slices a week with fish as sandwich spread was set to category one, which was 
equivalent to eating one meal of oily fish or more a week. When we analysed eating 
any kind of fish, the sum of the dichotomised values of lean fish, oily fish, and fish as 
sandwich spread were reclassified into two categories. If the sum of the three 
dichotomised values was zero, it was equivalent to never eating fish, or less than once a 
week. If the sum was one or more, it was equivalent to eating fish once a week or more.  
4.6.1.3 Tobacco exposure 
Parental smoking during pregnancy was assessed with two questions, where the women 
were asked if they or their partner were smoking at start pregnancy, if they were 
smoking now and daily and/or weekly cigarette consumption. A separate question was 
asked about the total numbers of cigarettes smoked indoors. Smoking was coded as a 
dichotomous variable, if they were smoking more than one cigarette a week they were 
coded as smokers, if the answer was no they were coded as non-smokers, and if the 
answers to all questions on smoking were missing they were coded as missing. 
4.6.2 Outcome variables 
4.6.2.1 Parent-reported outcome variables 
The questionnaire consisted of 26 questions designed to assess symptoms of allergic 
diseases, and two questions on infectious diseases and hospitalisation during the first 
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two years of life (Appendix 5). Three main requirements were specified in developing 
the questionnaire:  
First, the extent of the questionnaire should be sufficient to estimate symptoms and 
complaints consistent with asthma, rhinoconjunctivitis, and eczema/dermatitis, and to 
describe the use of health care services and treatment for these diseases. Second, the 
questionnaire should be suitable to complete during a maternal and child health centre 
consultation of average duration, i.e. 30 minutes.  Third, it should be designed to obtain 
satisfactory validity. 
We used parent-reported eczema or doctor-diagnosed asthma at 2 years as the primary 
outcome variable (Paper IV). Asthma was defined as answering “yes” to; “Has the 
child ever had doctor-diagnosed asthma?” Eczema was defined as answering “yes” to 
both; “Has the child ever had eczema?”, and “Has the child ever had an itchy rash 
coming and going for at least six months?” 
4.6.2.2 Outcome variables from medical records 
In the “Children’s health questionnaire” ten of the questions revealed information that 
could be expected to be found in medical records. Information obtained from various 
medical records in primary health care, paediatric practices, and in hospitals, was used 
in paper III to assess reliability by evaluating the agreement between answers given on 
these ten questions and information obtained from medical records. Two investigators 
assessed all the information in the health records, and then both completed a 
registration form for each participant. When doubt or disagreement in interpretation of 
the medical records was experienced, consensus between the investigators was obtained 
through discussion.  
4.7 Statistical methods 
4.7.1 Tests used 
Chi-square statistics were used for testing comparisons between the cohorts and groups 
for reported binomial data like smoking, atopic disease, pets in dwelling unit and 
dichotomised dietary factors (Paper I, II and IV). Independent sample T-test was used 
to test comparisons between the cohorts and groups for continuous data, like age, 
education and birth weight. A 95% confidence interval was based on binomial 
distribution for dichotomous data, and normal distribution for continuous data.  The 
level of significance was set to p = 0.05 (Paper I, II and IV). 
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We used generalised linear models (GLM) with binomial regression in a predictive 
model (STATA version 10.0) to adjust smoking prevalence (Paper II). Binary logistic 
regression models were used to estimate adjusted odds ratios (aORs) (Paper I, II and 
IV). Kappa statistics were used to analyse the agreement between answers given in the 
questionnaire and information obtained from different medical records. Estimated 
observed agreement and proportional agreement were also used (Paper III). Kendall’s 
tau-b correlation was used to test inter-correlation between different dietary variables 
(Paper IV). 
 
Absolute risk reductions were estimated and given with 95% CI intervals (Paper IV).  
Confounding factors were identified by a priori knowledge and tested firstly in 
univariate logistics regression and finally in multivariate regression analyses. 
Adjustments were made for gender, familial atopy (none, one, two, or three), parental 
smoking one year after birth (none, one or both parents); children’s consumption of cod 
liver oil and vegetables at 1 year of age, parental homeowner status as a proxy for 
social class during the first year of life, and exclusively breastfeeding for more than 4 
months (Paper I, II and IV).  
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5 Main results 
5.1 Review of paper I 
Background 
This study aimed to evaluate the impact of a primary prevention intervention program 
on risk behavior for allergic diseases among children in a pre- and postnatal primary 
healthcare setting. 
Methods 
The Prevention of Allergy among Children in Trondheim, Norway (PACT) study 
invited all pregnant women and parents to children up to 2 years of age in the 
community to participate in a non-randomized, controlled multiple life-style 
intervention study aiming to increase dietary intake of cod liver oil and oily fish for 
women during pregnancy and for infants during the first 2 years of life, to reduce 
parental smoking and to reduce indoor dampness. A control cohort with “follow up as 
usual” was established before the intervention cohort. Questionnaires were completed 
for both cohorts in pregnancy, 6 weeks after birth and when the children were 1 and 2 
years of age. Trends in exposure and behavior are described. 
Results 
Intake of oily fish and cod liver oil increased statistically significantly among women 
and infants in the intervention cohort compared to the control cohort. There was a low 
postnatal smoking prevalence in both cohorts with a trend towards a decreasing 
smoking prevalence in the control cohort.  There was no change in indoor dampness or 
in behavior related to non- intervened life-style factors.  
Conclusions 
The dietary intervention seemed to be successful. The observed reduced smoking 
behavior could not be attributed to the intervention program, and the latter had no effect 
on indoor dampness. 
  
5.2 Review of paper II 
Background 
There is a demand for strategies to promote smoking cessation in high-risk populations 
like pregnant women who smoke and their partners. The objectives of this study were 
to investigate parental smoking behaviour during pregnancy after introduction of a 
prenatal, structured, multi-disciplinary smoking cessation programme in primary care, 
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and to compare smoking cessation among pregnant women in Trondheim, Bergen and 
all of Norway. 
Methods 
Sequential birth cohorts were established to evaluate the intervention programme from 
September 2000 to December 2004 in primary care as part of the Prevention of Allergy 
among Children in Trondheim (PACT) study. The primary outcome variable was self- 
reported smoking behaviour six weeks after birth. Data from the Medical Birth Registry 
of Norway (MBR) was used to describe smoking behaviour during pregnancy in 
Trondheim, Bergen and all of Norway, 1999–2004.   
Results   
At inclusion during pregnancy, 25% (CI 95% 20–31) and 32% (CI 95% 26–38), p= 
0.17, of the women who smoked before pregnancy were still smoking in the 
intervention and control cohorts, respectively. Maternal smoking prevalence at 
inclusion in the intervention cohort was 5% (CI 95% 4–6) compared with 7% (CI 95% 
6–9), p=0.03, in the control cohort. At six weeks postnatal, 72% (CI 95% 59–83) and 
68% (CI 95% 57–77), p =0.34, of the maternal smokers at inclusion still smoked. No 
significant difference in paternal smoking was found between the cohorts after the 
intervention period. Data from the MBR showed a significantly higher proportion of 
women who stopped smoking during pregnancy in Trondheim than in Bergen in 2003 
and 2004, p=0.03 and <0.001, respectively.   
Conclusions 
No impact on parental smoking behaviour between the cohorts was observed after the 
smoking intervention programme. Of the women who stopped smoking during 
pregnancy, most stopped smoking before the intervention. However, we observed a 
significantly higher quitting rate in Trondheim than in Bergen in 2003 and 2004, which 
may have been facilitated by the supplemental attention on smoking behaviour the 
PACT study initiated.    
5.3 Review of paper III 
Background 
Primary intervention – reducing second hand smoking (SHS), indoor dampness, and 
increased intake of n-3 fatty acids – for allergic diseases such as asthma, 
rhinoconjunctivitis, and eczema/dermatitis in children, was started in Trondheim in 
2002. To our knowledge, no validated or reliable questionnaires for the study age 
 49
groups were available. Aim: To test the reliability of a revised questionnaire for 
studying atopic disease in children aged 2 to 6 years in Trondheim.  
Methods 
Seventy-seven families were invited to fill in a questionnaire adapted from the ISAAC 
protocol which was made appropriate for the age group studied. Completed 
questionnaires and information from medical records were compared, and the 
agreement was analysed by Kappa statistics and proportional agreement.  
Results 
Agreement was excellent for questions reporting current information such as doctor-
diagnosed asthma (kappa=0.88), whether or not the child had had an allergy test 
(kappa=0.82), and use of antibiotics (kappa=0.81). The agreement was good for 
questions concerning doctor or hospital treatment for asthma (kappa=0.59), medication 
for asthma (kappa=0.58), symptoms of eczema (kappa=0.56), medication for allergic 
disease (kappa=0.45), and past infections (kappa=0.53).  
Conclusions 
Questions on asthma diagnosis, allergy testing, and use of antibiotics were reliable. 
Questions on medical treatment for eczema, allergic rhinoconjunctivitis and infections 
were less reliable, representing a potential source of information bias and possible 
misclassification. 
5.4 Review of paper IV 
Background 
There are ambiguous results regarding the role n-3 polyunsaturated fatty acids (n-3 
PUFAs) and fish might play in primary prevention of allergic diseases. The aim was to 
investigate the association between cod liver oil and fish consumption during 
pregnancy and the in first year of life and asthma and eczema at 2 years of age.  
Methods 
From the Prevention of Allergy among Children in Trondheim study (PACT), a 
prospective birth cohort study in primary health care in Trondheim, Norway, 3086 
children were followed prospectively from 1 year to approximately 2 years of age. 
The primary outcome variable was parental reported asthma and eczema at 2 years.  
Results  
Mean age for introducing fish in the diet was 9.1 months. Excluding children with 
incident eczema before 1 year, a reduced risk of developing eczema was found if the 
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child was eating fish once a week or more, adjusted odds ratio (aOR) for any kind of 
fish 0.62 (CI 95% 0.42 to 0.91 p= 0.02), for oily fish, aOR 0.21 (CI 95% 0.05 to 0.86 
p= 0.03), for lean fish, aOR 0.67 (CI 95% 0.41 to 1.08 p= 0.10). The associations 
between maternal diet and eczema at 2 years and between the dietary factors and 
doctor-diagnosed asthma were all insignificant.   
Conclusions 
Fish consumption in infancy was more important than maternal fish intake during 
pregnancy in preventing eczema in childhood. The intake of fish per se, not specifically 
n-3 PUFAs, was most important in preventing eczema. 
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6 General discussion 
6.1 Methodological considerations 
A result of a non-randomised trial may reflect the true effects of the intervention on the 
exposure or on behaviour and subsequently the incidence of disease under study. The 
result may also have alternative explanations, such as chance or random error or as a 
result of systematic error or bias. 
   
6.2 Validity 
Validity refers to the ability of variable estimates to reflect, on average, what they are 
intended to reflect. The most common reasons for invalid estimates for variables 
relating exposure to disease are sample selection bias, information bias, and 
confounding. Validity can be divided into “internal” validity, and “external” validity. In 
general, internal validity corresponds to making correct inferences about the study 
population. External validity refers to making correct inferences about other 
populations (generalisability)[104]. 
6.3 Internal validity 
Internal validity, in essence, is whether the study’s findings result from the intervention 
being studied, and are not due to chance or some other factor. Internal validity is how 
well the study was set up and executed to prevent confounding, selection bias, and 
information bias.    
6.3.1 Study design  
Several study designs were considered when planning the study. One option was to 
select another city in Norway as control. In such a design it would be difficult to adjust 
for climate, pollution, ethnicity and education, and the investments in infrastructure 
would be costly, therefore it was abandoned due to cost and lack of resources. A second 
option was to divide Trondheim in two parts; a control and an intervention district. This 
would lead to a problem with migration of participants and health workers, and a public 
and community-based intervention including the entire primary health care in the 
municipality, as in this study, would be impossible to implement without contaminating 
a co-existing control cohort. A randomised study on individual level would have the 
same problems with contamination of the intervention measures to the control cohort. 
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The choice was therefore a consecutive cohort design with a one-year difference 
between the control cohort and intervention cohort. A controlled non-randomised 
design is appropriate to provide relevant data for testing costs in a limited-resource 
environment, and to enable an evaluation of how the intervention measures were 
implemented by typical primary health care professionals in daily clinical work in a 
real-life setting. The effectiveness of new interventions can be monitored when 
implemented in a large scale in a real life setting. Using an observational design with a 
comparison group may allow plausibility statements to be made. Non-randomised 
designs can supply the evidence-based public health practice literature with data 
regarding implementation of interventions in ordinary public health that randomised 
controlled trials cannot[105].  
 
The consecutive cohort design with a one-year difference between the control cohort 
and intervention cohort might have biased the results toward a better effect of the 
intervention as a consequence of possible time trends. Particularly tobacco smoking 
could be subject to this, as there was a decline in smoking prevalence among pregnant 
Norwegian women in the current period[106]. Such insecurities probably cannot be 
completely avoided in a large-scale, real-life prospective study setting. This design also 
ensured high conformity between the cohorts regarding population size, race/ethnicity, 
maternal educational level, income, environment, urbanisation and social 
characteristics[107].  
6.3.2 Choice of questions 
Use of questionnaires is an essential epidemiological tool. Epidemiological findings are 
often based partly or completely on responses to questionnaires. We used 
questionnaires to collect information on exposures, outcomes, modifiers and 
confounders.  
6.3.3 Life-style questionnaires 
Information on exposure modifiers and confounders was collected by questionnaires 
completed mainly by mothers at inclusion in the study, and at 6 weeks, 1 year and 2 
years after birth of their child. Validated questionnaires covering the three 
interventional topics were not available at the time, and questions were adapted from 
various sources[12,98-100]. Parental smoking during pregnancy was assessed with two 
questions in which the women were asked if they or their partner were smoking at the 
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start of the pregnancy, if they were smoking now and their daily and/or weekly 
cigarette consumption. A separate question was asked about the total number of 
cigarettes smoked indoors. If the answers to all questions on smoking were missing 
they were coded as missing.  
 
Housing conditions and indoor dampness was assessed with one question asking for 
eight different indicators on indoor dampness, such as mould or musty smell, moist 
cardboard and newspapers after storage, dew on windows, moist spots on ceilings, 
walls or wallpapers, leakage detected on water pipes or taps, leakage from roof or 
ground, or moisture in floors.  If “yes” to any question, the follow-up question was 
whether the problem was repaired.  Alternatively the answer could be “no” to all. 
 
Information on consumption of vegetables, cod liver oil, lean fish (cod and coalfish) 
and oily fish (redfish, halibut, salmon, trout, herring and mackerel) as meals and 
sandwich spread were collected by using a set of validated semi-quantitative food 
frequency questions with six categories: never, less than once a week, once a week, 
twice a week, three times a week and four times a week or more. A limitation of the 
food frequency questions was that total daily energy intake could not be derived from 
the collected data.  Not adjusting for energy intake may be a limitation in nutritional 
epidemiology (Paper IV)[108]. The questionnaires covered a wide range of modifiers 
and confounders.  
The questionnaires did not cover parental alcohol consumption. This was a deliberate 
choice as we feared questions on alcohol would reduce the acceptability and thereby 
reduce the participation rate[109]. 
6.3.4 Additional study  
Educational data and data on socioeconomics were by accident left out. Maternal and 
paternal education was not accounted for in the original questionnaires. Thus 1189 
randomly-selected parents answered questions on education, either written or by 
telephone interview. We also used homeowner status as a proxy for socioeconomic 
status in the regression analysis (Paper I, II and IV). 
6.3.5 Health questionnaire 
No validated questionnaires to assess the prevalence of risk factors and incidence of 
asthma, rhinoconjunctivitis and eczema/dermatitis among children between 2 and 6 
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years were found when we planned the PACT study. We searched for Validity, and 
Reliability of questionnaire on atopy and allergy among children (Medline and 
Cochrane search). Most of the existing literature was about variation of the 
International Study of Asthma and Allergies in Childhood (ISAAC)[7]. ISAAC is an 
international project aiming to determine the prevalence of asthma, allergic rhinitis and 
eczema in children living in different countries. The written questionnaire includes 
questions on respiratory and skin symptoms. However, ISAAC was constructed for and 
applies to older children, not for children aged 2 years. To evaluate the effect of the 
intervention, existing questionnaires from the ISAAC protocol had to be revised for the 
actual age group in this study.  
 
Three main requirements were specified in developing the questionnaire: First, the 
extent of the questionnaire should be sufficient to estimate symptoms and complaints 
consistent with asthma, rhinoconjunctivitis, and eczema/dermatitis, and to describe use 
of health care services and treatment for these diseases. Second, it should be possible to 
complete the questionnaire during a maternal and child health centre consultation of 
average duration, i.e., 30 minutes.  Third, it should be designed to obtain satisfactory 
validity.  
6.3.6 Acceptability of questions 
A brief questionnaire to determine feasibility and time consumption was completed by 
36 participants in a pilot study. The median time spent completing the questionnaire 
was 6.5 minutes (range 1–15 minutes). About half the participants (18 out of 36) 
managed to complete the form while waiting for the maternity centre consultation, the 
rest completed it after the consultation. Six parental couples were invited to comment 
on the design and comprehensibility of the questionnaire in a modified focus group 
evaluation.  Comments on the extent and comprehensibility were collected from this 
group. This evaluation led to rephrasing of some questions. Overall there were few 
comments and proposals for amendments (Paper III).  
6.3.7 Precision/Accuracy 
When measuring health-related phenomena in an epidemiological study, it is important 
to achieve the highest levels of precision and accuracy. Precision refers to the degree to 
which there is variation in a measurement. Accuracy refers to the degree to which the 
measurement is, on average, correct. If each time a phenomenon is measured, the result 
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is the same, but all measurements are far away from the true value, there is high 
precision but low accuracy. If measurements vary widely, but their average is close to 
the true value, there is accuracy but not precision. 
6.3.8 Validity and reliability of the questionnaires 
The focus group discussions might be seen as constructing validity, as the discussions 
were also about what the question was really about. On the other hand, the major effort 
in the focus group was to challenge the parents on what their understanding was of the 
questions so that they would be able to give the same answer each time. 
Simultaneously, we compared information from the questionnaire on the chosen items 
and corresponding information from medical records to estimate whether the 
information was reproducible from other sources, not whether it was repeatable. In 
contrast with validity studies, reliability studies assess the extent to which results agree 
when obtained by different approaches. The medical records could not be viewed as a 
reference standard and that is why we find it more appropriate to use the term reliability 
(Paper III) 
6.3.9 Confounding  
Three conditions are traditionally given as necessary (but not sufficient) for a factor to 
be a confounder[110]. First, a confounder is a factor that is predictive of disease in the 
absence of the exposure under study. A confounder need not be a genuine cause of the 
disease under study, but merely “predictive”. Hence, surrogates for causal factors (for 
example, age and socioeconomic status) may be regarded as potential confounders, 
even though they are not direct causal factors. Second, a confounder must be associated 
with exposure in the source population at the start of follow-up (that is, at baseline).  
Third, a variable that is affected by the exposure that is an intermediate in the causal 
pathway between exposure and disease should not be treated as a confounder because 
to do so could introduce serious flaws in the inference of the results. We identified 
confounding factors by a priori knowledge. Maternal age and child’s sex were obvious 
confounders and were adjusted for in all analyses. Parietal status, atopic predisposition 
and parental smoking habits were also considered to be confounders, and they were 
tested in several models and used in some statistical analyses (Paper I, II and IV). One 
obvious confounder was by accident missing in our data; socioeconomic status. As a 
proxy for socioeconomic status we adjusted for homeowner status (Paper I, II and IV).  
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Pets in the household are used as a confounder in many epidemiological studies on 
allergy. We did not use pets because, as far as we can see there is no association 
between the exposures under study and pet-keeping, a criteria that must be fulfilled if 
pets should be considered to be confounding (Paper I, II and IV).    
6.3.10  Reversed causality 
Effect modification of diet, or reverse causation, would occur if early signs of allergic 
disease in children influenced the introduction of different foods, such as fish, in the 
children’s diet. The onset of eczema commonly occurs very early in life when decisions 
related to continued breastfeeding or introduction of food items are being made; 
introducing the possibility of effect modification. To address this possibility, we used 
parent-reported allergic disease at 1 year of age in a stratified analysis. The associations 
between dietary factors at 1 year of age and reported allergic disease at 2 years of age 
were then tested in two steps in order to avoid effect modification of diet, in the second 
step children whose mothers reported allergic disease at 1 year of age were excluded 
(Paper IV). 
6.3.11 Bias 
6.3.11.1 Selection bias  
Selection bias is an error in choosing the individuals or groups to take part in a study, 
i.e., different inclusion of controls and cases. Ideally, the subjects in a study should be 
very similar to one another and to the larger population from which they are drawn (for 
example, all individuals with the same disease or condition). If there are important 
differences, the results of the study may not be valid. 
6.3.11.2 The non-participant study  
To investigate if there was a selection bias among participants in the PACT study we 
conducted a non-participant study, where 391 parents who consecutively visited 
maternal postnatal care were asked to complete a short and anonymous questionnaire 
on age, socioeconomic status, allergic disease and smoking behaviour, regardless of 
their participation in the PACT study. The non-participant study showed no selection 
bias for participants in the PACT study regarding age, socioeconomics, allergic disease, 
or smoking behaviour. 
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6.3.11.3 Recall bias and misclassification 
Recall bias relates to different recall of information or exposure in cases that have 
experienced an adverse outcome (having a child with asthma, eczema or ARC) and 
those who have not. Recall bias may have occurred and led to misclassification because 
parents who had children with one of the diseases under study were more likely to 
remember or report a particular exposure during pregnancy or during infancy because 
the exposure could be more meaningful to cases than to controls. Parents who were 
smoking could be more likely to under-report smoking if their child had asthma, or the 
reporting of a child’s diet could be influenced if the child developed eczema early in 
life. The outcome variables were also vulnerable to misclassification, which is 
inevitable in most studies. The consequence of this type of bias depends on whether the 
misclassification is non-differential (random) or differential (not random).     
6.3.11.4 Non-differential misclassification 
Non-differential misclassification of exposure occurs when misclassification is not 
related to the disease status, and misclassification of disease status is non-differential if 
exposed and non-exposed people are equally likely to be misclassified according to 
disease status[110]. Under-reporting or selective memorisation could have led to 
misclassification of exposure variables. If this misclassification of exposure variables 
were the same in the study groups, the effect of this random misclassification would 
have minimised the differences between the groups, and resulted in an underestimation 
of the true effect (paper I, II and IV). Maternal food intake during pregnancy and the 
children’s diet during infancy were retrospectively assessed when the children were 1 
year of age, and therefore vulnerable to recall bias and misclassification of exposure. 
Misclassification of lean and oily fish may also have occurred. To avoid 
misclassification, different species of fish in each group were exemplified in the 
questionnaire. It is reasonable to believe that random misclassification has occurred and 
as a result weakened the observed associations between eating fish and reduced 
prevalence of eczema at 2 years (Paper IV). 
 
Having a child is perhaps one of the greatest events in anyone’s life. The recall ability 
is related to the significance and meaningfulness of an event, hence mothers can recall 
their diet in pregnancy with some accuracy[111].  This has probably minimised the 
recall bias in Paper IV.      
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6.3.11.5 Differential misclassification 
The recall and reporting of a socially stigmatised exposure, like cigarette smoking 
during pregnancy, may have been affected. The intervention group (Paper II) were 
more aware of the aim of the study, and hence non-random or differential 
misclassification may have occurred and brought the risk estimate towards nil.    
6.3.12 Participation 
6.3.12.1 Participation rate 
Thirty two of 35 general practices (104 general practitioners), all seven community-
based midwives and all 20 maternity health centres in Trondheim participated in the 
PACT study. In the cross sectional control cohort the participation rate varied from 
49% to 64% for the different age groups.  During the inclusion period some 8400 
pregnant women in Trondheim were eligible to the intervention cohort, 2860 women 
were included. This gave a participation rate of about 34% in the intervention cohort. 
The discouraging participation rate was a consequence of low inclusion activity among 
many GPs and midwifes, and was not a consequence of self-selection among women. 
There is no reason to assume a selection bias, as confirmed by results from the non-
participant study which included 391 subjects.  
6.3.12.2 Loss to follow up  
Of the 3839 women who were included during pregnancy (Paper II), 2132 (56%) 
answered the questionnaire at 6 weeks after the birth. This is a high loss to follow-up, 
and was due to forgetfulness or failing routines for follow-up among the health 
professionals. One would also expect a certain degree of exhaustion among GPs and 
midwives in a study of such duration[112]. If the loss to follow-up is assigned to 
forgetfulness or low attention during follow-up both among participants and health 
professionals, it may be assumed that the participants are lost at random. This is 
supported by the observation that baseline characteristics between drop-outs in the two 
cohorts differed only for single mothers. If so, even a loss to follow-up of 60% is 
shown not to represent important bias[113]. Importantly, we had almost no active 
withdrawals in either of the cohorts.  
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6.4 External validity 
External validity, or generalisability, involves the extent to which the results of the 
PACT study can be generalised to a larger group of subjects, for example, women or 
children living outside Trondheim (Paper I, II–IV). There are several threats to external 
validity; the most important is perhaps the participants under study. Are the participants 
in PACT representative of pregnant women in Trondheim and other parts of Norway? 
The PACT study comprises approximately 34% of the eligible women in Trondheim 
and, as described under the section “Participation”, we claim this is a representative 
sample of women and children living in Trondheim.  
 
Comparing data from PACT with MBR data for all pregnant women in Trondheim, we 
found no difference in the prevalence of smoking at the start of pregnancy before the 
intervention commenced in 2002. This strengthens our belief that the PACT population 
is representative for pregnant women in Trondheim. There is, to our knowledge, no 
good evidence to indicate that pregnant women in Trondheim differ from pregnant 
women in other large cities in Norway, but such differences cannot be ruled out.    
 
The large unselected population in PACT also makes it possible to generalise results 
from dietary and housing dampness intervention (Paper I), and the association found 
between fish consumption at 1 year and reduced risk of eczema at 2 years (Paper IV).  
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7 Discussion of main findings 
7.1 Behavioural changes and changes in exposure 
7.1.1 Smoking intervention 
A significant and stable decline in maternal and paternal smoking frequencies was 
reported from the start of pregnancy, through 6 weeks postnatal, and at 1 and 2 years 
postnatal. The smoking frequency was almost halved at all four assessment points of 
time. The significant differences in parental smoking prevalence between the cohorts 
could not be ascribed the intervention directly, but were most probably due to time 
trends in the study period, as shown by the trend analysis in the control cohort. When 
we performed a stratified analysis according to smoking behaviour at the time of 
inclusion in the study, we observed no impact of the smoking intervention during 
pregnancy. The high quitting rate observed in both cohorts (approximately 70%) was 
apparently due to spontaneous quitting before inclusion. Therefore only a hardcore of 
resilient smokers were left for the intervention programme, women who had made their 
choice to continue smoking during pregnancy probably despite knowledge of the 
harmful effects and social stigma. This is in agreement with results from several other 
smoking intervention studies in pregnancy[114,115]. We found a very high rate of 
spontaneous quitting in the intervention cohort compared with what has been found in 
other studies[114,116]. This result was confirmed when we analysed the MBR data for 
Trondheim, Bergen and Norway (Figure 2 in Paper II). The MBR data for Trondheim 
comprise both women participating in the PACT study and non-participating women. 
The women in the two cities had been exposed to the same national legislation and anti-
smoking campaigns. What differed between the two cities were the PACT study and 
the fact that the intervention programme was adopted as an integrated part of the 
recommended maternity care life-style counselling programme throughout Trondheim.  
 
One interpretation may be that the PACT study in this way increased the attention on 
the health hazards of smoking in pregnancy among GPs and midwifes, and also among 
the parents-to-be, and in this way brought about the significantly higher smoking 
cessation rate observed in the MBR data for Trondheim compared with Bergen.  This 
may have been facilitated by the supplemental attention on smoking behaviour the 
PACT study initiated in Trondheim, and thus the PACT study may have reinforced the 
national anti-smoking campaigns which took place during the study period. The 
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intervention, in this way, might have influenced the results on the macro level in 
Trondheim, but no impact on pregnant women when comparing the two cohorts was 
observed. A 10%–20% false-negative rate has been reported to exist among women 
who report quitting smoking early in their pregnancy[114]. Social awareness following 
the increased attention about the hazards of smoking during pregnancy, and the 
implementation of a new law banning smoking in restaurants coinciding with the 
initialisation of the intervention, may have facilitated a higher false-negative rate of 
reporting quitting in the intervention group.  Accordingly, the far better smoking 
cessation rate among pregnant women in Trondheim compared with Bergen and 
Norway during 2002–2004 could be explained by differences in false-negative rates. 
We also found a very low prevalence of reported indoor smoking in both cohorts. This 
may indicate that there was awareness in both cohorts of the harmful effect of SHS on 
small children, but answering according to social desirability may also explain this 
result.  
 
7.1.2 The dietary intervention 
The dietary intervention was for mothers to take cod liver oil supplement and to eat oily 
fish twice a week during pregnancy, and to add cod liver oil to the children’s diet from 
4 to 6 weeks of age. Oily fish should be introduced into the children’s diet from 6 
months of age. We did not intervene on intake of vegetables, breastfeeding, formula or 
other dietary factors. 
 
During pregnancy, the numbers taking cod liver oil more than four times a week 
increased significantly in the intervention group compared with the control group. The 
women also ate oily fish and lean fish more often during pregnancy in the intervention 
group compared with the control group, and there were no time trends regarding cod 
liver oil, fish and vegetable intake during pregnancy either in the intervention group or 
the control group.  
Among the children we found that a statistically significant higher proportion took cod 
liver oil at least four times a week in the intervention cohort at 1 and 2 years of age. 
The proportion having oily fish at least once a week was substantially higher at 1 year 
and 2 years of age in the intervention group compared with the control group, and there 
was a positive trend for eating oily fish in both groups at 1 and 2 years of age. There 
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was a statistically significant difference in the intake of lean fish between the groups, 
both among 1 year olds and 2 year olds. The intake of any kind of fish was larger at 1 
year of age in the intervention group, but at 2 years of age the difference was no longer 
statistically significant. An interpretation of this may be that oily fish was substituted 
for lean fish in the children’s diet. We did not observe any difference between the 
cohorts regarding intake of vegetables.   
 
The frequency of breast feeding at six weeks did not differ between cohorts, while the 
proportion of mothers who reported, at 1 year postpartum, having breastfed exclusively 
for more than 4 months was significantly higher in the intervention cohort. We 
therefore conclude that the dietary intervention was successful; we observed a desired 
increase in intake of cod liver oil and oily fish, and no or minor change in intake of the 
dietary factors not intervened upon. 
 
7.1.3 Housing dampness intervention 
The reporting of indoor dampness was approximately 4% and was constant over and 
within the groups at 6 weeks and 1 and 2 years of age. The indoor housing dampness 
intervention resulted in no measurable effect in lowering the housing dampness in the 
intervention group. We found, however, a strong consistency in the reporting of indoor 
dampness, both over time and between the groups. This consistency might be 
interpreted as the questions used on housing dampness in the “Risk factor 
questionnaires” were repeatable and hence reliable.  
 
7.1.4 Conclusion of interventions 
The interventional programme was structured, repeated, multidisciplinary, and 
implemented within the framework of ordinary primary health care. Smoking behaviour 
was initially recorded and only families where mother or father smoked were offered 
smoking intervention. Dietary intervention and intervention on housing dampness were 
given to all families.  Why did the intervention lead to a change in behaviour as regards 
intake of cod liver oil and oily fish, but no change in behaviour leading to reduced 
housing dampness or smoking? 
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One explanation may be that the health workers, especially the health visitors, were 
familiar with and accustomed to informing mothers about diet during pregnancy and 
infancy. Indoor climate and housing dampness was a new issue for most of the health 
workers, however, and we also observed a small resistance against this topic amongst 
the health workers. The smoking intervention, too, was apparently a topic most health 
workers were already informing parents about, with success. The time trends were so 
strong, however, that it was difficult to measure any effect of the intervention.    
 
In conclusion, structured interventional programmes can be adapted and implemented 
within the framework of ordinary primary health care. Different health professions in 
primary health care can cooperate to bring about pre- and postnatal changes in life-style 
and risk/protective behaviour to reduce assumed risk for allergic disease in childhood.  
 
7.2 Reliability of questionnaire 
We chose to test the reliability of the questionnaire by comparing the parents’ answers 
with the information retrieved from medical records. This method has been widely used 
for both reliability testing and for validating questionnaires in other medical conditions, 
but to our knowledge, when we started, not for the diseases investigated in this study 
[117,118]. However, a similar approach to the one we used was used for comparison of 
clinically-diagnosed asthma with parent-reported doctor-diagnosed asthma in children 
aged 1–6 years in a Swedish study published in 2006[119]. ISAAC-based questions 
were also used in this questionnaire and the authors found that the written questionnaire 
was able to find 54% of the children with a medical record of asthma. The sensitivity of 
the questionnaire was 77%, the specificity was 97.5%. The prevalence of asthma was 
the same whether it was based on the written questionnaire or medical records, but 
nearly half of the individual asthmatics identified using the two approaches differed. 
Our approach was to look at agreement between medical records and parent-reported 
answers, not only for asthma, but also for other questions about which we could expect 
to find information in medical records. A first prerequisite for a correct classification of 
reported disease endpoints is that the information given is reliable. Diagnosis of atopic 
diseases such as asthma, eczema and ARC are based on the medical history, repeated 
consultations and knowledge of the child’s family and living conditions. As medical 
records give an overview of all contacts in primary and specialist care over time, 
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diagnosis of atopic diseases is probably best based on such information. We found 
excellent agreement for questions reporting factual information, such as if the child has 
had an allergy test and has been prescribed antibiotics together with specific diseases or 
doctor’s diagnosis of asthma. The latter is in accordance with findings in the 
Obstructive Lung Disease in Northern Sweden Study (OLIN study), where the same 
question was evaluated[18]. Also, in an another study that reliability tested questions on 
asthma, allergic rhinitis, and conjunctivitis in a Finnish questionnaire, the findings were 
similar[99]. The potential for classification errors, however, was considerable for 
questions on using treatment for skin rash or eczema, any medicines for allergic 
disease, and whether the child has been treated by a doctor or has been hospitalised for 
allergic disease/complaints. The most important issue was to distinguish between the 
information based on the parents’ opinions and experience and the information they 
have shared with and/or received from the health services on any level. Still, the 
deficiencies in the communication and in the understanding between parents and 
medical staff, and the shortcomings in updating the medical records, would impair the 
agreement. Knowledge of the agreement is, however, important as inferences of 
research results should include the possibilities of misclassification.  
 
Using medical records as a “reference standard” for disease prevalence is, however, 
only satisfactory provided physicians apply diagnostic criteria correctly. Whether the 
doctor-diagnosed diseases meet the standard criteria for the current diseases, and 
thereby the validity of the questionnaire, was studied in a separate endpoint and validity 
study (Paper III) The validity of answering “yes” to both questions: “Has your child 
ever had eczema?”, and “Has your child ever had an itchy rash which was coming and 
going for at least six months?”, compared with atopic dermatitis diagnosed by the UK 
criteria was estimated as sensitivity and specificity. The combination of “yes” to both 
questions had a sensitivity of 69.4% and a specificity of 88.7%[120]. We found that the 
agreement between information given by the parents in the form and information 
obtained by examining medical records was good to excellent for the questions 
estimating prevalence of disease. The questionnaire may possibly underestimate the use 
of anti-allergic medication, as well as doctor’s treatment for allergic disease. No 
question was overestimating the prevalence of allergic symptoms or medication use and 
we conclude that the new questionnaire was both reliable and valid for estimating the 
prevalence of the allergic diseases under study. 
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7.3 The association between fish oil and fish consumption and eczema and 
doctor-diagnosed asthma at two years 
In this present study we found a rather indifferent effect of maternal fish and cod liver 
oil intake during pregnancy on allergic disease in their offspring, and we observed no 
dose-response relationship. Previous studies have found that increased maternal intake 
of fish during pregnancy has a protective effect against the development of allergic 
diseases in their offspring[59,64]. However, Calvani et al. and Sausenthaler et al. did 
not account for the infant’s diet during the first year of life. We found a strong 
correlation between maternal diet during pregnancy (fish, vegetables and cod liver oil) 
and the infant’s diet at 1 year of age. Therefore, inferences on associations between 
maternal diet during pregnancy and subsequent development of allergy in offspring 
must be taken with caution as long as the infant’s diet is not accounted for.   
 
We found that the associations between cod liver oil intake during early childhood and 
any allergic disorder at 2 years of age were insignificant and inconsistent. Our results 
are in line with a large randomised controlled trial to test modification of n-6/n-3 
dietary intake in the first five years of life on children with a family history of asthma. 
The investigators were successful regarding change in the children’s plasma n-6/n-3 
ratio, but no effect on the prevalence of asthma, wheezing, eczema or atopy was 
found[63]. A Cochrane review also lends meagre support to the hypothesis that marine 
fatty acids have an allergy-protective effect[61]. This review did not address the issue 
of whether consumption of fish per se may improve asthma control due to some active 
component in fish other than fatty acids.  
 
When modification due to disease (or reverse causality) was accounted for, we found a 
strong and consistent negative association between fish intake early in life and parent- 
reported eczema at 2 years of age. The association was strongest for oily fish, but also 
statistically significant for any kind of fish. The association between lean fish and 
reported eczema was statistically insignificant. We observed no association between 
cod liver oil or oily fish and doctor-diagnosed asthma at 2 years. Our findings indicate 
that components in fish other than n-3 PUFA should be considered when seeking 
possible mechanisms in preventing allergic disorders. Fish constitutes important 
nutrients other than n-3 PUFAs, such as proteins (rich in essential amino acids), 
vitamins (A, D and B12), minerals (selenium and iodine), and trace elements beneficial 
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for children’s development. Perhaps a combination of n-3 PUFAs and unknown factors 
that we find especially in oily fish is necessary to achieve a protective effect.  
Equivalent to this hypothesis may be the findings in basic research and observational 
studies that have suggested that vitamin E or vitamin C may reduce the risk of 
cardiovascular disease. However, given as synthesised or extracted supplementation in 
randomised clinical trials, neither vitamin E nor vitamin C supplementation has shown 
a reduction in the risk of major cardiovascular events[121]. Is it best for human beings 
to eat natural foodstuffs? Eating natural food gives access to other components than 
those extracted and given as supplements. From our results, we cannot rule out that n-3 
PUFAs reduce the risk of asthma and eczema, but our findings certainly justify a search 
for other allergy-protective components in fish beyond n-3 PUFAs – either factors that 
have a protective effect themselves or in combination with n-3 PUFAs. 
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8 Conclusions 
Primary prevention to reduce risk factors for allergic diseases is possible in the frame of 
ordinary primary care, but there are some constraints. Given that the interventional 
topic is familiar to the health worker, as is the dietary intervention, it is possible to 
change behaviour, but when it comes to more unfamiliar topics like, for instance, 
indoor dampness; it seems difficult to change behaviour. The smoking intervention 
coincided with very strong time trends in smoking cessation, seven out of ten women 
stopped smoking early in pregnancy and few and perhaps just the most resilient 
smokers were left to intervene on. We observed no impact of the smoking intervention 
programme in pregnancy on the individual level, but the intervention may have 
contributed to a very high smoking cessation rate during the intervention period among 
the whole group of pregnant women in Trondheim, regardless of participation in the 
PACT study. The intervention programme may have given an additional impact to the 
legislation and national anti-smoking campaigns that took place during the study 
period. To achieve reduced smoking during pregnancy on a community level it seems 
important to maintain a “social” stress both through national and local anti smoking 
campaigns. On the other hand, on the individual level new approaches must be 
developed for the resilient pregnant smokers who do not quit despite the increasing 
social stigma. 
 
The questions we used to assess allergic disease among 2 year olds were reliable and no 
responses to questions were overestimating the prevalence of allergic disease. There is, 
however, a possibility that the responses to questionnaire underestimated the use of 
anti-allergic medication and doctor’s treatment for allergic disease.  
 
Consumption of cod liver oil and oily fish during pregnancy showed no association 
with reported eczema or doctor-diagnosed asthma in 2 year olds. Neither was intake of 
cod liver oil during infancy associated with reported allergic diseases at 2 years. Any 
kind of fish, and especially intake of oily fish at one year of age, however, showed a 
strong and consistent negative association with reported eczema at 2 years of age. We 
hypothesise that there may be some allergy-protective components in fish other than or 
in addition to n-3 PUFAs that act either alone or in combination with n-3 PUFAs. Our 
findings certainly justify searching for this unknown component. 
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9 Further research 
9.1 Within PACT 
Further research in PACT will first focus on the effectiveness of the intervention on the 
incidence of disease and sensitisation, first assessed at 2 years, then at 6 years of age. 
As mentioned in the introduction, the design of the PACT study is well suited for 
conducting sub-studies, and two sub-studies are ongoing. The IMPACT study can 
supply new information on aetiological factors and pathogenetic mechanisms in allergic 
diseases, in particular, in respect to the relationship between microbial exposure early 
in life, immunological development and allergic disease. These results can 
subsequently be used in designing new prophylactic strategies in primary prevention of 
asthma, eczema and rhinitis. 
 
The other sub-study, the probiotic study in PACT (ProPACT) intends to test earlier 
findings that probiotics has a substantial clinical effect on eczema, but no effect on 
sensitisation. This study will provide new insight in the possible underlying 
immunological or anti-inflammatory mechanisms regulating the prevalence of eczema.  
 
9.2 Other questions to be solved outside PACT 
The ISAAC study has documented considerable variation in disease prevalence 
between east and west, rural and urban areas, the poor and the rich[5,7]. The risk 
factors investigated so far do not have a geographic or socio-economic presence to 
explain these differences in allergy prevalence. This necessitates a search for new or 
lost environmental factors, distributed in a way that can explain these variations in 
disease prevalence[2,5,8]. 
 
How does immunity develop in new-borns and infants? What are the gene/environment 
interactions? What might be the determinants and critical periods for this development? 
How might the relationship between certain exposures and immunological development 
influence the prevalence of allergic diseases[122]? The PACT study may give answers 
to some of these questions, but many have to be solved outside the PACT study and 
sub-studies.  
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Abstract  
Background 
This study aimed to evaluate the impact of a primary prevention intervention program on risk 
behavior for allergic diseases among children in a pre- and postnatal primary healthcare 
setting. 
Methods 
The Prevention of Allergy among Children in Trondheim, Norway (PACT). study invited all 
pregnant women and parents to children up to 2 years of age in the community to participate 
in a non-randomized, controlled multiple life-style intervention study aiming to increase 
dietary intake of cod liver oil and oily fish for women during pregnancy and for infants during 
the first 2 years of life, to reduce parental smoking and to reduce indoor dampness. A control 
cohort with “follow up as usual” was established before the intervention cohort. 
Questionnaires were completed for both cohorts in pregnancy, 6 weeks after birth and when 
the children were 1 and 2 years of age. Trends in exposure and behavior are described. 
Results 
Intake of oily fish and cod liver oil increased statistically significantly among women and 
infants in the intervention cohort compared to the control cohort. There was a low postnatal 
smoking prevalence in both cohorts with a trend towards a decreasing smoking prevalence in 
the control cohort.  There was no change in indoor dampness or in behavior related to non- 
intervened life-style factors.  
Conclusions 
The dietary intervention seemed to be successful. The observed reduced smoking behavior 
could not be attributed to the intervention program, and the latter had no effect on indoor 
dampness.  
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Background  
A parliamentary bill was presented in 1997 to initiate preventive measures against the rising 
incidence of asthma, allergy and eczema among Norwegian children during the last decades. 
Trondheim was chosen to develop, implement and evaluate relevant prophylactic measures in 
collaboration between the political and medical authorities in the community and the 
Norwegian University of Science and Technology (NTNU). Such interventions should be 
transferable to other communities for implementation in primary health care without extra 
cost or time-expenditure.  The recognized adjuvant factors of dietary N-3 polyunsaturated 
fatty acids (N-3 PUFAs) [1,2] smoking and environmental second hand smoke (SHS) [3,4], 
and indoor dampness [5,6] associated with morbidity and severity of allergic disease were 
chosen as interventional topics. An applicable and structured interventional program for  
simultaneous intervention on all three factors was then developed. A primary assignment was 
to find out to what extent pregnant women and parents would comply with the behavior 
recommendations in the intervention program when implemented in a real-life setting. Thus 
the study aimed to evaluate the impact of a primary prevention intervention program on risk 
behavior for allergic diseases among children in a pre- and postnatal primary healthcare 
setting in Trondheim, Norway. 
 
Methods 
Study population 
In 2000 the PACT study was initiated as a cohort study in primary health care in Trondheim, 
Norway, a community of 165 000 inhabitants and approximately 2100 deliveries per year. 
Prophylactic measures to induce behavioral changes regarding tobacco smoking, consumption 
of cod liver oil, oily fish, and indoor dampness were developed in collaboration between 
general practitioners (GPs), midwives, public health visitors and parents using a Delphi 
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technique[7]. In all, 32 of 35 general practices (altogether 104 GPs), all seven community 
based midwifes and all 20 maternity health centers in Trondheim agreed to participate. 
Admission to a control cohort to monitor changes and trends in lifestyle and diet habits and 
trends in incidence of allergic diseases started in September 2000. These women had a 
“follow up as usual”. All women who received an invitation and gave written informed 
consent to participate were included in the study with no further selection criteria. Yearly 
cohorts of pregnant women, children at 6 weeks, 1 year and 2 years of age were recruited 
consecutively until recruitment to the intervention started for the actual year-group, and the 
last 2 year old was included in December 2004.  Information on risk factors and life-style 
were collected in parental self-reported questionnaires in ordinary consultations during 
pregnancy, 6 weeks after birth and at scheduled check-ups at 1 and 2 years of age. End points 
such as allergic disease together with a health inventory were completed in separate 
questionnaires at 2 and 6 years of age[8].  
Recruitment to the intervention cohort started in June 2002, with all participants included by 
GPs and midwifes during pregnancy. Inclusion criteria were as for the control cohort, with a 
follow up and data collection with the same questionnaires at the same ages as in the control 
cohort. This inclusion ended in June 2006. The collection of questionnaires at 2 years after 
birth was completed in March 2009. The data collection will continue until the children are 6 
years old, providing cross-sectional data in both cohorts permitting estimates for trends in 
exposure, behavior and disease.   
 
Interventional topics and strategies 
Increased N-3 PUFAs to pregnant women and children was of considerable interest before the 
study started[1,2]. In Norway a daily supplement of cod-liver oil is very common and already 
recommended for children and adults alike. In the intervention program we aimed for a 
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dietary intake of N-3 PUFAs of at least two meals of oily fish a week and 5 ml cod-liver oil a 
day in pregnancy (5 ml cod liver oil = 1.2 g N-3 PUFA).  Cod liver oil was to be introduced to 
the child from 4-6 weeks of age increasing to 5 ml/ day, and oily fish at least twice a week 
from 6 months of age as dinner or sandwich spread. We did not intervene on intake of 
vegetables, breastfeeding, formula or other dietary factors. 
Reduced SHS exposure was chosen, recognizing the harmful effects of tobacco smoke 
exposure to pregnant women, mothers and small children as a generally accepted and 
avoidable risk factor[9,10]. The group adapted a clinic-based brief “5A” office intervention 
based on the “A Clinical Practice Guideline for Treating Tobacco Use and 
Dependence”[11,12].    
Reduced indoor dampness was chosen as the relatively cold and humid climate in central 
Norway predisposes to high indoor dampness and because the scientific basis for an 
intervention on indoor dampness was well founded when the study started [13,14]. The 
interventional strategy provided advice on how to detect, and advice on how to reduce indoor 
dampness and its consequences: Simple advice regarding inspection of signs of dampness as 
damage due to moisture on walls and floors, mould and/or musty smell, and solutions such as 
simple ventilation by opening windows regularly and avoiding drying of clothes in living 
rooms were recommended.  
 
Implementation 
In Norway the normal schedule at the time constituted of 8-10 prenatal consultations with a 
GP or midwife from week 8-10 in pregnancy followed by 10 postnatal consultations with 
public health visitors at maternity care centers during the child’s first year of life. Thereafter 
the schedule was to see all children at 15 and 24 months. Children regarded at risk for disease 
were seen more often. The intervention program was implemented as the recommended 
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maternity care life-style counseling program throughout the city, regardless of participation in 
the PACT-study or not. The officially recommended time-schedule for primary care pre- and 
postnatal follow-ups in Norway was followed for both cohorts. This program was accessible 
and recommended for all women, free of charge, and with a nation-wide attendance rate of 
nearly 100 % in both urban and rural areas. The interventions were repeated at scheduled 
consultations throughout pregnancy until 2 years postnatal, either simultaneously or 
sequentially, at least five times for each topic both pre- and postnatal, assuming no extra time 
expenditure. All participating GPs, midwives and nurses were offered a course on the 
interventional program and strategies, including a three hours course on smoking cessation 
and relapse prevention to ensure a consistent intervention and improve on possible low self-
confidence in life style counseling skills [15].  Written guidelines, including self-help 
material, were distributed to all primary care health professionals and the intervention was 
designed to be the best of one’s ability be delivered as an integrated part of ordinary maternity 
care in a personalized and individually adapted way, based on possible former knowledge of 
the family in question. The intention was to obtain awareness, agreement, adoption and 
adherence to the interventional topics both for health professionals and recipients. 
Interference with the health professionals and participants from the study-group was limited 
to what might have been expected from officials in ordinary clinical practice. In accordance 
with this there was no monitoring of the implementation of the intervention program activity 
among the health professionals in the intervention group.  
 
Questionnaires  
Exposure variables 
Validated questionnaires for the actual age-group were not available at the time, so questions 
were adapted from various sources [16-21]. Information regarding age for introduction of a 
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variety of food products, including different kinds of porridge, bread, vegetables, fruit, 
commercially produced baby dinner, homemade baby dinner, fish, cows’ milk, and eggs were 
obtained when the children were 1 year of age. Duration of breastfeeding, time for 
introduction and type of infant formula, vitamins and cod liver oil, information on housing 
conditions, parental smoking at start of pregnancy and 1 year after birth, indoor smoking, and 
pregnancy related complications were collected. Information on consumption of vegetables, 
cod liver oil, lean fish (cod and coalfish) and oily fish (redfish, halibut, salmon, trout, herring 
and mackerel) as dinner and sandwich spread were collected by using validated semi 
quantitative food frequency questions with six categories: never, less than once a week, once 
a week, twice a week, three times a week and four times a week or more, and re-categorized 
later in the analyses[22,23].  
Parental smoking during pregnancy was assessed with two questions where the women were 
asked if they or their partner were smoking at start of pregnancy, if they were smoking now 
and daily and/or weekly cigarette consumption. A separate question was asked about the total 
numbers of cigarettes smoked indoors. Smoking was coded as a dichotomous variable, if 
subjects were smoking more than one cigarette a week they were coded as smokers, if the 
answer was no they were coded as non-smokers, and if the answers to all questions on 
smoking were missing they were coded as missing.  
Housing conditions and indoor dampness were assessed with one question asking for eight 
different indicators on indoor dampness, as mould or musty smell, moist cardboard and 
newspapers after storage, dew on windows, moist spots on ceilings, walls or wallpapers, 
leakage detection on water pipes or faucet, leakage from roof or ground, or moisture in floors.  
Dampness index was defined by the sum of reported dampness indicators with a sum ≥3 as 
cutoff.  
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Outcome variables 
The questionnaire on health was completed when the child was 2 and 6 years old and adapted 
to our age group from ISAAC [24]. This questionnaire was tested for reliability in a separate 
study [25]. No biomarkers regarding nicotine, fatty acids or indoor dampness were used. 
Non-participant study 
To investigate if there was a selection bias in the PACT-study we conducted an additional 
non-participants-study where 391 parents who consecutively visited different maternal 
postnatal care centers  were asked to complete a short and anonymous questionnaire on age, 
socioeconomics, allergic disease and smoking behavior, and if they were participating in the 
PACT-study or not. 
 
Approvals  
The Regional Committee for Medical Research Ethics for Central Norway approved of the 
study (Ref 120-2000). The study was granted a licence by the Norwegian Data Inspectorate to 
process personal health data and one of the parents signed a written informed consent formula 
(Ref 2003/953-3 KBE/-). 
 
Statistical analysis 
Reporting and analyses are presented according to recommendations in TREND [26]. To 
estimate a change in exposure before and after implementing the intervention program, 
parental reports on behavior both intervened and not intervened upon were compared. 
Population size in the intervention cohort was based on a prevalence of asthma among 6 years 
old children estimated to 5%. To identify a reduction in prevalence of 40 % or more, the 
population size had to be 2100 children (Alfa 0.05 and a power of 90%). With an expected 
30% lost to follow up we needed to include 3000 children in the intervention cohort.  
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SPSS for Windows® ver.15.0 (Chicago, Ill. USA) was used for all statistical analyses.  Cross- 
sectional data were collected for annual cohorts using questionnaires Q2, Q3 and Q4 (Fig. 1). 
With binary logistic regression models prevalence of exposure factors throughout the study 
period was used to estimate p for trend in both cohorts. Comparisons between the cohorts 
were tested with the Chi-square statistics for binomial data and independent t-test for 
continuous data. Confidence interval (CI) was based on binomial distribution for dichotomous 
data, and normal distribution for continuous data. Level of significance was set to p = 0.05, 
two-tailed. Comparisons between the cohorts were performed for women during pregnancy 
and breastfeeding and for children during first and second year of life.   
Confounding factors were identified by a priori knowledge, and maternal age, parity, parental 
allergic disease and homeowner status were tested in several models and decided as the 
resulting set of covariates.  
 
Results  
Population 
There were no differences regarding maternal age, gender, and birth weight between the 
cohorts.  In the intervention cohort there were fewer primiparous and single women, they had 
somewhat longer education, fewer of the parents had allergic disease and there were more 
homeowners (Table 1).  
Behavioral changes 
The dietary intervention 
During pregnancy the intake of cod liver oil more than four times a week increased 
significantly from 42% to 66% in the intervention group compared to the control group  
(Table 2). The women also ate both oily fish and lean fish more often during pregnancy in the 
intervention group compared to the control group, and there were no time trends regarding 
diet during pregnancy either in the intervention group or in the control group (Table 2).  
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Among the children we found a very high and equal proportion of approximately 60% having 
cod liver oil supplement at 6 weeks postnatal in both cohorts (Table 2). During the first 2 
years of life the proportion of infants continuing the cod liver oil supplement was about 10 
percentage points higher in the intervention cohort (Tables 3-4). The proportion having oily 
fish at least once a week was about 14 percentage points higher at 1 year and 2 years of age in 
the intervention group compared to the control group (Tables 3-4), and there was a positive 
time trend for eating oily fish in both cohorts at 1 and 2 years of age. There was a statistically 
significant higher intake of lean fish in the intervention cohort at 1 year postnatal, changing to 
a significantly higher intake in the control cohort at 2 years of age with no time trend in either 
cohort. The overall fish intake at one year of age was higher in the intervention cohort, but at 
2 years of age the difference was no longer statistically significant (Tables 3-4).  
Smoking intervention 
A significant and stable decline in maternal and paternal smoking frequencies was reported 
from start of pregnancy, through 6 weeks postpartum, and at 1 and 2 years postnatal (tables 2-
4). The smoking frequency was almost halved at all four assessment points of time in the 
intervention cohort compared to the control cohort with a minimum for maternal smoking of 
5,3% at 6 weeks postnatal and a minimum of 11,5% for paternal smoking at 2 years postnatal. 
There was a continuous annual trend for reduced parental smoking in the control cohort, but 
no further annual trend in reduced postnatal parental smoking in the intervention cohort at 1 
and 2 years after birth (tables 2-4).  
Housing dampness intervention 
Indoor dampness index ≥3 was reported by approximately 4% of the participants and constant 
over and within both cohorts at 6 weeks, 1 and 2 years of age (tables 2-4). 
Change in non-intervened risk factors 
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While there was a reported frequency of some 8%-10% keeping a dog, stable between the 
cohorts and over time, the frequency of keeping a cat was some 2 percentage points higher in 
the intervention cohort at six weeks, at 1 and 2 years (Tables 2-4). 
The proportion of children who ate vegetables almost daily was inconstantly different 
between the cohorts. At 1 year, relatively fewer children had vegetables almost daily in the 
intervention cohort, while at 2 years there was no difference (Tables 3-4).  The frequency of 
breastfeeding at 6 weeks did not differ between cohorts, while the proportion of mothers that 
reported at 1 year to have breastfed exclusively for more than 4 months was significantly 
higher in the intervention cohort (Tables 2 - 3).  
The non-participants-study 
The comparison of participants in the PACT-study (n= 172) with non-participants (n=219), 
demonstrated only minor and insignificant differences regarding mean age and education. 
There was a tendency towards reporting more allergic disease and less smoking at start of 
pregnancy among participants in PACT, but this difference was not statistically significant 
(Table 5). 
Discussion 
Pregnancy and the first years of life is a period of frequent contact with health professionals 
and a favorable period for implementing relevant life-style interventions. The PACT study 
was conducted over an 8 years period with a historical control cohort established over a 2 
years period immediately before the intervention started. The results showed that the dietary 
intake of lean and oily fish and cod liver oil was statistically significant higher in the 
intervention cohort, both for mothers during pregnancy and for children during the first 2 
years of life. Parental smoking prevalence was generally low postnatal, particularly among the 
mothers, with a statistically significant difference between the cohorts. There was, however, a 
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statistically significant annual trend in the control cohort. There was no difference between 
the cohorts regarding an indoor dampness index ≥ 3. 
The comparisons at different age levels permit presentation of behavioral trends. A behavioral 
trend in the control cohort or in both cohorts simultaneously implies that a possible difference 
between the cohorts must be interpreted with caution and that other explanations than the 
intervention program should be considered.  
Parents in the intervention group seemed to be more persistent in continuing cod liver oil 
supplement for their infants. There was an annual trend towards increased oily fish intake 
among children in both cohorts during first 2 years of life probably reflecting a gradual 
introduction of fish in the diet for all children. There was, however, a persistent and 
significant difference in oily fish intake between the cohorts at both 1 and 2 years and a shift 
towards an increased share of lean fish in the diet in the control cohort during the period. A 
probable interpretation of this may be that oily fish was substituted for lean fish in the 
children’s diet in the intervention group, which was in accordance with the intervention 
program.  
The low smoking prevalence and annual trend towards less smoking in both cohorts during 
pregnancy are in accordance with earlier findings showing significantly increasing difference 
in smoking cessation between pregnant women in Trondheim and the comparable city of 
Bergen and all of Norway in the actual time period [12]. The PACT study period coincided 
with new legislation on smoking in public places and ongoing national campaigns against 
smoking.  The increased smoking cessation rate observed among pregnant women in 
Trondheim compared to Bergen and Norway  could possibly be a consequence of the ongoing 
PACT-project as such, with the increased focus on life-style factors during pregnancy and 
infancy in general and smoking cessation in particular. Interestingly, the continuous smoking 
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intervention did not seem to have any additional effect on the few remaining smokers in the 
intervention group.  
We observed no difference in the housing dampness index between the cohorts. This may 
reflect a low adherence to the housing dampness intervention. Indoor climate was an 
unknown and unaccustomed subject for intervention among both health professionals and 
recipients. Even more expensive and extensive actions as improved roofing and drainage of 
buildings could have been recommended, but the program had no resources to follow up on 
this level. The stable fraction of approximately 4% reporting indoor dampness index ≥ 3 
within and between both cohorts at all ages indicates that the question on this topic was highly 
reliable.  
The strengths of the study are the controlled cohort design with a large number of pregnant 
women followed prospectively in the intervention cohort, and the assessment of risk-factor 
behavior that was consistent through the observation period and across cohorts. The non-
randomized design was adapted to comply with the assignment to investigate the 
effectiveness of interventions implemented in the way new guidelines usually are in ordinary 
primary health care[27]. We decided on a design with a control cohort 1 year in advance of 
the intervention primarily because a public and community based intervention including the 
entire primary health care in the municipality would have been impossible to implement 
without contaminating a co-existing control cohort.  Secondly, this design also ensured high 
conformity between the cohorts regarding population size, race/ethnicity, maternal 
educational level, income, environment, urbanization and social characteristics [28]. This was 
supported by the results from the additional non-participants-study that included 391 subjects, 
indicating no major selection bias.  Only self reported questionnaires were used, as this is a 
common and feasible way of assessing information in large epidemiologic studies[21,29]. For 
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smoking behavior self reported questionnaires are known to have equal or better reliability, 
compared to interviews using a structured questionnaire [30,31].  
A potential weakness may be that the cohort design with a 1 year difference between the 
control cohort and intervention cohort might have biased the results toward a better 
effectiveness of the intervention as a consequence of possible annual trends. Although the 
intervention program was adopted as the official prophylactic program in the community, and 
nearly 100% of pregnant women visit their GP regularly, only some 34% of the eligible 
pregnant women participated in the PACT study. The moderate participation rate was a 
consequence of the long duration of the study resulting in a decreasing awareness of the 
study[32] causing low participation among many GPs and midwifes in the community, and 
not as a result of self selection among participants. Importantly, we had almost no 
withdrawals in either cohort. Moreover, we deliberately did not monitor how far the health 
care providers implemented the interventions or followed the guidelines. Such a registration 
procedure could in effect be an intervention to improve the interventional efforts among the 
health professionals, thereby not complying with the need that the intervention program 
should be transferable to primary health care in other communities without extra cost or time 
expenditure. The implementation strategies were considered modest in accordance with the 
real-life demand, and the effectiveness of the interventional program was exclusively based 
on parental self-reported risk-factor behavior questionnaires [33,34].  
Conclusions  
GPs, midwives, health visitor nurses and parents in the community were jointly responsible 
for developing an intervention program that were implemented as an official community 
strategy in primary health care without extra cost or time expenditure. The dietary 
intervention to increase the intake of cod liver oil and oily fish in pregnancy and among 
mothers and children first 2 years was successful. The observed reduced smoking behavior 
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could not be attributed to the intervention, and there was no effect of the intervention on 
indoor dampness. Investigations to develop strategies for successful interventions in primary 
health care are still needed. 
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A total of 7845 participants in the control cohort completed 13647 self-reported questionnaires from 2002-2005.  
The intervention cohort was completed in March 2009. 
* Total population of children born in Trondheim during inclusion period. 
Q1=Questionnaire on behavior and risk factors at first antenatal check-up during pregnancy 
Q2=Questionnaire on behavior and risk factors at 6 weeks of age.  
Q3=Questionnaire on behavior and risk factors at 1 year of age. 
Q4=Questionnaire on behavior and risk factors at 2 years of age  
In this paper Q2, Q3 and Q4 in both cohorts have been used. 
Control cohort  
(Cross-sectional) 
 
Children 6 weeks postnatal: 
N*=4900 
 
Inclusion: 
Started September 1st 2000 
Stopped March 30th 2003 
Control cohort  
(Cross-sectional) 
 
Pregnant women at first 
antenatal check-up: 
N*=3675 
 
Inclusion: 
Started September 1st 2000 
Stopped May 30th 2002 
Control cohort  
(Cross-sectional) 
 
Children 2 years postnatal: 
N*=9100 
 
Inclusion: 
Started September 1st 2000 
Stopped March 30th 2005 
Questionnaire Q3 
n=3892 
Control cohort  
(Cross-sectional) 
 
Children 1 year postnatal: 
N*=7000 
 
Inclusion: 
Started September 1st 2000 
Stopped March 30th 2004 
Questionnaire Q4  
 n=4823 
 
Intervention cohort 
(Cross sectional follow-up) 
 
Pregnant women at first 
antenatal check-up:  
N*=8400 
 
Inclusion  
Started June 1st 2002 
Ended June 30th 2006 
Questionnaire Q2 
n=1685 
Questionnaire Q3 
n=1214 
Questionnaire Q4 
n=1267  
 
Questionnaire Q2  
n=3142 
Questionnaire Q1 
n=1790 
Questionnaire Q1 
n=2860 
n=1685 
n=1004 
n=868 
n=210 
n=107 
n=292 
Fig 1. Flow-chart for the PACT-study 2000 - 2009 
Table 1. Characteristics of parents and children participating in the intervention cohort 
and the control cohort  
 
 
 
Cohorts 
 Intervention  Control  
 Mean (SD) 
Age mother (years) 29,5 (4,3) 29,2(4,7) 
Education mother 
(years) 15,7 (2,5) 15,4 (2,6) 
Education father 
(years) 15,1 (2,9) 15,0 (3,1) 
Birthweight (grams) 3610 (544) 3590 (573) 
 N (%) p-value 
Gender (male) 48,4 50,1 0,16 
Primiparous 44,9 52,2 <0,001 
Single mother 1,9 4,3 <0,001 
Parental atopy* 68,5 69,4 0,56 
Homeowner** 84,1 78,5 <0,001 
*Mother and /or father  ever had asthma, allergic rhinoconjunctivitis or eczema. 
** At 6 weeks postnatal 
 
 
 
Table 2.  Different exposure and risk behaviours assessed at 6 weeks after birth and the change in annual prevalence for the intervention  
cohort and for the control cohort (PACT 2009). 
 
 
Comparisons of risk behaviour between the intervention cohort and the control  cohort are presented as OR with 95% CI (Based on logistic regression).  
Change in annual prevalence (intervention cohort 2004-2007, control cohort 2000-2003) presented as p- value for trend.  
*Adjusted for maternal age, parity, parental atopy and homeowner. 
 Intervention Cohort (n = 1685) Control Cohort (n = 3142) 
 Rate % 95% CI P trend* Rate % 95% CI P trend* OR* 95% CI 
At start pregnancy 
Maternal smoking 283/1636 17.3 15.5-19.2 0.001 702/2969 23.6 22.2-25.2 0.01 0.70 0.60-0.82 
Paternal smoking 292/1594 18.3 16.5-20.3 0.001 652/2803 23.3 21.7-24.9 0.03 0.80 0.68-0.94 
During pregnancy 
Maternal cod liver oil intake 4 times a week or 
more 1098/1660 66.1 63.8-68.4 0.59 1288/3055 42.2 40.4-43.9 0.16 2.44 2.15-2.78 
Maternal oily fish intake once a week or more  624/1553 40.2 37.8-42.6 0.61 858/2812 30.5 28.8-32.2 0.36 1.51 1.32-1.72 
Maternal lean fish intake once a week or more  658/1666 39.5 37.2-41.9 0.61 807/3055 26.4 24.9-28.0 0.40 1.80 1.58-2.06 
Maternal vegetable almost daily 876/1476 59.3 56.8-61.9 0.25 1548/2704 57.2 55.4-59.1 0.15 1.06 0.93-1.21 
At 6 weeks after birth 
Maternal smoking 87/1634 5.3 4.3-6.5 0.002 317/2934 10.8 9.7-12.0 <0.001 0.55 0.42-0.70 
Paternal smoking 200/1587 12.6 11.1-14.3 0.04 593/2768 21.4 19.9-23.0 0.01 0.59 0.49-0.70 
Keeping dog in house  142/1566 9.1 7.7-10.6 0.69 289/2826 10.2 9.16-11.4 0.95 0.83 0.67-1.03 
Keeping cat in house  174/1566 11.1 9.7-12.8 0.58 251/2826 8.9 7.9-10.0 0.90 1.32 1.07-1.64 
Indoor dampness Index ≥ 3 69/1672 4.1 3.3-5.2 0.66 129/3062 4.2 3.6-5.0 0.88 1.08 0.79-1.46 
Breastfeeding  1644/1665 98.7 98.1-99.2 0.39 3061/3110 98.4 97.9-98.8 0.81 1.00 0.59-1.71 
Child having cod liver oil supplement 1011/1665 60.7 58.4-63.0 0.57 1786/3102 57.6 55.8-59.3 0.66 1.03 0.93-1.21 
Table 3. Different exposure and risk behaviours at 1 year after birth and the change in annual prevalence for the intervention cohort and for 
the control cohort (PACT 2009). 
 
 
 
 
Comparisons of risk behaviour between the control cohort and the intervention cohort are presented as OR with 95% CI (Based on logistic regression).  
Change in annual prevalence (intervention cohort 2005-2008, control cohort 2000-2004) presented as p- value for trend. 
*Adjusted for maternal age, parity, parental atopy, homeowner. 
 Intervention Cohort (n = 1214) Control Cohort (n = 3892) 
 Rate % 95% CI P trend* Rate % 95% CI P trend* OR* 95% CI 
At 1 year after birth 
Maternal smoking 105/1198 8.8 7.3-10.5 0.17 720/3755 19.2 18.0-20.5 <0.001 0.47 0.38-0.59 
Paternal smoking 148/1144 12.9 11.1-15.0 0.15 724/3468 20.9 19.6-22.3 <0.001 0.64 0.52-0.77 
Keeping dog in house 95/1139 8.3 6.9-10.1 0.11 318/3560 8.9 8.0-9.9 0.74 0.90 0.71-1.16 
Keeping cat in house 122/1139 10.7 9.0-12.7 0.87 312/3560 8.8 7.9-9.7 0.46 1.33 1.06-1.67 
Indoor dampness index 47/1205 3.9 2.9-5.2 0.44 158/3800 4.2 3.6-4.8 0.27 1.00 0.72-1.41 
Children’s diet at 1 year of age 
Exclusively breastfed 4 months or more 957/1206 79.4 77.0-81.5 0.008 274/3856 71.1 69.6-72.5 0.14 1.46 1.25-1.72 
Cod liver oil 4 times  a week or more 568/1209 47.0 44.2-49.8 0.34 1497/3858 38.8 37.3-40.4 0.77 1.27 1.11-1.46 
Any kind of fish once a week or more 712/1213 58.7 55.9-61.4 0.03 1879/3872 48.5 47.0-50.1 0.06 1.53 1.33-1.74 
Oily fish once a week or more 445/1213 36.7 34.0-39.4 0.02 908/3878 23.4 22.1-24.8 <0.001 1.88 1.63-2.17 
Lean fish once a week or more 582/1204 48.3 45.5-51.2 0.29 1679/3855 43.6 42.0-45.1 0.46 1.24 1.08-1.42 
Vegetables almost daily 889/1198 74.2 71.7-76.6 0.76 2910/3814 76.3 75.0-77.7 0.79 0.87 0.74-1.01 
Table 4. Different exposure and risk behaviours at 2 years after birth and the change in annual prevalence for the intervention  
cohort and for the control cohort (PACT 2009). 
 
Comparisons of risk behaviour between the control cohort and the intervention cohort are presented as OR with 95% CI (Based on logistic regression).  
Change in annual prevalence (intervention cohort 2006-2009, control cohort 2000-2005) presented as p- value for trend. 
*Adjusted for maternal age, parity, parental atopy, homeowner. 
 
 
 Intervention Cohort (n = 1267) Control Cohort (n = 4826) 
 Rate % 95% CI P trend* Rate % 95% CI P trend* OR* 95% CI 
At 2 years after birth 
Maternal smoking 123/1244 9.9 8.4-11.7 0.87 885/4661 19.0 17.9-20.1 <0.001 0.50 0.41-0.61 
Paternal smoking 136/1183 11.5 9.8-13.4 0.11 760/4217 18.0 16.9-19.2 <0.001 0.62 0.51-0.75 
Keeping dog in house 96/1198 8.0 6.6-9.7 0.53 368/4403 8.4 7.6-9.2 0.23 0.95 0.75-1.21 
Keeping cat in house 133/1198 11.1 9.4-13.0 0.41 398/4403 9.0 8.2-9.9 0.71 1.31 1.06-1.62 
Indoor dampness index 46/1259 3.7 2.7-4.9 0.10 170/4740 3.6 3.1-4.2 0.11 1.03 0.74-1.45 
Children’s diet at 2 years of age 
Cod liver oil 4 times  a week or more 539/1257 42.9 40.2-45.6 0.43 1609/4767 33.8 32.4-35.1 0.80 1.44 1.27-1.64 
Any kind of fish once a week or more 926/1258 73.6 71.1-76.0 0.87 3398/4782 71.1 69.8-72.3 0.96 1.13 0.98-1.30 
Oily fish once a week or more 625/1264 49.4 46.7-52.2 0.04 1679/4809 34.9 33.6-36.3 <0.001 1.85 1.63-2.10 
Lean fish once a week or more 768/1256 61.1 58.4-63.8 0.61 3086/4776 64.6 63.3-66.0 0.07 0.85 0.75-0.97 
Vegetables almost daily 630/1252 50.3 47.6-53.1 0.25 2340/4735 49.4 48.0-50.8 <0.001 1.01 0.89-1.15 
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Abstract
Background: There is a demand for strategies to promote smoking cessation in high-risk
populations like smoking pregnant women and their partners. The objectives of this study were to
investigate parental smoking behaviour during pregnancy after introduction of a prenatal,
structured, multi-disciplinary smoking cessation programme in primary care, and to compare
smoking behaviour among pregnant women in the city of Trondheim with Bergen and Norway.
Methods: Sequential birth cohorts were established to evaluate the intervention programme from
September 2000 to December 2004 in primary care as a part of the Prevention of Allergy among
Children in Trondheim study (PACT). The primary outcome variables were self reported smoking
behaviour at inclusion and six weeks postnatal. Data from the Medical Birth Registry of Norway
(MBR) were used to describe smoking cessation during pregnancy in Trondheim, Bergen and
Norway 1999–2004.
Results: Maternal smoking prevalence at inclusion during pregnancy were 5% (CI 95% 4–6) in the
intervention cohort compared to 7% (CI 95% 6–9), p = 0.03, in the control cohort. Of the pre-
pregnancy maternal smokers 25% (CI 95% 20–31) and 32% (CI 95% 26–38), p = 0.17, were still
smoking at inclusion in the intervention and control cohorts, respectively. Six weeks postnatal 72%
(CI 95% 59–83) and 68% (CI 95% 57–77), p = 0.34 of the maternal smokers at inclusion still
smoked. No significant difference in paternal smoking between the cohorts was found after the
intervention period. Data from the MBR showed a significantly higher proportion of women who
stopped smoking during pregnancy in Trondheim than in Bergen in 2003 and 2004, p = 0.03 and <
0.001, respectively.
Conclusion: No impact on parental smoking behaviour between the cohorts was observed after
the smoking intervention programme. Of the women who stopped smoking during pregnancy most
of them stopped smoking before the intervention. However, we observed a significantly higher
quitting rate in Trondheim than in Bergen in 2003 and 2004 which may have been facilitated by the
supplemental attention on smoking behaviour the PACT study initiated.
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BMC Public Health 2008, 8:325 http://www.biomedcentral.com/1471-2458/8/325Background
Smoking in pregnancy is a well documented and poten-
tially avoidable risk factor for a multitude of conditions,
including miscarriage, low birth weight, perinatal death,
childhood asthma and atopic disease [1-3]. Despite evi-
dence-based knowledge of the harmful effects, tobacco
smoking is still prevalent during pregnancy.
Prevalence studies in the 1980s showed that one in three
pregnant women in Norway smoked during pregnancy, at
that time among the highest smoking prevalence in
Europe [4-6]. Eriksson et al. showed that the point preva-
lence of smoking at 18 weeks of gestation in Trondheim
was 34% in 1987 compared to 22% in 1994, a statistically
significant reduction. No effect of the national campaign
against smoking during pregnancy launched in 1989 was
found [7]. Public health interventions and smoking bans
have since then shown success in some Western countries
[8]. Norway has a history of more than 40 years of regula-
tion of tobacco advertising and tobacco smoking in pub-
lic. The 1975 Tobacco Act involved an advertising ban, 16
years age limit for buying tobacco products and labelling
of tobacco products. Restrictions on smoking in public
restaurants, bars, cafes, pubs and discotheques came in
1993, but a total ban on smoking in restaurants and bars
first took effect on June 1st 2004. The first national com-
prehensive mass media campaign on tobacco and health
for many years was accomplished during the study period
in 2003.
A review article from 2000 stated that pregnancy and the
postpartum period provide a window of opportunity to
promote smoking cessation[9]. A Cochrane review from
2004 concluded that smoking cessation programmes in
pregnancy reduce the proportion of women who continue
to smoke [10]. Further, a meta analysis from 2000 found
that a brief cessation counselling session of 5–15 minutes,
when delivered by a trained provider with the provision of
pregnancy specific self help materials, significantly
increased rates of cessation among pregnant smokers, and
these evidence based procedures were recommended to
be adopted by all prenatal health care providers [11].
In 1997 the Norwegian Government appointed Trond-
heim as a model city to try out a new public intervention
to counteract the rising incidence of asthma and allergic
diseases. It was a prerequisite that the intervention pro-
gramme should be possible to implement in ordinary pre-
and postnatal care, without extra cost, and within normal
consultation timeframe. The PACT-study was initiated in
collaboration between the Norwegian University of Sci-
ence and Technology (NTNU) and the municipality of
Trondheim. The PACT study is a still ongoing, controlled,
prospective, intervention study that was started in 2000
[12]. The primary objectives of the PACT study were to
investigate the effectiveness of the risk-factor intervention
on behavioural changes among parents, secondly to
investigate the efficacy on the incidence of allergic dis-
eases in the offspring from increasing omega-3- fatty acid
intake and reducing parental smoking and indoor damp-
ness [13].
The objectives of this study were to investigate parental
smoking behaviour during pregnancy after introduction
of a prenatal, structured, multi-disciplinary smoking ces-
sation programme in primary care, and to compare smok-
ing behaviour among pregnant women in the city of
Trondheim with Bergen and Norway.
Methods
The study was performed in the city of Trondheim, the
capitol city in middle Norway with 160 000 inhabitants
and approximately 2100 deliveries per year. The city holds
a University with 20 000 students and 4500 employees. In
all, 28 of 35 general practices (90 general practitioners),
all eight community based midwifes and all 20 maternity
health centres in Trondheim agreed to participate in the
PACT study.
Cohorts and subjects
Sequential birth cohorts were established to evaluate the
intervention programme. From September 1st 2000 to
May 30th 2002 all pregnant women who consulted their
GPs or community based midwifes for pregnancy care
were eligible to participate in the control cohort of the
PACT study. Of some 3600 eligible pregnant women in
Trondheim during this period, 1788 (50%) women were
included and completed the pregnancy questionnaire
(Q1), and 1023 (57%) of the participating women com-
pleted the questionnaire (Q2) six weeks after delivery
(Figure 1). Participating women in the control cohort
received common, nationwide recommended, advice on
life-style, including smoking behaviour, following the
routines each health-worker was familiar with at that
time.
From June 1st 2002 to December 15th 2004 women were
invited and included to the intervention cohort of the
study. Of some 5200 pregnant women eligible to partici-
pate in the intervention cohort during this period, 2051
(40%) women gave their consent and answered the preg-
nancy questionnaire, and 1109 (54%) of the participating
women completed the questionnaire six weeks after deliv-
ery.
All pregnant women were eligible to the PACT study if
they were able to understand and fill in a questionnaire in
Norwegian language with no other inclusion or exclusion
criteria for either cohort.Page 2 of 10
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The intervention programme on diet, indoor dampness,
and smoking cessation was developed in collaboration
with midwives, maternity care nurses, GPs, and parents as
a multiple health behaviour intervention. The smoking
intervention programme was a brief office intervention
Flow chartigure 1
Flow chart. The same questionnaires were used in both cohorts. Q1 = questionnaire during pregnancy, measurement of 
smoking behaviour at start pregnancy and at inclusion at first antenatal check-up. Q2 = questionnaire at six weeks postnatal, 
measurement of present smoking behaviour.
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Department of Health and Human Services Public Health
Service (USHPS) guideline "Treating Tobacco Use and
Dependence. Clinical Practice Guideline"[15]. From June
2002 the intervention was adopted by the city health
authorities to be implemented by all health professionals
as an integrated part of the recommended maternity care
life-style counselling programme in primary health care
throughout Trondheim, regardless of participation in the
PACT study or not. The intervention programme contin-
ued throughout pregnancy at GP and midwife consulta-
tions. The recommended primary care prenatal schedule
for follow-up in Norway was the same for both cohorts
and constitutes of 8–10 prenatal consultations with a GP
or midwife from week 8–10 in pregnancy. This pro-
gramme has been accessible to all women in Norway for
many years, free of charge, and with an attendance rate of
nearly 100%. The women were invited to bring their part-
ners to the consultations, and if he was a smoker they were
encouraged to make a smoking cessation effort together.
Midwifes, public health nurses and GPs were offered a
three hours course to improve smoking cessation counsel-
ling skills, to obtain a consistent intervention and inspire
enthusiasm [16]. All midwifes and 22 of the 28 participat-
ing group practices attended the course. In addition, all
participating midwifes and GPs were supplied with writ-
ten strategy guidelines describing the intervention in
detail. Some 7% of the participating women in the inter-
vention cohort were included by GPs that did not attend
the three hours course. All women included in the inter-
vention cohort were regarded as intervened upon whether
their GP had delivered the intervention or not. Self-help
materials to be offered to the participants were also dis-
tributed to all primary care health professionals. Continu-
ous smoking cessation groups were allocated to the
maternity care centres and administered by public health
nurses. The health professionals received four follow-up
newsletters during the intervention.
Outcome variables
PACT data
The primary outcome variable was self-reported parental
smoking behaviour at six weeks postnatal. The partici-
pants were asked to complete a self-reported life-style
questionnaire including smoking behaviour at the first
maternity clinic check-up (gestational week 8–12) and
later at six weeks after delivery. Parental smoking during
pregnancy was assessed with two questions at the antena-
tal questionnaire. The women were asked if they or their
partner were smoking at the beginning of pregnancy, if
they were smoking now and daily and/or weekly cigarette
consumption. A separate question was asked about the
total numbers of cigarettes smoked indoors. The same
questions were asked six weeks postnatal. Smoking was
coded as a dichotomous variable, if they were smoking
more than one cigarette a week they were coded as smok-
ers, if the answer was "no" they were coded as non-smok-
ers, and if the answers to all questions on smoking were
missing they were coded as missing. No biomarker such as
hair nicotine was measured.
National data
Aggregated data from the Medical Birth Registry of Nor-
way (MBR) were used to illustrate smoking cessation in
Norway and the two comparable cities of Bergen and
Trondheim from 1999 to 2004.
Bergen is the second largest city in Norway, with 245 000
inhabitants and around 3200 deliveries per year, with a
University with some 16 000 students. Smoking data from
the MBR were available from 1999–2004. These data are
collected as a mandatory procedure at discharge from any
maternity ward in Norway. Forms are completed by a
midwife or physician interview and by using the hospital
medical records. The women are asked if they smoked at
the beginning or end of pregnancy, and they can answer
"no", "occasionally" and "yes". Smoking was coded as a
dichotomous variable, "occasionally" and "yes" were
coded as smokers,"no" as non-smokers. Data were availa-
ble for approximately 90% of the women who gave birth
during the period from 1999 to 2004 according to infor-
mation from the MBR.
The non-responder study
To investigate if there was a selection bias among partici-
pants in the PACT study we conducted an non-responder
study where 391 parents who consecutively visited mater-
nal postnatal care were asked to complete a short and
anonymous questionnaire on age, socioeconomics, aller-
gic disease and smoking behaviour, regardless of partici-
pation in the PACT-study or not.
Educational data
Maternal and paternal education was not accounted for in
the original questionnaire. Thus, some 800 randomly
selected parents answered questions on education (797
women and 812 men), either written or by telephone
interview.
Approvals
The Regional Committee for Medical Research Ethics for
Central Norway approved the study (Ref 120–2000). The
study was granted license by the Norwegian Data Inspec-
torate to process personal health data and one of the par-
ents signed a written informed consent formula (Ref
2003/953-3 KBE/-).Page 4 of 10
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SPSS for Windows® ver.14.0 (Chicago, Ill. USA) was used
for all statistical analyses. Comparisons between groups
were tested by chi square tests for categorical data and
independent t-tests for continuous data. Confidence inter-
vals (95% CI) were estimated for prevalence and odds
ratio using binomial distribution for dichotomous data,
and normal distribution for continuous data. Confound-
ing factors were identified by a priori knowledge, and
maternal age at the beginning of pregnancy, parity; mari-
tal status, homeowner (as a proxy for social status) and
paternal smoking at the beginning of pregnancy were
tested in several models. The resulting set of covariates
included maternal age at the beginning of pregnancy, par-
ity and marital status. We used GLM with binomial regres-
sion in a predictive model (STATA ver. 10.0) to adjust
smoking prevalence at the beginning of pregnancy, at
inclusion and at 6 weeks post partum in both cohorts.
Parental smoking was stratified into smokers and non-
smokers at the beginning of pregnancy and at time of
inclusion, and binary logistic regression models were used
to estimate adjusted odds ratio (aOR) for smoking at
inclusion and at six weeks postnatal, respectively, in the
intervention cohort compared to the control cohort.
Finally, binary logistic regression models were used to
estimate aORs for the associations between smoking ces-
sation before inclusion (spontaneous quitting) and back-
ground factors The results are analysed and presented
according to the STROBE recommendations [17].
Results
Some 28 of 35 general practices in Trondheim included a
total of 2657 women into both cohorts by end 2004, rang-
ing from 14 to 348 per practice, with 69% of the practices
including more than 40 participants. The community
midwives included altogether 1181 women. This gave a
participation rate of about 44% of the eligible pregnant
women in Trondheim. The non-responder study on 391
parents showed no selection bias for participants in the
PACT-study regarding age, socioeconomics, allergic dis-
ease, or smoking behaviour (table 1).
Background characteristics of the intervention and control 
cohorts
There were significantly more primiparous women, fewer
single mothers, more educated women and more drop-
outs in the intervention cohort. The cohorts did not differ
regarding maternal age, paternal education; the number
of cigarettes smoked a day by mother or father, neither at
the beginning of pregnancy nor at inclusion. The charac-
teristics of the cohorts are presented in table 2.
Comparing dropouts from the intervention and control
cohorts neither their mean age, 28.7 years (SD 4.8) and
28.5 years (SD 4.8) p = 0.56, nor being a homeowner, OR
1.1 (CI 95% 0.9–1.3) p = 0.43, nor the proportion who
smoked more than 10 cigarettes a day, OR 1.1(CI 95%
0.7–1.6) did differ. There were, however, significantly
more single women among dropouts in the intervention
cohort, OR 1.3 (CI 95% 1.1–1.6) p = 0.004 (table 3).
Among the women who smoked at inclusion, 140 and
184 women in the intervention cohort and control
cohort, respectively, there was no significant difference in
dropouts as 80 smokers dropped out from the interven-
tion cohort and 90 smokers from the control cohort, (p =
0.15). Information on smoking among dropouts was
missing for 7% and 5% in the intervention and control
cohort, respectively.
Smoking prevalence
The maternal smoking prevalence in the intervention
cohort was significantly lower at the beginning of preg-
nancy and at inclusion, but not at six weeks post partum.
Paternal smoking prevalence did not differ between the
cohorts at the beginning of pregnancy, but was signifi-
cantly lower in the intervention cohort at inclusion and
six weeks post partum (table 4).
Table 1: The non-responder study (N = 391). Characteristics of responders and non-responders to the PACT study
Non-responders (n = 219) Responders (n = 172)
n % CI 95% n % CI 95% p-value
Atopy in the family* 120 55.0 48.4–61.6 109 63.4 56.2–70.6 0.1
Mothers smoking at the beginning of pregnancy 46 21.0 15.6–26.4 28 16.3 10.8–21.8 0.25
Mothers smoking now 23 10.6 6.5–14.7 16 9.3 5.0–13.6 0.74
Fathers smoking at the beginning of pregnancy 39 18.6 13.5–23.8 32 18.9 13.1–24.8 1
Fathers smoking now 37 17.5 12.5–22.5 23 13.5 8.4–18.6 0.32
Median Mean SD Median Mean SD p-value
Maternal age 30 30.8 5.1 30.5 30.7 4.8 0.89
Maternal education (years) 15 15.1 2.1 16 15.6 2.5 0.08
Fathers education (years) 15 15.1 3.1 16 15.3 2.9 0.64
*Atopy = mother or father or sibling reporting at least one atopic diseasePage 5 of 10
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Data stratified according to smoking behaviour at the
beginning of pregnancy demonstrated that in the inter-
vention cohort only one in four of the smoking women
continued to smoke from the beginning of pregnancy
until inclusion, with no significant difference between the
cohorts. In contrast, most men continued to smoke in the
same period, but significantly fewer in the intervention
cohort. Very few men and women started smoking from
the beginning of pregnancy until inclusion (table 5). In
one model participants with missing smoking data were
recoded as smokers. Neither in this model did we find any
significant difference between the cohorts regarding
smoking behaviour 6 weeks postnatal for women smok-
ing at inclusion, aOR = 0.72 (95% CI 0.42–1.22, p = 0.22)
When we stratified according to smoking behaviour at
inclusion we found that most women who smoked at
inclusion continued smoking during pregnancy, about 7
in 10 women smoked at six weeks postnatal, with no sig-
nificant difference between the cohorts. We found the
same result among their partners. Some two percent of
those who were non-smokers at inclusion were smoking
at six weeks postnatal with no significant difference
between the cohorts (table 6).
When we looked at both cohorts combined women who
were at risk for continued smoking after the beginning of
pregnancy and still smoking at inclusion were living sin-
gle, multiparous women and women who smoked more
than 10 cigarettes a day. At the beginning of pregnancy
518 (25%) of the women were smoking more than one
cigarette weekly, 25 women had missing data, and 493
women were included in the analysis (table 7). At high
risk for continued smoking at inclusion were multiparous
women smoking > = 10 cigarettes a day compared to all
other smoking women at the beginning of pregnancy, OR
3.5, p < 0.001.
Indoor smoking
At inclusion 18% of the parental smokers in the interven-
tion cohort, and 28% in the control cohort reported
indoor smoking (p = 0.01). At six weeks post partum only
one parent in the intervention cohort and nine parents
(5%) of the parental smokers reported indoor smoking (p
= 0.04). When all with missing data on indoor smoking
were recoded as indoor smokers 5% and 8% were indoor
smokers in the intervention cohort, and control cohort,
respectively.
Smoking cessation in Trondheim, Bergen and Norway
Data from MBR showed a quitting rate of about 30–40%
from 1999 to 2002 with no difference between Trond-
heim, Bergen and Norway. In 2003 and 2004 the propor-
tion of women who stopped smoking during pregnancy
in Trondheim increased seemingly more than in Bergen
Table 2: Characteristics of the intervention cohort (N = 2051) and the control cohort (N = 1788) at inclusion n = number of 
participants included in analysis
Intervention cohort Control cohort
n % 95% CI n % 95% CI p-value
Single mother* 1072 1.9 1.1–2.7 994 3.8 2.6–5.0 0.01
Primiparous 2051 56.6 54.5–58.7 1785 48.6 46.3–50.9 <0.001
n mean SD n mean SD
Maternal age (years) 2044 28.6 4.6 1766 28.8 4.7 0.14
Maternal education (years)† 283 16.1 2.2 514 15.8 2.3 0.05
Paternal education† 289 15.4 2.7 523 15.2 2.9 0.34
No. of cig. a day among smokers at the beginning of pregnancy Mother 462 8.6 7.9 475 8.0 6.1 0.19
Father 438 9.8 8.3 413 9.6 6.7 0.68
No. of cig. a day among smokers at inclusion Mother 140 5.3 7.4 184 4.9 4.0 0.57
Father 355 8.8 8.6 356 8.2 6.4 0.27
*Data from questionnaire 6 weeks postnatal
† Data available for 797 women and 812 men
Table 3: Maternal smoking prevalence among drop-outs
Intervention cohort Control cohort
n % 95% CI n % 95% CI p-value
Drop-outs* 942 45.9 42.7–49.8 765 42.8 39.3–46.3 0.05
Maternal smoking prevalence at the beginning of pregnancy 877 25.1 22.2–28.0 729 27.3 24.1–30.5 0.33
Maternal smoking prevalence during pregnancy 877 9.1 7.2–11.0 723 12.4 10.0–14.8 0.03
*Drop-outs = answered questionnaire in pregnancy but not answered questionnaire six weeks postnatalPage 6 of 10
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pregnancy smoking women stopped smoking at the
beginning of pregnancy or during pregnancy in 2004.
Discussion
We found a low smoking prevalence at inclusion, 4.9%
and 7.1% in the intervention cohort and the control
cohort, respectively. Only a quarter of the pre-pregnancy
smoking women still smoked at inclusion time with no
difference between the cohorts. During the intervention
period from inclusion until six weeks postnatal, 7 in 10
smokers still smoked six weeks postnatal with no signifi-
cant difference between the cohorts. At inclusion 18% and
28% reported indoor smoking in the intervention cohort
and the control cohort, respectively. At six weeks postnatal
very few of the smokers reported indoor smoking, only
one parent in the intervention cohort, and nine parents in
the control cohort.
Data from MBR illustrating quitting rates in Trondheim,
Bergen and Norway showed a seemingly higher propor-
tion of women who stopped smoking at the beginning or
during pregnancy in Trondheim than in Bergen in 2003
and 2004.
The study had a controlled design comparing sequential
total and unselected cohorts of pregnant women from the
beginning of pregnancy until six weeks postnatal. Choos-
ing a controlled design including whole birth cohorts
made it possible in a real life approach to test the interven-
tion programme. The assessment of smoking behaviour
was consistent through the observation period and across
cohorts, and independent of clinical practice. Further-
more, the majority of care providers were trained and
motivated to deliver the recommended intervention
modalities on repeated occasions both to those who
smoked and those who had quit smoking [18]. Finally,
when health professionals take part in a scheduled and
structured intervention, it may counteract any potential
negative beliefs and attitudes against promoting smoking
cessation [19]. The possibility to compare smoking cessa-
tion nationally and in the two comparable university cit-
ies of Trondheim and Bergen in the same period that the
sequential cohorts in PACT were investigated was an addi-
tional strength of the study.
The one year time difference between the control cohort
and intervention cohort might have biased the results
towards a better effect of the intervention due to secular
trends. However, this was the design of choice primarily
because a public and community based intervention
including the entire primary health care in the municipal-
ity would be impossible to implement without contami-
nating a co-existing control cohort. Secondly, comparing
total birth cohorts also ensured high conformity between
the cohorts regarding population size, race/ethnicity,
maternal educational level, income, environment, urban-
ization and social characteristics [20]. The use of self
reported questionnaires on smoking behaviour were
adopted based on documentation indicating equal or bet-
Table 4: Adjusted* parental smoking prevalence in the intervention cohort and the control cohort
Intervention cohort Control cohort
Maternal smoking prevalence % 95% CI % 95% CI aOR 95% CI p-value
At the beginning of pregnancy 21.7 19.4–24.1 25.1 22.7–27.6 0.78 0.61–1.00 0.05
At inclusion 4.9 3.5–6.4 7.1 5.6–8.6 0.63 0.42–0.95 0.03
6 weeks postnatal 5.8 4.3–7.4 7.6 6.0–9.2 0.72 0.49–1.06 0.09
Paternal smoking prevalence
At the beginning of pregnancy 21.9 19.2–24.6 24.7 21.8–27.5 0.86 0.69–1.07 0.17
At inclusion 17.0 14.5–19.5 21.2 18.5–23.9 0.76 0.60–0.97 0.03
6 weeks postnatal 14.5 12.2–16.9 17.9 15.4–20.4 0.78 0.60–1.00 0.05
*Parental smoking prevalence adjusted for maternal age at start pregnancy, first child and marital state.
Table 5: Prevalence of parental smokers at inclusion stratified according to smoking behavior at the beginning of pregnancy
Parental smoking prevalence at inclusion
Smoking behavior at the beginning of pregnancy Intervention cohort Control cohort
n % 95% CI n % 95% CI aOR 95% CI p-value
Mother non-smoking 1 0.1 0–0.8 1 0.1 0–0.9
Mother smoking 57 24.7 19.5–30.6 82 31.7 26.3–37.6 0.66* 0.43–1.04 0.17
Father non-smoking 3 0.4 0.1–1.2 3 0.5 0–1.4
Father smoking 162 75.3 69.2–80.7 176 84.6 79.1–88.9 0.58† 0.35–0.96 0.03
*Adjusted for first child, maternal age and paternal smoking at start pregnancy
†Adjusted for first child and maternal agePage 7 of 10
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questionnaire [21,22]. Furthermore, a Norwegian valida-
tion study had already shown that Norwegian pregnant
women generally reported their smoking habits correctly
[23]. We used no biomarkers for tobacco smoking, as this
is unfeasible in large epidemiologic studies, and earlier
studies have demonstrated that such biomarkers give little
or no additional accuracy to the registration of smoking
behaviour when compared to self reported smoking in
pregnancy [24,25].
Participation and dropouts
During the study period starting September 1st 2000 and
ending December 15th 2004, 3839 of some 8800 eligible
pregnant women in Trondheim took part in the PACT
study, giving a participation rate of 44%. The participa-
tion rate was a consequence of low inclusion activity
among many GPs and midwifes, and not a consequence
of self selection among women. There is no reason to
assume a selection bias, as confirmed by results from the
non-responder study which included 391 subjects.
Of the 3839 women that were included during pregnancy,
2132 (56%) answered the questionnaire six week postna-
tal. This is a high loss to follow-up, and most probably
due to forgetfulness or failing routines for follow-up
among the health professionals. One would also expect a
certain degree of exhaustion among GPs and midwives in
a study of such longevity [26]. If the loss to follow-up is
assigned to forgetfulness or low attention during follow-
up both among participants and health professionals, it
may be assumed that the participants are lost at random.
This is supported by the observation that baseline charac-
teristics between dropouts in the two cohorts only differed
for single mothers. If so, even a loss to follow-up of 60%
is shown not to represent important bias [27]. Impor-
tantly, we had almost no active withdrawals in either
cohort.
We found no significantly reduced parental smoking prev-
alence in the intervention cohort six weeks postnatal
when we performed a stratified analysis according to
smoking behaviour at inclusion. The high quitting rate
observed in both cohorts was apparently due to spontane-
ous quitting before inclusion. Therefore only a hardcore
of resilient smokers were left to intervene on, women who
had taken their choice of continued smoking during preg-
nancy probably despite knowledge of the harmful effects
and social stigma. In this respect multiparous women
who smoked more than 10 cigarettes a day were at highest
risk. This is in agreement with results from several other
smoking intervention studies in pregnancy [28,29].
We found a very low prevalence of reported indoor smok-
ing in both cohorts which may indicate that there was
awareness in both cohorts of the harmful effect of SHS on
Table 6: Comparison of parental smoking between the cohorts after the smoking intervention programme
Parental smoking prevalence 6 weeks post partum
Smoking behaviour Intervention cohort Control cohort
at inclusion: n % 95% CI n % 95% CI aOR 95% CI p-value
Mother non-smoking 20 2,1 1,3–3,2 27 3,2 2,2–4,6 0,77* 0,42–1,42 0,40
Mother smoking 42 72,4 59,1–83,3 57 67,9 57,3–76,9 1,54* 0,63–3,73 0,34
Father non-smoking 24 2,9 2,0–4,4 21 3,1 2,0–4,7 0,92† 0,53–1,59 0,76
Father smoking 116 69,9 62,5–76,4 134 74,0 67,2–79,9 0,61† 0,35–1,04 0,07
Stratified analysis according to smoking behaviour at inclusion, crude prevalence stated for smoking.
*aORs adjusted for maternal age, first child, and paternal smoking at the beginning of pregnancy
†aORs adjusted for first child and maternal age
Table 7: Logistic regression of background factors predicting maternal smoking at inclusion* among pre-pregnancy smokers
Adjusted odds ratio for smoking at inclusion
aOR 95% CI p-value
Maternal age < = 24 years vs. reference
> 31 years 1.57 0.82–3.02 0.18
Primiparous vs. reference
multiparous 1.71 1.09–2.69 0.02
Married or cohabitant vs. reference
living single 3.01 1.43–6.34 0.004
Mother smoking <= 10 cig. a day vs. reference
> 10 cig. a day 3.07 2.04–4.64 < 0.001
*(1 = smoking, n = 150) (0 = non-smoking = spontaneous quitters, n = 362)Page 8 of 10
(page number not for citation purposes)
BMC Public Health 2008, 8:325 http://www.biomedcentral.com/1471-2458/8/325small children, but answering according to social desira-
bility may also explain this result.
Smoking cessation in Trondheim and Bergen
The MBR aggregated data showed a higher quitting rate
during pregnancy in Trondheim than in Bergen after the
intervention programme in the PACT study commenced.
The MBR data for Trondheim comprise both women par-
ticipating in the PACT study and non-participating
women. The women in the two cities had been exposed
for the same national legislation and anti smoking cam-
paigns. What differ between the two cities are the PACT
study and the fact that the intervention programme was
adopted as an integrated part of the recommended mater-
nity care life-style counselling programme throughout
Trondheim. An interpretation may be that the PACT study
in this way have increased the attention on the health haz-
ards of smoking in pregnancy, both among GPs and mid-
wifes, but also among the parents to be, and in this way
brought about the significantly higher smoking cessation
rate observed in the MBR data for Trondheim compared
to Bergen.
Conclusion
A new smoking intervention programme as part of a mul-
tiple health behaviour intervention did not reduce paren-
tal smoking prevalence during pregnancy in the
intervention cohort compared to the control cohort. Most
women were spontaneous quitters and gave up smoking
early in pregnancy before the intervention took place. We
found a low indoor smoking prevalence in both cohorts,
which may reflect a high degree of awareness of the harm-
ful effects of smoking during pregnancy. Data from the
MBR showed a higher quitting rate in Trondheim com-
pared to Bergen in 2003 and 2004 which may have been
facilitated by the supplemental attention on smoking
behaviour the PACT study initiated.
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Proportion of women who stopped smoking during pregnancy in Trondheim, Bergen and Norway 1999–2004Figure 2
Proportion of women who stopped smoking during pregnancy in Trondheim, Bergen and Norway 1999–2004. 
Data from the Medical Birth Registry in Norway. †p = 0.43 for difference in smoking cessation between Trondheim and Bergen 
2002. *p = 0.03 for difference in smoking cessation between Trondheim and Bergen 2003. §p = < 0.001 for difference in smok-
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Abstract
Background: Primary intervention – reducing second hand smoking (SHS), indoor dampness, and increased intake of omega-3-fatty
acids – for allergic diseases such as asthma, rhinoconjunctivitis, and eczema/dermatitis in children was started in Trondheim in 2002. To
our knowledge, no validated or reliable questionnaires for the study age groups were available.
Aims: To test the reliability of a revised questionnaire for studying atopic disease in children two to six years old in Trondheim.
Methods: Seventy-seven families were invited to fill in a questionnaire adapted from the ISAAC protocol which was made appropriate
for the age group studied. Completed questionnaires and information from medical records were compared, and the agreement was
analysed by Kappa statistics and proportional agreement. 
Results: Agreement was excellent for questions reporting current information such as doctor-diagnosed asthma (κ=0.88), whether or
not the child had had an allergy test (κ=0.82), and use of antibiotics (κ=0.81). The agreement was good for questions concerning doctor
or hospital treatment for asthma (κ=0.59), medication for asthma (κ=0.58), symptoms of eczema (κ=0.56), medication for allergic
disease (κ=0.45), and past infections (κ=0.53).
Conclusion: Questions on asthma diagnosis, allergy testing, and use of antibiotics were reliable. Questions on medical treatment for
eczema, allergic rhinoconjunctivitis and infections were less reliable, representing a potential source of information bias and possible
misclassification. 
© 2008 General Practice Airways Group. All rights reserved.
T Øien, et al. Prim Care Resp J 2008; 17(3): 164-168. 
doi:10.3132/pcrj.2008.00023
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Introduction
The municipality of Trondheim, Norway, was chosen for a
large study on the effectiveness of primary prevention for
asthma, rhinoconjunctivitis, and eczema/dermatitis, in
children from birth up to two years of age – the Prevention of
Allergy among Children in Trondheim study (PACT).1 The
interventions included reducing second-hand smoking (SHS)
and indoor dampness, and increasing intake of omega-3-fatty
acids. 
After searching on Medline and the Cochrane database, no
validated or reliable questionnaires for assessing the prevalence
of risk factors and the incidence of asthma, rhinoconjunctivitis
and eczema/dermatitis in children aged two to six years old
were found. Most of the existing questionnaires were
variations of those used in the ISAAC study2 for use in older
children. 
To evaluate the effect of the intervention, existing ISAAC
questionnaires had to be revised for the study age group. Three
main requirements were specified for the development of the
questionnaire: first, the extent of the questionnaire should be
sufficient to estimate symptoms and complaints consistent with
asthma, rhinoconjunctivitis, and eczema/dermatitis, and to
PRIMARY CARE RESPIRATORY JOURNAL
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describe use of health care services and treatment for these
diseases; second, the questionnaire should be possible to
complete during a maternal and child health centre
consultation of average duration (i.e. 30 minutes); and third, it
should be designed to obtain satisfactory validity.
The aim of this study therefore was to test the reliability of
a new questionnaire used in the PACT study for studying
symptoms of asthma, rhinoconjunctivitis, and eczema/
dermatitis among children two to six years old. 
Methods
A collaborative group of primary care physicians and
maternity and child healthcare nurses was established to
develop the questionnaire. A modified focus group evaluation
– which included a group of 12 parents (six couples) – was
then performed to assess whether or not the requirements
were met, and to study the feasibility of the questionnaire.
Comments on the extent and comprehensibility of the
questionnaire were collected from this group. 
After development, the questionnaire consisted of 26
questions on symptoms of allergic diseases, and two
questions on infectious diseases and hospitalisation in the
first two years of life. Ten of the questions revealed
information that could be expected to be found in medical
records. The reliability was assessed by evaluating the
agreement between answers to these ten questions and
information obtained from various medical records in primary
health care, paediatric practices and in hospitals. 
The study group consisted of two populations of children
in Trondheim. The first was a random group of parents of 47
children with few incident cases (pilot study of the
questionnaire).  To increase the number of incident cases a
second group of parents of 30 children was randomly
selected among those with a positive answer to questions on
doctor-diagnosed asthma and/or parental-reported eczema
from the control group in the PACT study.
We obtained written consent from 38 parents (of 47
invited) in the pilot study, and results from these are used in
the analysis. A brief feasibility and time consumption
questionnaire was completed by 36 participants in the pilot
study. For both groups, information was requested from their
primary physician, together with information in medical
records from the municipality emergency centre, hospital
admissions, maternity ward centres and paediatricians in
Trondheim. For 66 of the 77 (86%) participants the
information was sufficient to complete all 10 items (see Table 1).
The questionnaire was evaluated by comparing the
answers given in the questionnaires with the information
obtained from the children’s medical records. Two
investigators assessed all information in the health records,
and then both completed a registration form for each
participant. When doubt or disagreement in interpreting the
medical records was experienced, consensus between the
investigators was obtained through discussion. The data
collection was finished in 2001.
For statistical analysis, we used SPSS for Windows® ver.
12.0 and Excel. To analyse the agreement between answers
given in the questionnaire and information obtained from
different medical records, estimated observed agreement,
proportional agreement, and Kappa statistics with 95%
confidence intervals (CI) were used.3,4
The study was approved by the Regional Committee for
Medical Research Ethics and the establishment of patient
Register was licensed by the Norwegian Data Inspectorate.
Results
Feasibility and time consumption
The mean age of the 36 children in the feasibility study was
33.4 months, with a range of 24-66 months. Median time
spent completing the questionnaire was 6.5 minutes (range
1-15). Eighteen of 36 participants managed to complete the
form whilst waiting for the maternity centre consultation; the
rest completed it after the consultation. 
Modified focus group evaluation 
The modified focus group evaluation – which included six
parental couples who were invited to comment on the design
PRIMARY CARE RESPIRATORY JOURNAL
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Number of participants invited Questionnaires in Feasibility and Modified focus Written consent 
reliability time consumption group and information
study questionnaire evaluation obtained
Pilot study 
47 children invited at maternity care centres 38 36 children 6 parents 38 children
Control group PACT
30 children reported having asthma and/or 28 28 children 
eczema in questionnaire
Table 1. Patient numbers and participation.
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and comprehensibility of the questionnaire – led to the
rephrasing of some questions. As an example, the concept
“infectious disease” was poorly understood and replaced
with a list of “some of the following diseases” (see Question
9, Table 2). Overall, there were a few comments and
proposals for amendments to the questionnaire.
Agreement between the questionnaire and information
in medical records
Ten questions – for which the answers given could be
expected to be verified by information in the children’s
medical records – were selected for reliability testing. If
introductory questions were answered by “no”, the parents
were instructed to go to the next section of the questionnaire
leading to different numbers in the analysis (N). The answer
“don’t know” was excluded from the main analysis. The
number of “don’t knows” varied between zero and two in
the 10 questions.  
The results are shown in Table 2. The agreement, assessed
as kappa, varied considerably for the different questions.
There was excellent agreement for questions reporting actual
information like doctor-diagnosed asthma (κ=0.88, (0.76-
1.0)) and whether or not the child had had an allergy test
(κ=0.82, (0.66-0.97). The proportion of observed agreement
for these two questions was also very high, 0.94 and 0.92,
respectively. Proportional agreement was also very high both
for “yes” and “no”, 0.93 and 0.95, respectively. 
PRIMARY CARE RESPIRATORY JOURNAL
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Questionnaire Obtained from records N Kappa OA n PA
(CI 95 %) yes/no
1. Has your child ever been diagnosed Asthma/wheezing 53 0.88 0.94 23 0.93/0.95
as having asthma by a doctor? > 2 obstructive episodes (0.76-1.0) (50/53)
2. Has your child ever been treated by Treatment for asthma 31 0.59 0.80 18 0.84/0.75
doctor or hospitalised for asthma? (0.31-0.88) (25/31)
3. In the past 12 months, has your child Asthma medication 31 0.58 0.80 19 0.85/0.73
used any medicines, pills, puffers or other prescribed (0.28-0.88) (25/31)
medication for wheezing or asthma?
4. Has your child ever had an itchy rash Eczema 64 0.56 0.78 32 0.72/0.41
coming and going for at least 6 months? (0.38-0.75) 50/64
5. In the past 12 months, has your child Eczema medication 65 0.33 0.71 26 0.49/0.80
used any medicines, ointments, creams, prescribed (0.11-0.54) (46/65)
pills or other medications for an itchy 
skin rash or eczema?
6. In the past 12 months, has your child Allergy medication 65 0.45 0.91 7 0.50/0.95
used any medicines for allergic disease? prescribed (0.08-0.82) (59/65)
7. Has your child ever had an allergy test, Allergy test 64 0.82 0.92 21 0.87/0.94
skin prick test or blood test? (0.66-0.97) (59/64)
8. Has your child ever been treated by Treated by physician 63 0.39 0.80 9 0.50/0.88
doctor or hospitalised for: Hay fever,  or hospitalised (0.12-0.66) (51/63)
blocked nose or itchy-watery eyes?  for atopic disease?
Eczema? Urticaria?
9. Has your child ever had any of the Infection reported 66 0.53 0.82 52 0.88/0.65
following diseases? Common cold? in record (0.30-0.76) (54/66)
Ear infection? Bronchitis? RS-virus infection? 
False croup? Pneumonia? Urinary tract 
infection? Gastric flu/tummy bugs?
10. Are any of the following diseases treated Antibiotic treatment 53 0.81 0.91 29 0.92/0.89
with penicillin/antibiotics? reported in records (0.65-0.97) (48/53)
N = number in analysis, 0 < κ < 0.4 denotes poor agreement, 0.4 < κ < 0.75 denotes good agreement, κ > 0.75 denotes excellent agreement 
OA = Observed agreement, n = number of reported yes, PA = Proportional agreement for yes/no
Table 2. Agreement between 10 questions from the questionnaire, and medical record data.
Assessing atopic disease in children two to six years old: reliability of a revised questionnaire
167
The agreement was good for questions concerning
doctor or hospital treatment for asthma, symptoms of
eczema, and medication for allergic and past infections. The
agreement for medication for asthma was good, while the
agreement was poor for eczema medication (κ=0.33, [0.11-
0.54]). The agreement was also poor for doctor treatment or
hospitalisation for hay fever, eczema and urticaria. 
Discussion
The families lived in areas of mixed socio-economic population
and were considered representative for the current age group
in Trondheim.
We found excellent agreement for questions reporting
factual information such as whether or not the child had had
an allergy test or doctor-diagnosed asthma, use of antibiotics,
and a history of specific diseases. The potential for
classification errors, however, was considerable for questions
on treatment for skin rash or eczema, any medicines for
allergic disease, and whether the child had been treated by a
doctor or had been hospitalised for allergic complaints or
diseases.
We chose to test the reliability of the questionnaire by
comparing the parents’ answers to the information retrieved
from medical records. This method has been widely used for
both reliability testing and for validating questionnaires in
other medical conditions, but to our knowledge, not for the
diseases investigated in this study.5-7 A first prerequisite for a
correct classification of reported disease endpoints is that the
information given is reliable. Diagnosis of atopic diseases such
as asthma, rhinoconjunctivitis, and eczema/dermatitis is
based on the medical history, repeated consultations, and
knowledge of the child’s family and living conditions. As
medical records give an overview of all contacts in primary
and specialist care over time, diagnosis of atopic diseases is
probably best based on such information. Using medical
records as a “reference standard” for disease prevalence is,
however, only satisfactory provided that the physicians apply
diagnostic criteria correctly. Whether the doctor-diagnosed
diseases meet the standard criteria for the current diseases,
and thereby the validity of the questionnaire, is being studied
in a separate endpoint and validity study.
The questionnaire information on doctor-diagnosis of
asthma is highly reliable, which  is in accordance with findings
in the Obstructive Lung Disease in Northern Sweden Study,
where the same question was evaluated.8 A Finnish study on
the reliability of a questionnaire for asthma, allergic rhinitis,
and conjunctivitis presented similar findings.9
A better agreement could be expected for doctor or
hospital treatment for asthma. The lack of excellent
agreement could be ascribed to a perception that the
question was understood as a specific question about
hospital admission or hospital treatment only. In four
questionnaire responses the parents reported no doctor
treatment or hospitalisation for asthma, but the records
actually provided information on multiple primary care
consultations for asthma. No hospitalisation was confirmed.
Rephrasing the question would probably increase the
agreement level.
A higher agreement for the question on medical
treatment for asthma could also be expected. A higher
proportional agreement for “yes” indicates that a positive
response is more reliable than a negative response. From the
findings in the medical records, our interpretation was that
some parents seemed to misapprehend, indicating that
asthma medication was perceived as an anti-allergic
medicine.
The kappa value for the question on eczema medication
was low. However, observed agreement and proportional
agreement for “no” was high. This paradox is discussed in
detail by Feinstein and Cicchetti.10 This question is very
specific for detecting children who are not being treated for
eczema. One interpretation could be that many parents treat
their children’s eczema themselves with over-the-counter
medication, and do not consult their physician for this
problem.
A low kappa value for use of anti-allergic medication in
the past year was found. A high observed agreement, a
relatively low proportional agreement for “yes”, and very
high proportional agreement for “no” was observed. The
paradox of high agreement and low kappa is in this case
probably due to prevalence bias, with only five positive
responders.11 As a consequence, this question is unsuitable
for detecting children treated for allergy, but its specificity for
identifying children not treated for allergy is excellent.
There was poor agreement with a low report on doctor-
treated or hospitalisation for hay fever, eczema and urticaria.
Observed agreement for this question, and proportional
agreement for “no”, was high. Together with a relatively low
proportional agreement for “yes” this could be due to a
perception that the question was exclusively about hospital
admission or hospital treatment. Consequently, a more
precise question on contact with health services due to
allergic conditions is required. For questions 5, 6 and 8,
therefore, a positive answer is prone to misclassification and
thereby unreliable. A negative answer, however, contains less
classification error, and is in this respect more trustworthy. All
three should be specified in more detail and retested.
The study population consisted of two groups of children,
both randomly selected from the control cohort of PACT. A
possible bias might be introduced by the selection of the
second group, stratified by positive answers to having asthma
or allergic disease. An increased awareness on atopic disease
PRIMARY CARE RESPIRATORY JOURNAL
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among these parents may affect the reliability of the answers
given. For the disease endpoints ‘asthma’ and ‘eczema’,
however, they would be representative as the awareness of
diagnostic information would be the same for corresponding
groups of parents. The method may yet increase the reliability
for some of the other questions. However, this method was
chosen as a manageable way to collect enough data from
different medical records.
Conclusions
A newly developed questionnaire for use in the PACT study
for estimating the prevalence of asthma, rhinoconjunctivitis,
and eczema/dermatitis among children aged two to six years
old was tested for reliability. The questionnaire was adapted
from the ISAAC protocol, was modified to suit the age of the
study population, and contained questions on symptoms,
investigation, diagnosis and treatment for atopic disease. We
found that the agreement between parent-reported
information and the information obtained by examining
medical records was good to excellent for the questions
estimating prevalence of disease. The questionnaire may
possibly underestimate the use of anti-allergic medication, as
well as doctor treatment for allergic disease. No question
overestimated the prevalence of atopic symptoms or
medication use. 
It appears to be important to differentiate between the
information based on parents’ opinions and experience, and
the information they have shared with and/or received from
the health services on any level. Still, the deficiencies in
communication and in the understanding between parents
and medical staff, and the shortcomings in updating the
medical records, could impair any agreement. Knowledge of
the agreement is, however, important as inferences of
research results should include the potential for
misclassification.
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Appendix 1 
 
Questionnaire Q1: 
Questions on risk factors and behaviour during pregnancy in Norwegian 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Barneallergistudien i Trondheim
1.   Hvor mange barn har du og barnefaren tilsammen ?
gutter jenter
2.   Har du, barnefaren eller noen av barna noen gang hatt astma, eksem eller allergi i øyne/nese ?
Ja Nei
Hvis ja, kryss av for de familiemedlemmer det gjelder (flere kryss) :
Deg selv
Astma       Eksem      Allergi i øyne/nese
Barnefarens særkullsbarn
Dine særkullsbarn
Fellesbarn
Barnefaren
Hvis ja,   angi alder i dag, når astmasykdommen startet, om sykdommen
                fortsatt er til stede, og når den eventuelt sluttet.
3.   Har du, barnefaren eller fellesbarn noen gang hatt astmasykdom ? Ja Nei
Hvis nei, gå til spørsmål 5.
Alder           Startalder      Har fortsatt              Sluttalder   
i dag                astma              astma (kryss)           astma
Deg selv
Barnefaren
Fellesbarn 2
Fellesbarn 1
Fellesbarn 3
år
år
år
år
år
år
år
år
år
år
år
år
år
år
år
1 forts. på baksiden
Spørreskjema om arv og livsstilsfaktorer i svangerskapet
Spørsmål om arv
Hvis nei, gå til spørsmål 8.
Skriv tydelige tall og kryss. Bruk svart eller blå penn.
. .Utfylt dato (dd.mm.åå)
(ta med fellesbarn og særkullsbarn, ikke fosterbarn og adoptivbarn). Antall barn :
Ingen barn  : (kryss)
60291
5.   Har, eller har du, barnefaren eller fellesbarn hatt eksemplager
      eller bruk eksemmedisin de siste 12 måneder ?    
Hvis ja, kryss av
for de det gjelder :
Ja Nei
Deg selv
Fellesbarn  3
Fellesbarn  2
Fellesbarn  1
Barnefaren
2
6.  Har, eller har du, barnefaren eller fellesbarn hatt allergi i
     øyne/nese eller brukt allergimedisiner ? Ja Nei
Hvis nei, gå til spørsmål 8.
Hvis ja, kryss av
for de det gjelder:  (flere kryss)
Deg selv 
Fellesbarn  3
Fellesbarn  2
Fellesbarn  1
Barnefaren
7.   Hvis du, barnefaren eller fellesbarn har allergi i øyne/nese, hvordan er det påvist  ?
                                                                         Allergi påvist ved
Allergi påvist ved blodprøve ?                         prikk(hud)-testing ?
Ja              Nei        Vet ikke                             Ja        Nei    Vet ikke
Deg selv 
Fellesbarn  3
Fellesbarn  2
Fellesbarn  1
Barnefaren
Hyppighet av eksemplager siste 12 måneder
                                                          Sjeldnere enn                  
Daglig     Ukentlig     Månedlig        månedlig
                         Allergi mot
                                      Husstøv/                  
Pollen       Dyrehår        midd              Andre
Brukt eksemmedisin
siste 12 måneder ?
 Ja        Nei
4.   Har, eller har du, barnefaren eller fellesbarn hatt astmaplager
      eller brukt astmamedisiner de siste 12 måneder ?
Deg selv 
Fellesbarn  3
Fellesbarn  2
Fellesbarn  1
Barnefaren
Hyppighet av astmaplager siste 12 måneder
                                                          Sjeldnere enn                   
Daglig     Ukentlig     Månedlig        månedlig
Ja Nei
Hvis ja, kryss av
for de det gjelder :
Brukt astmamedisin
siste 12 måneder ?
 Ja       Nei
Brukt allergimedisin
siste 12 måneder ?
 Ja         Nei
Kryss av for de
det gjelder :
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3Spørsmål om bolig / innemiljø i svangerskapet nå
8.    I hvilken type bolig bor du ?  (ett kryss) 15.  Hvor mange timer oppholder du deg i
       gjennomsnitt i boligen ?
16.  Hvilke av følgende husdyr oppholder seg i
       boligen ?         (flere kryss)
forts. på baksiden
Sokkelleilighet i enebolig
Enebolig/våningshus uten sokkel/kjeller
Rekkehus/kjedehus
Terrassehus
Boligblokk/bygård
Andre pelsdyr (marsvin, kanin o.l.)
Andre dyr
Hund
Katt
Fugl
Enebolig/våningshus med sokkel/kjeller I boligen
I eget soverom
timer per døgn
timer per døgn
18.   Hvilke energikilder brukes til oppvarming
        av boligen ?  (flere kryss)
17.   Bor du på gårdsbruk ? Ja Nei
Hvis ja, hvilke husdyr er det  på gården ?
              (flere kryss)
9.    Boligens byggeår ?  (årstall)
11.  Boligens boareal (cirka) ?
12.  Hvor mange personer bor det
       for tiden i boligen ?
m2
Hvilket år flyttet du inn i boligen ?
Tomannsbolig, firemannsbolig
Annen bolig
Ingen dyr
10.  Eier du/dere boligen ?
Ja, som selveiere
Ja, i borettslag
Nei
Sau
Andre husdyr
Kyr
Gris
Hest
Ingen husdyr
Fjørfe
Olje
Elektristitet
Vedfyring
Fjernvarme
Annet
13.  Hvor ofte
       vaskes boligen ?
14.  Har boligen sentralstøvsuger ? Ja Nei
ganger per måned
Hvor ofte
støvsuges  boligen ? ganger per måned
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419.   Har, eller har boligen hatt noen av følgende problemer ?
         (besvar alle spørsmål)
Mugglukt eller kjellerlukt
Dugg på vinduer (utenom ved dusjing, fosskoking og sterk kulde)
Fuktflekker på vegg eller tak (fuktflekker som skyldes mindre søl med
vann regnes ikke med her)
Vannlekkasjer fra sanitærinstallasjoner (rør, kraner, dusj, vask o.l.)
Blærer, bobler i eller misfarging av gulvbelegg
 Ja   Nei
Ja,               Nei,
utbedret      ikke utbedret
Hvis ja, er problemet utbedret ?
Vannlekkasjer fra yttertak
Vannlekkasjer fra grunnen/oversvømmelse
Ingen problemer
Aviser og pappesker blir ved lagring 'fuktige'
20.   Hvilke av følgende ventilasjonsutstyr er installert i boligen ?
A. Egen avtrekksvifte over komfyr
B. Egen avtrekksvifte i ventil i yttervegg på våtrom
C. Ventiler i yttervegg/vinduskarm eller luftevindu
D. Sentral avtrekksventilasjon (sentral vifte som gir avtrekk fra bad, toalett og kjøkken)
E. Ventilasjonsanlegg (sentral vifte som gir avtrekk fra bad, toalett og kjøkken, og
     en sentral vifte som gir tilførsel av luft til oppholdsrom og soverom)
Ja               Nei
Hvis ja på D eller E - Omtrent hvor mange timer per døgn er det for tiden i bruk :
- Omtrent hvor mange ganger per år skiftes filter :
Skriv 0 hvis ikke i bruk
Skriv 0 hvis ingen
21.   Hvor ofte gjennomluftes boligen for tiden ved å
        åpne vindu eller dører i minimum 3-5  minutter ?
        (ett kryss)
Aldri
Sjeldnere enn 1 gang om dagen
1 gang om dagen
2 ganger daglig
3 eller flere ganger daglig
22.   Hvilke av følgende aktiviteter foregår daglig i
        boligen uten at elektrisk avtrekksvifte/
        ventilasjon benyttes ?  (flere kryss)
Tørking av tøy
Koking av mat
Bruk av tørkeskap/tørketrommel
Dusjing (mer enn 5 minutter)
Bruk av luftfukter
Ingen aktiviteter
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531.   Hvilke overflater har veggene i soverommet
        og i oppholdsrommet du bruker mest ?
         (flere kryss)
Ubehandlet/lutet trepanel
Malt/lakkert trepanel
Annen overflate
32.   Har det blitt gjort noen av følgende endringer i
        boligen siste 12 måneder ?  (besvar alle spørsmål)
 Ja            Nei
Nytt furu trepanel eller furu gulv
Nytt vinyl gulv (PVC-plast)
Liming av tapet, strie, gulvbelegg etc.
Maling, lakkering
Andre endringer
Veggene i
ditt soverom
Veggene i
oppholdsrom
du bruker mest
29.   Hvor mange våtrom og andre rom har vinylgulv
        med gulvvarme ?  (Skriv 0 hvis ingen)
30.   Hvilke materialer er brukt på gulv i soverommet
        og i oppholdsrommet du bruker mest ?
        (flere kryss)
Våtrom (bad, vaskerom, WC) antall rom
Andre rom antall rom
Heldekkende tepper
Vinyl (PVC-plast)
Furu tregulv
Parkett/andre harde materialer
Annet
Gulv i ditt
soverom
Gulv i
oppholdsrom
du bruker mest
Annen malt/lakkert overflate
forts. på baksiden
23.   I hvilken etasje av bygningen er ditt soverom ?
         (ett kryss)
Sokkel
Kjeller
1. etasje
2. etasje eller høyere
24.   Sover du for tiden med åpent vindu ?
25.   Hva slags dyne eller pute bruker du nå ?
Syntetiske fibre
Dun
Ja Nei
Annet
Bruker ikke dyne eller pute
Dyne          Pute
26.   Hvor gammel er din nåværende dyne, pute og
        madrass ?
Alder   (under 1 år skriv 0)
år
år
år
Dyne
Pute
Madrass
28.   Tørkes sengetøyet
         i tørketrommel ? Ja Nei
27.   Hvor ofte vaskes
        sengetøyet ditt ? ganger per måned
Hvor ofte rengjøres
madrassen din ? ganger per år
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Spørsmål om kosthold
33.   Hvor ofte i gjennomsnitt spiser du torsk, sei
        eller annen mager fisk til middag ?     (ett kryss)
Aldri
Sjeldnere enn 1 gang i uken
1 gang i uken
2 ganger i uken
3 ganger i uken
4 ganger i uken eller oftere
34.   Hvor ofte i gjennomsnitt spiser du uer, kveite,
        laks, ørret, sild, makrell eller annen fet fisk til
        middag ?      (ett kryss)
35.   Hvor ofte i gjennomsnitt tar du tran eller
        fiskeoljekapsler ?        (ett kryss)
36.   Hvor mange brødskiver i gjennomsnitt spiser
        du der pålegget består av fet fisk (sild, sardiner,
        makrell, laks ol.) ?          (ett kryss)
Aldri
Mindre enn 1 skive i uken
1-2 skiver i uken
3-6 skiver i uken
1-2 skiver daglig
3-4 skiver daglig
5 eller flere skiver daglig
37.   Hvor ofte spiser du i gjennomsnitt grønnsaker
        til middag eller som egen rett (her menes rå
        eller kokte grønnsaker) ?       (ett kryss)
Aldri
Sjelden
Omtrent 1 gang i uken
2-3 ganger i uken
4-5 ganger i uken
Omtrent daglig
Spørsmål om røykevaner
39.   Røykte du eller ektefelle/
        samboer ved svangerskapets
        start ?
Du
Ektefelle/samboer
Nei, røykte ikke   Ja, røykte ukentlig                    Ja, røykte daglig
sigaretter ukentlig
sigaretter ukentlig
sigaretter daglig
sigaretter daglig
40.   Røyker du eller ektefelle/
        samboer nå ? Du
Ektefelle/samboer
Nei, røyker ikke   Ja, røyker ukentlig                   Ja, røyker daglig
sigaretter ukentlig
sigaretter ukentlig
sigaretter daglig
sigaretter daglig
41.   Røykes det innendørs hjemme ?
6
Aldri
Sjeldnere enn 1 gang i uken
1 gang i uken
2 ganger i uken
3 ganger i uken
4 ganger i uken eller oftere
Aldri
Sjeldnere enn 1 gang i uken
1 gang i uken
2 ganger i uken
3 ganger i uken
4 ganger i uken eller oftere
38.   Hva slags type fett blir brukt til matlaging
        (ikke på brødet) i din husholdning ?   (flere kryss)
Fra svangerskapets start til nå
Nei, det røykes    Ja, det røykes                           Ja, det røykes
ikke innendørs     ukentlig innendørs                   daglig innendørs
sigaretter ukentlig sigaretter daglig
Meierismør
Hard margarin
Bløt (soft) margarin
Smør/margarin blanding
Soyaolje
Olivenolje
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Appendix 2 
 
Questionnaire Q2: 
Questions on risk factors and behaviour at 6 weeks after birth in Norwegian 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.   Er barnet tvilling ?
1 forts. på baksiden
Spørsmål om barnet
Ja Nei Hvis tvilling, svar på alle spørsmålene for tvilling I, deretter svar
                  på spørsmål 1-6 og 47-51 for tvilling II på eget skjema.
2.   Barnets fødselsvekt ? gram
3.   Hvor mange søsken har barnet ?
       (ta med fellesbarn og særkullsbarn, ikke fosterbarn og adoptivbarn) brødre søstre
4.   Når ble barnet født i forhold til beregnet ultralydtermin ? (ett kryss)
Tidligere enn 2 uker før beregnet ultralydtermin
Mellom 3 uker før og 2 uker etter beregnet ultralydtermin
Senere enn 2 uker etter beregnet ultralydtermin
Barneallergistudien i Trondheim
Spørreskjema om livsstilsfaktorer ved 6 ukers alder
. .Utfylt dato   (dd.mm.åå)
og fødselslengde ? cm
5.   Har barnet blitt vaksinert ? Ja Nei
Hvis ja, hvilken vaksine ? BCG
6.   Har barnet hatt noen av sykdommene nedenfor ?
Forkjølelse
Ørebetennelse
Bronkitt
RS-virusinfeksjon
Lungebetennelse
Urinveisinfeksjon
Mage-tarminfeksjon
                       Hvis ja,
Ja        Nei      antall ganger
Er noen av sykdommene behandlet med penicillin/antibiotika ?
Antall søsken :
Ingen søsken  : (kryss)
Falsk krupp
Ja Nei Vet ikke
Hvis ja,
hvor mange behandlinger
Skriv tydelige tall og kryss. Bruk svart eller blå penn.
7.   Foreldrenes sivilstatus: Gift Samboer Enslig Annet
Hepatitt Andre
22600
8.   Har mor, far eller noen av barna noen gang hatt astma, eksem eller allergi i øyne/nese ?
Ja Nei
Hvis ja, kryss av for de familiemedlemmer det gjelder  (flere kryss) :
Mor
Astma       Eksem      Allergi i øyne/nese
Barnefarens særkullsbarn
Dine særkullsbarn
Fellesbarn
Far
Hvis ja,  angi alder i dag, når astmasykdommen startet, om sykdommen fortsatt er til stede,
               og når den eventuelt sluttet.
9.   Har, eller har mor, far eller fellesbarn noen gang hatt astmasykdom ? Ja Nei
Hvis nei, gå til spørsmål 11.
Alder           Startalder       Har fortsatt                       Sluttalder
i dag                astma               astma (kryss)                    astma
Mor
Far
Fellesbarn 2
Fellesbarn 1
Fellesbarn 3
år
år
år
år
år
år
år
år
år
år
år
år
år
år
år
Hvis nei, gå til spørsmål 14.
2
Spørsmål om foreldre og søsken
10.  Har, eller har mor, far eller fellesbarn hatt astmaplager eller brukt
       astmamedisiner de siste 12 måneder ?
Mor
Fellesbarn  3
Fellesbarn  2
Fellesbarn  1
Far
Hyppighet av astmaplager siste 12 måneder
          Sjeldnere enn                   
Daglig   Ukentlig    Månedlig     månedlig
Ja Nei
Hvis ja, kryss av for
              de det gjelder :
Brukt astmamedisin
siste 12 måneder
 Ja        Nei
11.  Har, eller har mor,far eller fellesbarn hatt eksemplager, eller brukt
       eksemmedisin de siste 12 måneder ?
Hvis ja, kryss av for
              de det gjelder :
Ja Nei
Mor
Fellesbarn  3
Fellesbarn  2
Fellesbarn  1
Far
Hyppighet av eksemplager siste 12 måneder
         Sjeldnere enn                  
Daglig  Ukentlig    Månedlig     månedlig
Brukt eksemmedisin
siste 12 måneder ?
 Ja        Nei
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312.  Har, eller har mor, far eller fellsbarn hatt allergi i øyne/nese, eller brukt allergimedisiner ?
Ja Nei
Hvis ja, kryss av (flere kryss)
for de det gjelder :
Mor
Fellesbarn  3
Fellesbarn  2
Fellesbarn  1
Far
13.  Hvis mor, far eller fellsbarn har allergi i øyne/nese, hvordan er det påvist  ?
Allergi påvist ved blodprøve ?                               Allergi påvist ved prikk(hud)-testing ?
Ja         Nei      Vet ikke    Ja          Nei        Vet ikke
Mor
Fellesbarn  3
Fellesbarn  2
Fellesbarn  1
Far
                    Allergi mot
                              Husstøv/                  
Pollen   Dyrehår    midd       Andre
Brukt allergimedisin
siste 12 måneder ?
 Ja        Nei
Kryss av for
de det gjelder :
14. Kryss av om mor hadde noen av følgende plager i siste svangerskap. Oppgi i hvilken periode, og
      om mulig navn på medisiner som ble brukt.
Plager i siste
svangerskap ?
Svangerskapsblødning
Svangerskapsforgiftning
Forhøyet blodtrykk
Svangerskapsdiabetes
Diabetes, insulinbehandlet
Diabetes, tablettbehandlet
Soppinfeksjon i skjeden
Skjedekatarr/uvanlig utflod
Forkjølelse
Influensa
Bronkitt
Lungebetennelse
Astma
Eksem
Allergi i øyne /nese
0-3 mnd 4-6 mnd 7-9 mnd
Periode i svangerskapet (flere kryss)
Medisinnavn
forts. på baksiden
Hvis nei, gå til spørsmål 14.
Andre plager
Ingen plager
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4Spørsmål om bolig / innemiljø  nå
15.  I hvilken type bolig bor barnet ?  (ett kryss) 22.  Hvor mange timer oppholder barnet seg  i
       gjennomsnitt i boligen ?
23.  Hvilke av følgende husdyr oppholder seg i
       boligen ?         (flere kryss)
Sokkelleilighet i enebolig
Enebolig/våningshus uten sokkel/kjeller
Rekkehus/kjedehus
Terrassehus
Boligblokk/bygård
Andre pelsdyr (marsvin, kanin o.l.)
Andre dyr
Hund
Katt
Fugl
Enebolig/våningshus med sokkel/kjeller
I boligen
I eget soverom
timer per døgn
timer per døgn
25.   Hvilke energikilder brukes til oppvarming
        av boligen ?  (flere kryss)
24.   Bor barnet på gårdsbruk ? Ja Nei
Hvis ja, hvilke husdyr er det  på gården ?
              (flere kryss)
16.  Boligens byggeår ?  (årstall)
18.  Boligens boareal (cirka) ?
19.  Hvor mange personer bor det
       for tiden i boligen ?
m2
Hvilket år flyttet du inn i boligen ?
Tomannsbolig, firemannsbolig
Annen bolig
Ingen dyr
17.  Eier du/dere boligen ?
Ja, som selveiere
Ja, i borettslag
Nei
Sau
Andre husdyr
Kyr
Gris
Hest
Ingen husdyr
Fjørfe
Olje
Elektristitet
Vedfyring
Fjernvarme
Annet21.  Har boligen sentralstøvsuger ? Ja Nei
20.  Hvor ofte
       vaskes boligen ? ganger per måned
Hvor ofte
støvsuges  boligen ? ganger per måned
22600
5 forts. på baksiden
26.   Har, eller har boligen hatt noen av følgende problemer ?
        (besvar alle spørsmål)
Mugglukt eller kjellerlukt
Dugg på vinduer (utenom ved dusjing, fosskoking og sterk kulde)
Fuktflekker på vegg eller tak (fuktflekker som skyldes mindre søl med
vann regnes ikke med her)
Vannlekkasjer fra sanitærinstallasjoner (rør, kraner, dusj, vask o.l.)
Blærer, bobler i eller misfarging av gulvbelegg
 Ja   Nei
Ja,               Nei,
utbedret      ikke utbedret
Hvis ja, er problemet utbedret ?
Vannlekkasjer fra yttertak
Vannlekkasjer fra grunnen/oversvømmelse
Ingen problemer
Aviser og pappesker blir ved lagring 'fuktige'
27.   Hvilke av følgende ventilasjonsutstyr er installert i boligen ?
A. Egen avtrekksvifte over komfyr
B. Egen avtrekksvifte i ventil i yttervegg på våtrom
C. Ventiler i yttervegg/vinduskarm eller luftevindu
D. Sentral avtrekksventilasjon (sentral vifte som gir avtrekk fra bad, toalett og kjøkken)
E. Ventilasjonsanlegg (sentral vifte som gir avtrekk fra bad, toalett og kjøkken, og
     en sentral vifte som gir tilførsel av luft til oppholdsrom og soverom)
Ja               Nei
Hvis ja på D eller E - Omtrent hvor mange timer per døgn er det for tiden i bruk :
- Omtrent hvor mange ganger per år skiftes filter :
Skriv 0 hvis ikke i bruk
Skriv 0 hvis ingen
28.   Hvor ofte gjennomluftes boligen for tiden ved å
        åpne vindu eller dører i minimum 3-5  minutter ?
        (ett kryss)
Aldri
Sjeldnere enn 1 gang om dagen
1 gang om dagen
2 ganger daglig
3 eller flere ganger daglig
29.   Hvilke av følgende aktiviteter foregår daglig i
        boligen uten at elektrisk avtrekksvifte/
        ventilasjon benyttes ?  (flere kryss)
Tørking av tøy
Koking av mat
Bruk av tørkeskap/tørketrommel
Dusjing (mer enn 5 minutter)
Bruk av luftfukter
Ingen aktiviteter
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38.   Hvilke overflater har veggene i soverommet og i
        oppholdsrommet barnet bruker mest ?
         (flere kryss)
Ubehandlet/lutet trepanel
Malt/lakkert trepanel
Annen overflate
39.   Har det blitt gjort noen av følgende endringer i
        boligen siste 12 måneder ?
 Ja            Nei
Nytt furu trepanel eller furu gulv
Nytt vinyl gulv (PVC-plast)
Liming av tapet, strie, gulvbelegg etc.
Maling, lakkering
Andre endringer
Vegg i
barnets
soverom
Vegg i barnets
mest brukte
oppholdsrom
36.   Hvor mange våtrom og andre rom har vinylgulv
        med gulvvarme ?  (Skriv 0 hvis ingen)
37.   Hvilke materialer er brukt på gulv i
        soverommet, og i oppholdsrommet barnet
        bruker mest ?        (flere kryss)
Våtrom (bad, vaskerom, WC) antall rom
Andre rom antall rom
Heldekkende tepper
Vinyl (PVC-plast)
Furu tregulv
Parkett/andre harde materialer
Annet
Annen malt/lakkert overflate
30.   I hvilken etasje av bygningen er barnets
        soverom ? (ett kryss)
Sokkel
Kjeller
1. etasje
2. etasje eller høyere
31.   Sover barnet for tiden med åpent vindu ?
32.   Hva slags dyne eller pute bruker barnet nå ?
Syntetiske fibre
Dun
Ja Nei
Annet
Bruker ikke dyne eller pute
Dyne          Pute
33.   Hvor gammel er barnets nåværende dyne, pute
        og madrass ?
Alder,  (under 1 år skriv 0)
år
år
år
Dyne
Pute
Madrass
35.   Tørkes sengetøyet i tørketrommel ?
Ja Nei
6
Gulv i
barnets
soverom
Gulv i barnets
mest brukte
oppholdsrom
34.   Hvor ofte vaskes
        sengetøyet til barnet ? ganger per måned
Hvor ofte rengjøres
madrassen til barnet ? ganger per år
22600
7Spørsmål om kosthold
40.   Hvor ofte i gjennomsnitt spiste mor torsk, sei
        eller annen mager fisk til middag ?
41.   Hvor ofte i gjennomsnitt spiste mor uer, kveite,
        laks, ørret, sild, makrell eller annen fet fisk til
        middag ?
42.   Hvor ofte i gjennomsnitt tok mor tran eller
        fiskeoljekapsler ?
43.   Hvor mange brødskiver i gjennomsnitt spiste
        mor der pålegget bestod av fet fisk (sild,
        sardiner, makrell, laks ol.) ?
44.   Hvor ofte spiste mor i gjennomsnitt
        grønnsaker til middag eller som egen rett (her
        menes rå eller kokte grønnsaker) ?
45.   Hva slags type fett ble brukt til matlaging
        (ikke på brødet) i mors husholdning ?
I svangerskapet og i ammeperioden
Meierismør
Hard margarin
Bløt (soft) margarin
Smør/margarin blanding
Soyaolje
Olivenolje
(flere kryss)
Aldri
Sjeldnere enn 1 gang i uken
1 gang i uken
2 ganger i uken
3 ganger i uken
4 ganger i uken eller oftere
I svanger-
skapet
I amme-
perioden
Aldri
Sjeldnere enn 1 gang i uken
1 gang i uken
2 ganger i uken
3 ganger i uken
4 ganger i uken eller oftere
I svanger-
skapet
I amme-
perioden
Aldri
Sjeldnere enn 1 gang i uken
1 gang i uken
2 ganger i uken
3 ganger i uken
4 ganger i uken eller oftere
I svanger-
skapet
I amme-
perioden
Aldri
Mindre enn 1 skive i uken
1-2 skiver i uken
3-6 skiver i uken
1-2 skiver i daglig
3-4 skiver i daglig
I svanger-
skapet
I amme-
perioden
5 eller flere skiver i daglig
Aldri
Sjelden
Omtrent 1 gang i uken
2-3 ganger i uken
4-5 ganger i uken
Omtrent daglig
I svanger-
skapet
I amme-
perioden
I svanger-
skapet
I amme-
perioden
46.  Har mor i ammeperioden spist noen av følgende matemner ?
Kumelk
Egg
Fisk
Skalldyr
Nøtter
Erter/belgfrukter
         Ofte
(minst ukentlig)
             Av og til
(noen ganger i måneden) En gang Aldri
forts. på baksiden
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8Spørsmål om barnets ernæring
47.    Har barnet fått morsmelk ?
48.    Får barnet morsmelk fremdeles ?
49.    Får barnet tran ?
50.    Får barnet annet vitamintilskudd ?
           (for eksempel Biovit, Sanasol)
51.    Får barnet morsmelkerstatning ?
Hvis ja, hvor gammelt var barnet da det
              startet med morsmelkerstatning ?
Hvis ja, hvilken type ?
Hvis nei, hvor gammelt var barnet da det
                sluttet med morsmelk ?
måneder
Collett
NAN
Nutramigen
Soyamelk
Annet
måneder
Ja Nei
Ja Nei
Ja Nei
Ja Nei
Ja Nei
Spørsmål om røykevaner
52.   Røykte du eller ektefelle/
        samboer ved svangerskapets
        start ?
Du
Ektefelle/samboer
Nei, røykte ikke         Ja, røykte ukentlig                    Ja, røykte daglig
sigaretter ukentlig
sigaretter ukentlig
sigaretter daglig
sigaretter daglig
53.   Røyker du eller ektefelle/
        samboer nå ? Du
Ektefelle/samboer
Nei, røyker ikke         Ja, røyker ukentlig                   Ja, røyker daglig
sigaretter ukentlig
sigaretter ukentlig
sigaretter daglig
sigaretter daglig
54.   Røykes det innendørs hjemme ? Nei, det røykes           Ja, det røykes                           Ja, det røykes
ikke innendørs            ukentlig innendørs                   daglig innendørs
sigaretter ukentlig sigaretter daglig
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Appendix 3 
 
Questionnaire Q3: 
Questions on risk factors and behaviour 1 year after birth in Norwegian 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.   Er barnet tvilling ?
1 forts. på baksiden
Spørsmål om barnet
Ja Nei Hvis tvilling, svar på alle spørsmålene for tvilling I, deretter svar
                  på spørsmål 1-6 og 47-57 for tvilling II på eget skjema.
2.   Barnets fødselsvekt ? gram
3.   Hvor mange søsken har barnet ?
       (ta med fellesbarn og særkullsbarn, ikke fosterbarn og adoptivbarn) brødre søstre
4.   Når ble barnet født i forhold til beregnet ultralydtermin ? (ett kryss)
Tidligere enn 2 uker før beregnet ultralydtermin
Mellom 3 uker før og 2 uker etter beregnet ultralydtermin
Senere enn 2 uker etter beregnet ultralydtermin
Barneallergistudien i Trondheim
Spørreskjema om livsstilsfaktorer ved 1 års alder
. .Utfyllt dato   (dd.mm.åå)
og fødselslengde ? cm
5.   Har barnet blitt vaksinert ? Ja Nei
6.   Har barnet hatt noen av sykdommene nedenfor ?
Forkjølelse
Ørebetennelse
Bronkitt
RS-virusinfeksjon
Lungebetennelse
Urinveisinfeksjon
Mage-tarminfeksjon
                       Hvis ja,
Ja        Nei      antall ganger
Er noen av sykdommene behandlet med penicillin/antibiotika ?
Antall søsken :
Ingen søsken  : (kryss)
Falsk krupp
Ja Nei Vet ikke
Hvis ja,
hvor mange behandlinger
Skriv tydelige tall og kryss. Bruk svart eller blå penn.
7.   Foreldrenes sivilstatus: Gift Samboer Enslig Annet
51410
8.   Har mor, far eller noen av barna noen gang hatt astma, eksem eller allergi i øyne/nese ?
Ja Nei
Hvis ja, kryss av for de familiemedlemmer det gjelder  (flere kryss) :
Mor
Astma       Eksem      Allergi i øyne/nese
Barnefarens særkullsbarn
Dine særkullsbarn
Fellesbarn
Far
Hvis ja,  angi alder i dag, når astmasykdommen startet, om sykdommen fortsatt er til stede,
               og når den eventuelt sluttet.
9.   Har, eller har mor, far eller fellesbarn noen gang hatt astmasykdom ? Ja Nei
Hvis nei, gå til spørsmål 11.
Alder           Startalder       Har fortsatt                       Sluttalder   
i dag                astma              astma (kryss)                    astma
Mor
Far
Fellesbarn 2
Fellesbarn 1
Fellesbarn 3
år
år
år
år
år
år
år
år
år
år
år
år
år
år
år
Hvis nei, gå til spørsmål 14.
2
Spørsmål om foreldre og søsken
10.  Har, eller har mor, far eller fellesbarn hatt astmaplager eller brukt
       astmamedisiner de siste 12 måneder ?
Mor
Fellesbarn  3
Fellesbarn  2
Fellesbarn  1
Far
Hyppighet av astmaplager siste 12 måneder
           Sjeldnere enn                   
Daglig   Ukentlig    Månedlig      månedlig
Ja Nei
Hvis ja, kryss av for
              de det gjelder :
Brukt astmamedisin
siste 12 måneder
 Ja        Nei
11.  Har, eller har mor,far eller fellesbarn hatt eksemplager, eller brukt
       eksemmedisin de siste 12 måneder ?
Hvis ja, kryss av for
              de det gjelder :
Ja Nei
Mor
Fellesbarn  3
Fellesbarn  2
Fellesbarn  1
Far
Hyppighet av eksemplager siste 12 måneder
          Sjeldnere enn                  
Daglig  Ukentlig    Månedlig      månedlig
Brukt eksemmedisin
siste 12 måneder ?
 Ja        Nei
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312.  Har, eller har mor, far eller fellesbarn hatt allergi i øyne/nese, eller brukt allergimedisiner ?
Ja Nei
Hvis ja, kryss av  (flere kryss)
for de det gjelder :
Mor
Fellesbarn  3
Fellesbarn  2
Fellesbarn  1
Far
13.  Hvis mor, far eller fellesbarn har allergi i øyne/nese, hvordan er det påvist  ?
Allergi påvist ved blodprøve ?                               Allergi påvist ved prikk(hud)-testing ?
Ja         Nei      Vet ikke    Ja          Nei        Vet ikke
Mor
Fellesbarn  3
Fellesbarn  2
Fellesbarn  1
Far
                    Allergi mot
                             Husstøv/                  
Pollen   Dyrehår    midd       Andre
Brukt allergimedisin
siste 12 måneder ?
 Ja        Nei
Kryss av for
de det gjelder :
14. Kryss av om mor hadde noen av følgende plager i siste svangerskap. Oppgi i hvilken periode, og
      om mulig navn på medisiner som ble brukt.
Plager i siste
svangerskap ?
Svangerskapsblødning
Svangerskapsforgiftning
Forhøyet blodtrykk
Svangerskapsdiabetes
Diabetes, insulinbehandlet
Diabetes, tablettbehandlet
Soppinfeksjon i skjeden
Skjedekatarr/uvanlig utflod
Forkjølelse
Influensa
Bronkitt
Lungebetennelse
Astma
Eksem
Allergi i øyne /nese
0-3 mnd 4-6 mnd 7-9 mnd
Periode i svangerskapet (flere kryss)
Medisinnavn
forts. på baksiden
Hvis nei, gå til spørsmål 14.
Andre plager
Ingen plager
51410
4Spørsmål om bolig / innemiljø nå
15.  I hvilken type bolig bor barnet ?  (ett kryss) 22.  Hvor mange timer oppholder barnet seg  i
       gjennomsnitt i boligen ?
23.  Hvilke av følgende husdyr oppholder seg i
       boligen ?         (flere kryss)
Sokkelleilighet i enebolig
Enebolig/våningshus uten sokkel/kjeller
Rekkehus/kjedehus
Terrassehus
Boligblokk/bygård
Andre pelsdyr (marsvin, kanin o.l.)
Andre dyr
Hund
Katt
Fugl
Enebolig/våningshus med sokkel/kjeller
I boligen
I eget soverom
timer per døgn
timer per døgn
25.   Hvilke energikilder brukes til oppvarming
        av boligen ?  (flere kryss)
24.   Bor barnet på gårdsbruk Ja Nei
Hvis ja, hvilke husdyr er det  på gården ?
              (flere kryss)
16.  Boligens byggeår ?  (årstall)
18.  Boligens boareal (cirka) ?
19.  Hvor mange personer bor det
       for tiden i boligen ?
m2
Hvor lenge har barnet
bodd i boligen ?
Tomannsbolig, firemannsbolig
Annen bolig
Ingen dyr
17.  Eier du/dere boligen ?
Ja, som selveiere
Ja, i borettslag
Nei
Sau
Andre husdyr
Kyr
Gris
Hest
Ingen husdyr
Fjørfe
Olje
Elektristitet
Vedfyring
Fjernvarme
Annet21.  Har boligen sentralstøvsuger ? Ja Nei
månederår
20.  Hvor ofte
       vaskes boligen ? ganger per måned
Hvor ofte
støvsuges  boligen ? ganger per måned
51410
5 forts. på baksiden
26.   Har, eller har boligen hatt noen av følgende problemer ?
        (besvar alle spørsmål)
Mugglukt eller kjellerlukt
Dugg på vinduer (utenom ved dusjing, fosskoking og sterk kulde)
Fuktflekker på vegg eller tak (fuktflekker som skyldes mindre søl med
vann regnes ikke med her)
Vannlekkasjer fra sanitærinstallasjoner (rør, kraner, dusj, vask o.l.)
Blærer, bobler i eller misfarging av gulvbelegg
 Ja   Nei
Ja,               Nei,
utbedret      ikke utbedret
Hvis ja, er problemet utbedret ?
Vannlekkasjer fra yttertak
Vannlekkasjer fra grunnen/oversvømmelse
Ingen problemer
Aviser og pappesker blir ved lagring 'fuktige'
27.   Hvilke av følgende ventilasjonsutstyr er installert i boligen ?
A. Egen avtrekksvifte over komfyr
B. Egen avtrekksvifte i ventil i yttervegg på våtrom
C. Ventiler i yttervegg/vinduskarm eller luftevindu
D. Sentral avtrekksventilasjon (sentral vifte som gir avtrekk fra bad, toalett og kjøkken)
E. Ventilasjonsanlegg (sentral vifte som gir avtrekk fra bad, toalett og kjøkken, og
     en sentral vifte som gir tilførsel av luft til oppholdsrom og soverom)
Ja               Nei
Hvis ja på D eller E - Omtrent hvor mange timer per døgn er det for tiden i bruk :
- Omtrent hvor mange ganger per år skiftes filter :
Skriv 0 hvis ikke i bruk
Skriv 0 hvis ingen
28.   Hvor ofte gjennomluftes boligen for tiden ved å
        åpne vindu eller dører i minimum 3-5  minutter ?
        (ett kryss)
Aldri
Sjeldnere enn 1 gang om dagen
1 gang om dagen
2 ganger daglig
3 eller flere ganger daglig
29.   Hvilke av følgende aktiviteter foregår daglig i
        boligen uten at elektrisk avtrekksvifte/
        ventilasjon benyttes ?  (flere kryss)
Tørking av tøy
Koking av mat
Bruk av tørkeskap/tørketrommel
Dusjing (mer enn 5 minutter)
Bruk av luftfukter
Ingen aktiviteter
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38.   Hvilke overflater har veggene i soverommet og i
        oppholdsrommet barnet bruker mest ?
         (flere kryss)
Ubehandlet/lutet trepanel
Malt/lakkert trepanel
Annen overflate
39.   Har det blitt gjort noen av følgende endringer i
        boligen siste 12 måneder ?
 Ja            Nei
Nytt furu trepanel eller furu gulv
Nytt vinyl gulv (PVC-plast)
Liming av tapet, strie, gulvbelegg etc.
Maling, lakkering
Andre endringer
Vegg i
barnets
soverom
Vegg i barnets
mest brukte
oppholdsrom
36.   Hvor mange våtrom og andre rom har vinylgulv
        med gulvvarme ?  (Skriv 0 hvis ingen)
37.   Hvilke materialer er brukt på gulv i
        soverommet, og i oppholdsrommet barnet
        bruker mest ?        (flere kryss)
Våtrom (bad, vaskerom, WC) antall rom
Andre rom antall rom
Heldekkende tepper
Vinyl (PVC-plast)
Furu tregulv
Parkett/andre harde materialer
Annet
Annen malt/lakkert overflate
30.   I hvilken etasje av bygningen er barnets
        soverom ? (ett kryss)
Sokkel
Kjeller
1. etasje
2. etasje eller høyere
31.   Sover barnet for tiden med åpent vindu ?
32.   Hva slags dyne eller pute bruker barnet nå ?
Syntetiske fibre
Dun
Ja Nei
Annet
Bruker ikke dyne eller pute
Dyne          Pute
33.   Hvor gammel er barnets nåværende dyne, pute
        og madrass ?
Alder,  (under 1 år skriv 0)
år
år
år
Dyne
Pute
Madrass
35.   Tørkes sengetøyet i tørketrommel ?
Ja Nei
6
Gulv i
barnets
soverom
Gulv i barnets
mest brukte
oppholdsrom
34.   Hvor ofte vaskes
        sengetøyet til barnet ? ganger per måned
Hvor ofte rengjøres
madrassen til barnet ? ganger per år
51410
7Spørsmål om kosthold
40.   Hvor ofte i gjennomsnitt spiste mor torsk, sei
        eller annen mager fisk til middag ?
41.   Hvor ofte i gjennomsnitt spiste mor uer, kveite,
        laks, ørret, sild, makrell eller annen fet fisk til
        middag ?
42.   Hvor ofte i gjennomsnitt tok mor tran eller
        fiskeoljekapsler ?
43.   Hvor mange brødskiver i gjennomsnitt spiste
        mor der pålegget bestod av fet fisk (sild,
        sardiner, makrell, laks ol.) ?
44.   Hvor ofte spiste mor i gjennomsnitt
        grønnsaker til middag eller som egen rett (her
        menes rå eller kokte grønnsaker) ?
45.   Hva slags type fett ble brukt til matlaging
        (ikke på brødet) i mors husholdning ?
I svangerskapet og i ammeperioden
Meierismør
Hard margarin
Bløt (soft) margarin
Smør/margarin blanding
Soyaolje
Olivenolje
(flere kryss)
Aldri
Sjeldnere enn 1 gang i uken
1 gang i uken
2 ganger i uken
3 ganger i uken
4 ganger i uken eller oftere
I svanger-
skapet
I amme-
perioden
Aldri
Sjeldnere enn 1 gang i uken
1 gang i uken
2 ganger i uken
3 ganger i uken
4 ganger i uken eller oftere
I svanger-
skapet
I amme-
perioden
Aldri
Sjeldnere enn 1 gang i uken
1 gang i uken
2 ganger i uken
3 ganger i uken
4 ganger i uken eller oftere
I svanger-
skapet
I amme-
perioden
Aldri
Mindre enn 1 skive i uken
1-2 skiver i uken
3-6 skiver i uken
1-2 skiver i daglig
3-4 skiver i daglig
I svanger-
skapet
I amme-
perioden
5 eller flere skiver i daglig
Aldri
Sjelden
Omtrent 1 gang i uken
2-3 ganger i uken
4-5 ganger i uken
Omtrent daglig
I svanger-
skapet
I amme-
perioden
I svanger-
skapet
I amme-
perioden
46.  Har mor under ammeperioden spist noen av følgende matemner ?
Kumelk
Egg
Fisk
Skalldyr
Nøtter
Erter/belgfrukter
         Ofte
(minst ukentlig)
             Av og til
(noen ganger i måneden) En gang Aldri
forts. på baksiden
51410
Spørsmål om barnets ernæring
47.    Har barnet fått morsmelk ?
49.    Får barnet annet vitamintilskudd ?
         (for eksempel Biovit, Sanasol)
Ja Nei
Ja Nei
50.    Får barnet morsmelkerstatning ?
Hvis ja, hvor gammelt var barnet da det
              startet  med morsmelkerstatning ?
Hvis ja, hvilken type ?
Collett
NA
Nutramigen
Soyamelk
Annet
måneder
Ja Nei
51.    Hvor gammelt var barnet da det
          startet  med følgende matslag ?
Alder i måneder
(kryss)
Ikke fått
Risgrøt
Maisgrøt
Hvetegrøt
Brødskive
Kokte grønnsaker
Middagsmat
på glass
Middagsmat
hjemmelaget
Fisk
48.    Har barnet noen gang fått tran ?
Ja Nei
Hvis ja, hvor gammelt var barnet da det fikk
             tran første gang ?
måneder
Hvis ja, hvor gammelt var barnet da det
              eventuelt sluttet med tran ?
måneder
Har barnet sluttet med tran ?
Ja Nei
Melk
Egg
8
52.   Hvor ofte i gjennomsnitt spiser barnet  torsk,
        sei eller annen mager fisk til middag ? (ett kryss)
Aldri
Sjeldnere enn 1 gang i uken
1 gang i uken
2 ganger i uken
3 ganger i uken
4 ganger i uken eller oftere
53.   Hvor ofte i gjennomsnitt spiser barnet uer,
        kveite, laks, ørret, sild, makrell eller annen fet
        fisk til middag ?  (ett kryss)
Aldri
Sjeldnere enn 1 gang i uken
1 gang i uken
2 ganger i uken
3 ganger i uken
4 ganger i uken eller oftere
Rå grønnsaker
Frukt
Hvis ja, hvor gammelt var barnet da det
              eventuelt sluttet med morsmelk ?
måneder
Hvis ja, har barnet eventuelt sluttet med
              morsmelk ?
Ja Nei
51410
54.   Hvor ofte i gjennomsnitt tar barnet tran
        eller fiskeoljekapsler ?  (ett kryss)
Aldri
Sjeldnere enn 1 gang i uken
1 gang i uken
2 ganger i uken
3 ganger i uken
4 ganger i uken eller oftere
55.   Hvor mange brødskiver i gjennomsnitt spiser
        barnet der pålegget består av fet fisk
        (sild, sardiner, makrell, laks ol.) ? (ett kryss)
Aldri
Mindre enn 1 skive i uken
1-2 skiver i uken
3-6 skiver i uken
1-2 skiver daglig
3-4 skiver daglig
5 eller flere skiver daglig
56.   Hvor ofte spiser barnet i gjennomsnitt
        grønnsaker til middag eller som egen rett ?
57.   Hva slags type fett brukes til matlaging
        i din husholdning og på brødet til barnet  ?
        (flere kryss)
Aldri
Sjelden
Omtrent 1 gang i uken
2-3 ganger i uken
4-5 ganger i uken
Omtrent daglig
Rå grønn-
saker
Kokte grønn-
saker
Spørsmål om røykevaner
58.   Røykte du eller ektefelle/
        samboer ved svangerskapets
        start ?
Du
Ektefelle/samboer
Nei, røykte ikke         Ja, røykte ukentlig                    Ja, røykte daglig
sigaretter ukentlig
sigaretter ukentlig
sigaretter daglig
sigaretter daglig
59.   Røyker du eller ektefelle/
        samboer nå ? Du
Ektefelle/samboer
Nei, røyker ikke         Ja, røyker ukentlig                   Ja, røyker daglig
sigaretter ukentlig
sigaretter ukentlig
sigaretter daglig
sigaretter daglig
60.   Røykes det innendørs hjemme ? Nei, det røykes           Ja, det røykes                           Ja, det røykes
ikke innendørs            ukentlig innendørs                   daglig innendørs
sigaretter ukentlig sigaretter daglig
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Meierismør
Hard margarin
Bløt (soft) margarin
Smør/margarin blanding
Soyaolje
Olivenolje
I hushold-
ningen
På brødet
til barnet
61.   Ble det røykt innendørs hjemme
        etter barnets første leveår ?
Nei, det ble ikke        Ja, det røykes                            Ja, det røykes
røykt innendørs         ukentlig innendørs                    daglig innendørs
sigaretter ukentlig sigaretter daglig
51410
 
 
 
 
Appendix 4 
 
Questionnaire Q4a: 
Questions on risk factors and behaviour 2 years after birth in Norwegian 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.   Er barnet tvilling ?
1 forts. på baksiden
Spørsmål om barnet
Ja Nei Hvis tvilling, svar på alle spørsmålene for tvilling I, deretter svar
                  på spørsmål 1-6 og 40-50 for tvilling II på eget skjema.
2.   Barnets fødselsvekt ? gram
3.   Hvor mange søsken har barnet ?
       (ta med fellesbarn og særkullsbarn, ikke fosterbarn og adoptivbarn) brødre søstre
4.   Når ble barnet født i forhold til beregnet ultralydtermin ? (ett kryss)
Tidligere enn 2 uker før beregnet ultralydtermin
Mellom 3 uker før og 2 uker etter beregnet ultralydtermin
Senere enn 2 uker etter beregnet ultralydtermin
Barneallergistudien i Trondheim
Spørreskjema om livsstilsfaktorer ved 2 års alder
. .Utfylt dato   (dd.mm.åå)
og fødselslengde ? cm
5.   Har barnet blitt vaksinert ? Ja Nei
6.   Har barnet hatt noen av sykdommene nedenfor ?
Forkjølelse
Ørebetennelse
Bronkitt
RS-virusinfeksjon
Lungebetennelse
Urinveisinfeksjon
Mage-tarminfeksjon
                       Hvis ja,
Ja        Nei      antall ganger
Er noen av sykdommene behandlet med penicillin/antibiotika ?
Antall søsken :
Ingen søsken  : (kryss)
Falsk krupp
Ja Nei Vet ikke
Hvis ja,
hvor mange behandlinger
Skriv tydelige tall og kryss. Bruk svart eller blå penn.
7.   Foreldrenes sivilstatus: Gift Samboer Enslig Annet
6464
8.   Har mor, far eller noen av barna noen gang hatt astma, eksem eller allergi i øyne/nese ?
Ja Nei
Hvis ja, kryss av for de familiemedlemmer det gjelder  (flere kryss) :
Mor
Astma       Eksem      Allergi i øyne/nese
Barnefarens særkullsbarn
Dine særkullsbarn
Fellesbarn
Far
Hvis ja,  angi alder i dag, når astmasykdommen startet, om sykdommen fortsatt er til stede,
               og når den eventuelt sluttet.
9.   Har, eller har mor, far eller fellesbarn noen gang hatt astmasykdom ? Ja Nei
Hvis nei, gå til spørsmål 11.
Alder           Startalder       Har fortsatt                       Sluttalder
 i dag                astma               astma (kryss)                   astma
Mor
Far
Fellesbarn 2
Fellesbarn 1
Fellesbarn 3
år
år
år
år
år
år
år
år
år
år
år
år
år
år
år
Hvis nei, gå til spørsmål 14.
2
Spørsmål om foreldre og søsken
10.  Har, eller har mor, far eller fellesbarn hatt astmaplager eller brukt
       astmamedisiner de siste 12 måneder ?
Mor
Fellesbarn  3
Fellesbarn  2
Fellesbarn  1
Far
Hyppighet av astmaplager siste 12 måneder
           Sjeldnere enn                   
Daglig   Ukentlig     Månedlig     månedlig
Ja Nei
Hvis ja, kryss av for
              de det gjelder :
Brukt astmamedisin
siste 12 måneder
 Ja        Nei
11.   Har, eller har mor,far eller fellesbarn hatt eksemplager, eller brukt
        eksemmedisin de siste 12 måneder ?
Hvis ja, kryss av for
              de det gjelder :
Ja Nei
Mor
Fellesbarn  3
Fellesbarn  2
Fellesbarn  1
Far
Hyppighet av eksemplager siste 12 måneder
           Sjeldnere enn                  
Daglig  Ukentlig    Månedlig       månedlig
Brukt eksemmedisin
siste 12 måneder ?
 Ja        Nei
6464
312.  Har, eller har mor, far eller fellesbarn hatt allergi i øyne/nese, eller brukt allergimedisiner ?
Ja Nei
Hvis ja, kryss av (flere kryss)
for de det gjelder :
Mor
Fellesbarn  3
Fellesbarn  2
Fellesbarn  1
Far
13.  Hvis mor, far eller fellesbarn har allergi i øyne/nese, hvordan er det påvist  ?
Allergi påvist ved blodprøve ?                               Allergi påvist ved prikk(hud)-testing ?
Ja         Nei      Vet ikke    Ja          Nei        Vet ikke
Mor
Fellesbarn  3
Fellesbarn  2
Fellesbarn  1
Far
                    Allergi mot
                             Husstøv/
Pollen   Dyrehår    midd       Andre
Brukt allergimedisin
siste 12 måneder ?
 Ja        Nei
Kryss av for
de det gjelder :
14. Kryss av om mor hadde noen av følgende plager i siste svangerskap. Oppgi i hvilken periode, og
      om mulig navn på medisiner som ble brukt.
Plager i siste
svangerskap ?
Svangerskapsblødning
Svangerskapsforgiftning
Forhøyet blodtrykk
Svangerskapsdiabetes
Diabetes, insulinbehandlet
Diabetes, tablettbehandlet
Soppinfeksjon i skjeden
Skjedekatarr/uvanlig utflod
Forkjølelse
Influensa
Bronkitt
Lungebetennelse
Astma
Eksem
Allergi i øyne /nese
0-3 mnd 4-6 mnd 7-9 mnd
Periode i svangerskapet (flere kryss)
Medisinnavn
forts. på baksiden
Hvis nei, gå til spørsmål 14.
Andre plager
Ingen plager
6464
4Spørsmål om bolig / innemiljø nå
15.  I hvilken type bolig bor barnet ?  (ett kryss) 22.  Hvor mange timer oppholder barnet seg  i
        gjennomsnitt i boligen ?
23.  Hvilke av følgende husdyr oppholder seg i
       boligen ?         (flere kryss)
Sokkelleilighet i enebolig
Enebolig/våningshus uten sokkel/kjeller
Rekkehus/kjedehus
Terrassehus
Boligblokk/bygård
Andre pelsdyr (marsvin, kanin o.l.)
Andre dyr
Hund
Katt
Fugl
Enebolig/våningshus med sokkel/kjeller
I boligen
I eget soverom
timer per døgn
timer per døgn
25.   Hvilke energikilder brukes til oppvarming
        av boligen ?  (flere kryss)
24.   Bor barnet på gårdsbruk Ja Nei
Hvis ja, hvilke husdyr er det  på gården ?
              (flere kryss)
16.  Boligens byggeår ?  (årstall)
18.  Boligens boareal (cirka) ?
19.  Hvor mange personer bor det
       for tiden i boligen ?
m2
Hvor lenge har barnet
bodd i boligen ?
Tomannsbolig, firemannsbolig
Annen bolig
Ingen dyr
17.  Eier du/dere boligen ?
Ja, som selveiere
Ja, i borettslag
Nei
Sau
Andre husdyr
Kyr
Gris
Hest
Ingen husdyr
Fjørfe
Olje
Elektristitet
Vedfyring
Fjernvarme
Annet21.  Har boligen sentralstøvsuger ? Ja Nei
månederår
20.  Hvor ofte
       vaskes boligen ? ganger per måned
Hvor ofte
støvsuges  boligen ? ganger per måned
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5 forts. på baksiden
26.   Har, eller har boligen hatt noen av følgende problemer ?
        (besvar alle spørsmål)
Mugglukt eller kjellerlukt
Dugg på vinduer (utenom ved dusjing, fosskoking og sterk kulde)
Fuktflekker på vegg eller tak (fuktflekker som skyldes mindre søl med
vann regnes ikke med her)
Vannlekkasjer fra sanitærinstallasjoner (rør, kraner, dusj, vask o.l.)
Blærer, bobler i eller misfarging av gulvbelegg
 Ja   Nei
Ja,               Nei,
utbedret      ikke utbedret
Hvis ja, er problemet utbedret ?
Vannlekkasjer fra yttertak
Vannlekkasjer fra grunnen/oversvømmelse
Ingen problemer
Aviser og pappesker blir ved lagring 'fuktige'
27.   Hvilke av følgende ventilasjonsutstyr er installert i boligen ?
A. Egen avtrekksvifte over komfyr
B. Egen avtrekksvifte i ventil i yttervegg på våtrom
C. Ventiler i yttervegg/vinduskarm eller luftevindu
D. Sentral avtrekksventilasjon (sentral vifte som gir avtrekk fra bad, toalett og kjøkken)
E. Ventilasjonsanlegg (sentral vifte som gir avtrekk fra bad, toalett og kjøkken, og
     en sentral vifte som gir tilførsel av luft til oppholdsrom og soverom)
Ja               Nei
Hvis ja på D eller E - Omtrent hvor mange timer per døgn er det for tiden i bruk :
- Omtrent hvor mange ganger per år skiftes filter :
Skriv 0 hvis ikke i bruk
Skriv 0 hvis ingen
28.   Hvor ofte gjennomluftes boligen for tiden ved å
        åpne vindu eller dører i minimum 3-5  minutter ?
        (ett kryss)
Aldri
Sjeldnere enn 1 gang om dagen
1 gang om dagen
2 ganger daglig
3 eller flere ganger daglig
29.   Hvilke av følgende aktiviteter foregår daglig i
        boligen uten at elektrisk avtrekksvifte/
        ventilasjon benyttes ?  (flere kryss)
Tørking av tøy
Koking av mat
Bruk av tørkeskap/tørketrommel
Dusjing (mer enn 5 minutter)
Bruk av luftfukter
Ingen aktiviteter
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38.   Hvilke overflater har veggene i soverommet og i
        oppholdsrommet barnet bruker mest ?
         (flere kryss)
Ubehandlet/lutet trepanel
Malt/lakkert trepanel
Annen overflate
39.   Har det blitt gjort noen av følgende endringer i
        boligen siste 12 måneder ?
 Ja            Nei
Nytt furu trepanel eller furu gulv
Nytt vinyl gulv (PVC-plast)
Liming av tapet, strie, gulvbelegg etc.
Maling, lakkering
Andre endringer
Vegg i
barnets
soverom
Vegg i barnets
mest brukte
oppholdsrom
36.   Hvor mange våtrom og andre rom har vinylgulv
        med gulvvarme ?  (Skriv 0 hvis ingen)
37.   Hvilke materialer er brukt på gulv i
        soverommet, og i oppholdsrommet barnet
        bruker mest ?        (flere kryss)
Våtrom (bad, vaskerom, WC) antall rom
Andre rom antall rom
Heldekkende tepper
Vinyl (PVC-plast)
Furu tregulv
Parkett/andre harde materialer
Annet
Annen malt/lakkert overflate
30.   I hvilken etasje av bygningen er barnets
        soverom ? (ett kryss)
Sokkel
Kjeller
1. etasje
2. etasje eller høyere
31.   Sover barnet for tiden med åpent vindu ?
32.   Hva slags dyne eller pute bruker barnet nå ?
Syntetiske fibre
Dun
Ja Nei
Annet
Bruker ikke dyne eller pute
Dyne          Pute
33.   Hvor gammel er barnets nåværende dyne, pute
        og madrass ?
Alder,  (under 1 år skriv 0)
år
år
år
Dyne
Pute
Madrass
35.   Tørkes sengetøyet i tørketrommel ?
Ja Nei
6
Gulv i
barnets
soverom
Gulv i barnets
mest brukte
oppholdsrom
34.   Hvor ofte vaskes
        sengetøyet til barnet ? ganger per måned
Hvor ofte rengjøres
madrassen til barnet ? ganger per år
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Spørsmål om barnets ernæring
40.    Har barnet fått morsmelk ?
42.    Får barnet annet vitamintilskudd ?
         (for eksempel Biovit, Sanasol)
Ja Nei
Ja Nei
43.    Har barnet fått morsmelkerstatning ?
Hvis ja, hvor gammelt var barnet da det
              startet  med morsmelkerstatning ?
Hvis ja, hvilken type ?
Collett
NA
Nutramigen
Soyamelk
Annet
måneder
Ja Nei
44.    Hvor gammelt var barnet da det
          startet  med følgende matslag ?
Alder i måneder
(kryss)
Ikke fått
Fisk
41.    Har barnet noen gang fått tran ?
Ja Nei
Hvis ja, hvor gammelt var barnet da det fikk
              tran første gang ?
Hvis ja, hvor gammelt var barnet da det
              eventuelt sluttet med tran ?
Har barnet sluttet med tran ?
Ja Nei
Melk
Egg
7
45.   Hvor ofte i gjennomsnitt spiser barnet  torsk,
        sei eller annen mager fisk til middag ? (ett kryss)
Aldri
Sjeldnere enn 1 gang i uken
1 gang i uken
2 ganger i uken
3 ganger i uken
4 ganger i uken eller oftere
46.   Hvor ofte i gjennomsnitt spiser barnet uer,
        kveite, laks, ørret, sild, makrell eller annen fet
        fisk til middag ?  (ett kryss)
Aldri
Sjeldnere enn 1 gang i uken
1 gang i uken
2 ganger i uken
3 ganger i uken
4 ganger i uken eller oftere
Hvis ja, hvor gammelt var barnet da det
              eventuelt sluttet med morsmelk ?
månederår
månederår
månederår
Kokte grønnsaker
Rå grønnsaker
Frukt
Hvis ja, har barnet eventuelt sluttet med
              morsmelk ?
Ja Nei
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47.   Hvor ofte i gjennomsnitt tar barnet tran
        eller fiskeoljekapsler ?  (ett kryss)
Aldri
Sjeldnere enn 1 gang i uken
1 gang i uken
2 ganger i uken
3 ganger i uken
4 ganger i uken eller oftere
48.   Hvor mange brødskiver i gjennomsnitt spiser
        barnet der pålegget består av fet fisk
        (sild, sardiner, makrell, laks ol.) ? (ett kryss)
Aldri
Mindre enn 1 skive i uken
1-2 skiver i uken
3-6 skiver i uken
1-2 skiver daglig
3-4 skiver daglig
5 eller flere skiver daglig
49   Hvor ofte spiser barnet i gjennomsnitt
        grønnsaker til middag eller som egen rett ?
50.   Hva slags type fett brukes til matlaging
        i din husholdning og på brødet til barnet  ?
        (flere kryss)
Aldri
Sjelden
Omtrent 1 gang i uken
2-3 ganger i uken
4-5 ganger i uken
Omtrent daglig
Rå grønn-
saker
Kokte grønn-
saker
Spørsmål om røykevaner
51.   Røykte du eller ektefelle/
        samboer ved svangerskapets
        start ?
Du
Ektefelle/samboer
Nei, røykte ikke         Ja, røykte ukentlig                    Ja, røykte daglig
sigaretter ukentlig
sigaretter ukentlig
sigaretter daglig
sigaretter daglig
52.   Røyker du eller ektefelle/
        samboer nå ? Du
Ektefelle/samboer
Nei, røyker ikke         Ja, røyker ukentlig                   Ja, røyker daglig
sigaretter ukentlig
sigaretter ukentlig
sigaretter daglig
sigaretter daglig
53.   Røykes det innendørs hjemme ? Nei, det røykes           Ja, det røykes                           Ja, det røykes
ikke innendørs            ukentlig innendørs                   daglig innendørs
sigaretter ukentlig sigaretter daglig
8
Meierismør
Hard margarin
Bløt (soft) margarin
Smør/margarin blanding
Soyaolje
Olivenolje
I hushold-
ningen
På brødet
til barnet
54.   Ble det røykt innendørs hjemme
        etter barnets første leveår ?
Nei, det ble ikke        Ja, det røykes                            Ja, det røykes
røykt innendørs         ukentlig innendørs                    daglig innendørs
sigaretter ukentlig sigaretter daglig
6464
9Barnepass
55.   Har barnet hatt daglig tilsyn av andre enn mor eller far siden fødselen ?
Ja Nei
Hvis ja, oppgi hvem som har hatt tilsyn med barnet, start, slutt og varighet av tilsynet ?
Dagmamma o.l. hjemme
Dagmamma o.l. utenfor hjemmet
Familiebarnehage
Barnepark
Barnehage
måneder
måneder
måneder
måneder
måneder
Barnets alder ved
start med tilsynet
måneder
måneder
måneder
måneder
måneder
Barnets alder ved
slutt med tilsynet
timer pr. uke
Tilsynets varighet
timer pr. uke
timer pr. uke
timer pr. uke
timer pr. uke
56.   Hva slags tilsyn har barnet nå ?
          (flere kryss)
Mor eller far hjemme
Dagmamma o.l. hjemme
Dagmamma o.l. utenfor hjemmet
Familiebarnehage
Barnepark
Barnehage
Annet
6464
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Barneallergistudien i Trondheim
1 forts. på baksiden
Spørreskjema om barnets helse ved 2 eller 6 års alder
2.   Har barnet noen gang hatt episoder med piping
       i brystet ?
Ja Nei Vet ikke
3.   Har barnet noen gang hatt episoder med surkling
eller tetthet i brystet ?
Ja Nei Vet ikke
7.   Har barnet hatt piping, surkling eller tetthet i
       brystet de siste 12 måneder ?  (ett kryss)
Ja, nesten daglig
Ja, 1-3 ganger pr. uke
Ja, 1-3 ganger pr. måned
Ja, sjeldnere enn 1 gang pr. måned
Nei
4.   Har barnet noen gang hatt tørr hoste om natten
      unntatt ved forkjølelse eller andre
      luftveisinfeksjoner ?
Ja Nei Vet ikke
1.   Har barnet noen gang hatt pustevansker ?
Ja Nei Vet ikke
. .Utfylt dato (dd.mm.åå)
5.   Har barnet noen gang hatt episoder med hvesing
      eller tung pust ?
Ja Nei Vet ikke
Hvis du har svart "Ja" på minst ett av spørsmålene over så fortsetter du med  spørsmål 6.
Hvis du har svart "Nei" på alle spørsmålene ovenfor, gå til spørsmål 18.
6.   Har barnet noen gang hatt anfall av piping,
      surkling eller tetthet i brystet i ro, når han/hun
      ikke er forkjølet ?
Ja Nei Vet ikke
8.  I de siste 12 månedene : Har barnet ditt vanligvis virket tett i brystet eller hostet opp slim :
Ved forkjølelse ?
Når han/hun ikke var forkjølet ?
Ja Nei Vet ikke
Er barnet ditt tett i brystet eller hoster opp slim
på de fleste dager (4 eller flere dager i uken, så lenge
som 3 måneder i året) ?
Ja Nei Vet ikke
Ja Nei Vet ikke
Skriv tydelige tall og kryss. Bruk svart eller blå penn.
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217.  Har barnet i løpet av de siste 12 måneder brukt
        tabletter, inhalasjonsmedisiner eller annen
        behandling for piping, tetthet i brystet eller
        astma ?
Ja Nei Vet ikke
12.  Forårsaker noe av det følgende piping, surkling
       eller tetthet i brystet ?  (besvar alle spørsmål)
Ja        Nei
Nyklippet gress, blomster, eller trær
Kontakt med dyr
Re senger eller husrengjøring
Løp eller annen aktivitet
Kulde
Hvis ja, gjør rede for medisinene barnet bruker :
              (Med fast medisin mener vi medisin som brukes
                 hver dag minst to måneder i året )
Ved behov Fast medisin
Før, under eller
etter anstrengelse
Acculate
Airomir
Atrovent
Bambec
Becotide
Berotec
Bricanyl
Flunitec
Flutide
Lomudal
Oxis
Pulmicort
Salbuvent
Serevent
Seretide
Singulair
Ventoline
14.  Har barnet fremdeles astma ?
Ja Nei
13.  Har barnet noen gang fått stilt diagnosen
       astma av lege ?
Ja Nei
Hvis ja, hvor gammel var barnet første gang det
               hadde astma ?
måneder
Hvis nei, gå til spørsmål 18.
16.  Har barnet noen gang fått behandling av
       lege eller vært  innlagt i sykehus for astma ?
Ja Nei
15.  Hvis barnet ikke lenger har astma, hvor gammelt
       var barnet da astmaen forsvant  ?
måneder
Annet
9.  I de siste 12 månedene : Har barnet ditt hatt tung
     pust, tetthet eller piping i brystet :
Under eller etter fysisk aktivitet ?
Når han/hun ikke har vært
fysisk aktiv ?
Ja Nei Vet ikke
10. I de siste 12 månedene : Har barnet ditt hatt tung
      pust, tetthet eller piping i brystet når :
Han/hun var forkjølet eller
hadde influensa ?
Han/hun ikke var forkjølet
eller hadde influensa ?
Ja Nei Vet ikke
11. Har barnet ditt noen gang våknet opp med  :
Pustevansker ?
Tetthet i brystet ?
Ja Nei Vet ikke
år
år
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26.  Har barnet noen gang fått behandling av
       lege eller vært innlagt i sykehus for :
       (besvar alle spørsmål)
Ja     Nei
Høysnue, neseallergi eller allergisk øyekatarr ?
Eksem ?
Elveblest (urtikaria) ?
3
25.  Er barnet allergitestet med hudtest/prikktest eller
       blodprøve ?
Hvis ja, hvilken allergi ble påvist ? (flere kryss)
Ja Nei Vet ikke
24.  Har barnet i løpet av de siste 12 måneder
       brukt allergimedisiner ?
Ja Nei Vet ikke
23.  Har barnet i løpet av de siste 12 månder brukt
       noen medisiner, salver, kremer, tabletter eller
       naturmedisiner mot eksem ?
Ja Nei Vet ikke
22.  Har barnet noen gang hatt kløende utslett som
        har kommet og gått i minst 6 måneder ?
Ja Nei Vet ikke
forts. på baksiden
20.  Har barnet noen gang hatt høysnue, neseallergi
       eller allergisk øyekatarr ?
Ja Nei Vet ikke
Hvis ja, hvor gammelt var barnet første gang det
              hadde høysnue, neseallergi eller
              allergisk øyekatarr ?
måneder
21.   Har barnet noen gang hatt eksem ?
Ja Nei Vet ikke
Hvis ja, hvor gammelt var barnet første gang det
              hadde eksem ?
måneder
19.  Har barnet hatt tett nese eller rennende nese
       uten å være forkjølet siste 12 måneder ?
Ja Nei Vet ikke
18.  Har barnet noen gang hatt tett nese, eller hatt
        rennende nese uten å være forkjølet ?
Hvis ja, når har eller har barnet hatt tett nese eller
              rennende nese uten å være forkjølet ?
              (flere kryss)
Ja Nei Vet ikke
Pollen
Dyrehår
Husstøv
Annen
Vet ikke
Vår Sommer Høst Vinter
år
år
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428. Opplysninger om sykehusinnleggelser :       
Siste innleggelse  -  dato ?         (dd.mm.åå)
Siste innleggelse  -  hvor ?
Barnets fastlege :
Legesenter :
27.  Har barnet hatt noen av sykdommene nedenfor ?  (besvar alle spørsmål)
Forkjølelse
Ørebetennelse
Bronkitt
RS-virusinfeksjon
Lungebetennelse
Urinveisinfeksjon
Mage-tarminfeksjon
                       Hvis ja,
Ja        Nei      antall ganger
Er noen av sykdommene behandlet med penicillin/antibiotika ?
Falsk krupp
. .
      Hvis ja,
Ja       Nei    Vet ikke       hvor mange behandlinger
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B A R N E A L L E R G I  S T U D I E N  I  T R O N D H E I M
P R E V E N T I O N  O F  A T O P Y  A M O N G  C H I L D R E N  I N  T R O N D H E I M .
Vil du hjelpe 
oss i arbeidet
med å forebygge  
barneallergi?
G r a v i d e
I den vestlige del av verden har tallet på barn
med allergiplager steget betydelig de siste 10-
15 årene. Årsakene til denne økningen er ikke
kjent, men mange fagfolk mener at miljøfor-
urensning, endrede kost- og livsstilsvaner og
forandringer i virus- og bakterieinfeksjoner 
har betydning. 
I denne studien vil vi se på virkningene av
flere forebyggende tiltak. I tillegg vil vi under-
søke samspillet mellom flere mulige årsaker til
barneallergi.
Trondheim kommune, forskningsmiljøene ved
NTNU og SINTEF Unimed og Folkehelsa går
nå i gang med en stor studie viet barneallergi.
Her vil vi undersøke effekten av å forebygge 
allergisykdommer som astma, eksem og høy-
snue hos små barn.
Til det trenger vi hjelp fra deg som er 
gravid.
H V
H V O R D A N  S K A L  S T U D I E N  G J E N N O M F Ø R E S ?
Vi vil studere effektene av ulike typer
forebyggende tiltak. For å få til det, må 
vi sammenligne gravide/ barn som følger
dagens opplegg ved legekontor og helse-
stasjoner (kontrollgruppen), med andre
som skal prøve ut nye tiltak fra 
sommeren 2001. 
Med dette inviterer vi deg til å delta i
kontrollgruppen som får de råd og den
veiledning som gis i dag. 
H VA  Ø N S K E R  V I  Å  S T U D E R E ?
T I L  D E G  S O M  E R  G R AV I D
O R I E N T E R I N G  O M
B A R N E A L L E R G I  
S T U D I E N  I
T R O N D H E I M
Å delta i kontrollgruppen innebærer å
svare på spørreskjema om allergiske syk-
dommer i familie/slekt, om livsstil og
boforhold (Livsstilskjema), og om barnets
helse og sykdom (Helseskjemaet). 
Livsstilsskjemaet besvares av gravide, og
etter fødselen skal det fylles ut ved seks-
ukers-undersøkelsen og ved ett- og toårs-
undersøkelsene på helsestasjonene. 
Helseskjemaet skal besvares ved to- og
seksårsalderen. 
Noen barn med allergisykdom eller 
plager som kan skyldes allergi, vil få 
tilbud om vanlig klinisk undersøkelse,
måling av lungefunksjon (pusteprøver) og
allergiutredning (allergitest og blodprø-
ver), så fremt dette ikke er utført hos den
ordinære helsetjenesten. I tillegg vil et til-
feldig utvalg av friske barn få et tilbud
om slik utredning. Dersom barnet er
undersøkt og utredet for allergi, kan vi få
vite resultatene av slike undersøkelser fra 
barnets helsejournaler.
TILLEGGSUNDERSØKELSE  OM ÅRSAKER T IL  BARNE ALLERGI
A  I N N E B Æ R E R  D E T  Å  VÆ R E  M E D  I  K O N T R O L L G R U P P E N ?
Hvis du har spørsmål nå eller seinere om studien og deltakelsen i den kan du kontakte:
Kommuneoverlege Helge Garåsen, Trondheim kommune Tlf. 73 54 87 47
Prosjektsekretær Anita Stølan, Institutt for samfunnsmedisinske fag og allmennmedisin Tlf. 73 59 68 97
Stipendiat og prosjektkoordinator Jon A. Jenssen, SINTEF Unimed Tlf. 73 59 10 06
Jon A. Jenssen Torbjørn Øien Ola Storrø Helge Garåsen
Stipendiat/siv.ing Stipendiat/lege Stipendiat/lege Kommuneoverlege
Du får med dette også et tilbud om å delta i en tilleggsstudie der vi skal
undersøke årsaker til utvikling av barneallergi.
I denne studien vil vi følge et mindre ut-
valg av barn (600 barn) fram til de er to
år. Her vil vi studere utviklingen av bak-
teriesammensetningen i barnets tarm.
Dette gjør vi ved å undersøke bakterie-
sammensetningen i avføringen og sam-
tidig studere faktorer som påvirker denne.
Når vi kjenner bakteriesammensetningen
i avføringen og vet om den endrer seg de
to første leveårene, kan vi studere om
dette har betydning for modningen av
immunapparatet og en eventuell utvikling
av barneallergi. 
Til denne studien trenger vi i tillegg til
opplysningene fra kontrollgruppen, av-
føringsprøve av mor før og ved fødselen
sammen med bakterieprøve av skjeden
ved fødselen. Fra barnet er det nødvendig
med avføringsprøver ved 10 dager,
6 uker, 4 måneder, 1 år og 2 år. I tillegg 
vil det være ønskelig med blodprøve fra 
barnet ved de samme tidspunktene, og fra
mor ved fødsel. Blodprøvene vil bli tatt
ved Regionsykehuset i Trondheim, av
personell som er spesialtrent til å ta blod-
prøver av små barn. Vi tilbyr bedøvelses-
krem på huden før prøvetakingen.
Hos noen av dere som deltar i tilleggs-
studien ønsker vi også å undersøke om
innelufta i barnets hjem inneholder midd,
muggsopp og allergiframkallende stoffer
fra husdyr, samt måle nikotininnholdet i
en liten hårprøve fra barnet. Dette fordi vi
ønsker å se om det er en sammenheng
mellom det vi finner her og en eventuell
utvikling av allergi hos barnet. Et utvalg
av de som har tegn til allergi ved toårs-
alderen og en tilsvarende gruppe uten
slike tegn, vil få tilbud om hjemmebesøk.
Besøket vil innebære prøvetaking av
innelufta i hjemmet.
VEDLAGT FØLGER ET SKJEMA FOR SAMTYKKE TIL Å DELTA I KONTROLL-
GRUPPEN OG ET SKJEMA FOR Å DELTA I TILLEGGSSTUDIEN.
N Å R  D U  H A R  S K R E V E T  U N D E R  S A M T Y K K E -
E R K L Æ R I N G E N  R I V E S  D E N  AV  O G  L E V E R E S .
SAMTYKKE-ERKLÆRING TIL KONTROLLG R U P P E N
Vi spør om tillatelse til å sammenholde opplysningene fra 
spørreskjema med opplysninger i:
Barnets helsekort, Barnets primærlegejournal og Barnets 
sykehusjournal.
Studien er vurdert av Regional Etisk Komite for Midt-Norge. 
Tillatelse til oppretting av forskningsregister er gitt av
Datatilsynet.
All personinformasjon vil bli behandlet strengt konfidensielt, og
all databearbeiding vil foregå på anonymiserte datasett. 
Videre ber vi om at du skriftlig bekrefter at du vil delta i studien.
Deltakelse i studien er frivillig, og et samtykke kan når som
helst trekkes tilbake uten nærmere begrunnelse. 
Deltakelsen medfører
- å besvare spørreskjema om risikofaktorer for 
barneallergi og om barnets helse
- utredning av allergi hos barnelege
Jeg samtykker i å delta i Barneallergistudien
ja  nei
Og at opplysningene sammen med resultatene 
fra tilleggsundersøkelser oppbevares til forskningsformål.
Og jeg tillater at opplysningene om barnets helse i spørre-
skjemaene sammenholdes med informasjon i barnets helsekort,
primærlegejournal og sykehusjournal.   
ja  nei
Trondheim den      /       /
…………………………….........……….……………………….
Signatur
VEND!
SAMTYKKE-ERKLÆRING TIL DELSTUDIEN
Du har samtykket i å delta i kontrollgruppen. Dersom du er 
villig til å delta i Delstudien, ber vi om at du skriftlig bekrefter
dette. Deltakelse i studien er frivillig, og et samtykke kan når
som helst trekkes tilbake uten nærmere begrunnelse. 
Deltakelsen medfører som en del av kontrollgruppen
- å besvare spørreskjema om risikofaktorer for 
barneallergi og om barnets helse
- utredning av allergi hos barnelege
I tillegg medfører deltakelsen
- innlevering av avføringsprøver og taking av 
blodprøver
Jeg samtykker i å delta i Delstudien,
ja  nei
og at opplysningene sammen med avføringsprøver og
blodprøver oppbevares til forskningsformål.
Trondheim den      /       /
…………………………….........……….……………………….
Signatur
HVIS DU HAR SPØRSMÅL OM SAMTYKKE- 
ERKLÆRINGEN, VENNLIGST KONTAKT:
Kommuneoverlege Helge Garåsen,
Trondheim kommune 
Tlf. 73 54 87 47
Prosjektsekretær Anita Stølan,
Institutt for samfunnsmedisinske fag og allmennmedisin 
Tlf. 73 59 68 97
Projektkoordinator Jon A Jenssen,
SINTEF Unimed 
Tlf. 73 59 10 06
Projektveileder Professor Roar Johnsen,
Institutt for samfunnsmedisinske fag og allmennmedisin 
Tlf. 73 59 75 80
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KOPI AV SAMTYKKE-ERKLÆRING 
Vi spør om tillatelse til å sammenholde opplysningene
fra spørreskjema med opplysninger i:
Barnets helsekort, Barnets primærlegejournal og Barnets 
sykehusjournal.
Studien er vurdert av Regional Etisk Komite for 
Midt-Norge. 
Tillatelse til oppretting av forskningsregister er gitt av
Datatilsynet.
All personinformasjon vil bli behandlet strengt konfidensielt,
og all databearbeiding vil foregå på anonymiserte datasett. 
Videre ber vi om at du skriftlig bekrefter at du vil delta i
studien. Deltakelse i studien er frivillig, og et samtykke kan
når som helst trekkes tilbake uten nærmere begrunnelse. 
Deltakelsen medfører
- å besvare spørreskjema om risikofaktorer for
barneallergi og om barnets helse
- utredning av allergi hos barnelege
Jeg samtykker i å delta i Barneallergistudien
ja  nei
Og at opplysningene sammen med resultatene 
fra tilleggsundersøkelser oppbevares til forskningsformål.
Og jeg tillater at opplysningene om barnets helse i spørre-
skjemaene sammenholdes med informasjon i barnets 
helsekort, primærlegejournal og sykehusjournal.  
ja  nei
Trondheim den      /       /
…………………………….........……….………………...
Signatur
Du har samtykket i å delta i kontrollgruppen. Dersom du
er villig til å delta i Delstudien ber vi om at du skriftlig
bekrefter dette. Deltakelse i studien er frivillig, og et 
samtykke kan når som helst trekkes tilbake uten nærmere
begrunnelse. 
Deltakelsen medfører som en del av Hovedstudien
- å besvare spørreskjema om risikofaktorer for 
barneallergi 
og om barnets helse
- utredning av allergi hos barnelege
I tillegg medfører deltakelsen
- innlevering av avføringsprøver og taking av 
blodprøver
Jeg samtykker i å delta i Delstudien,
ja  nei
og at opplysningene sammen med avføringsprøver og
blodprøver oppbevares til forskningsformål.
Trondheim den   /       /
…………………………….........……….………………...
Signatur
HVIS DU HAR SPØRSMÅL OM SAMTYKKE- 
ERKLÆRINGEN, VENNLIGST KONTAKT:
Kommuneoverlege Helge Garåsen,
Trondheim kommune 
Tlf. 73 54 87 47
Prosjektsekretær Anita Stølan,
Institutt for samfunnsmedisinske fag og allmennmedisin 
Tlf. 73 59 68 97
Projektkoordinator Jon A Jenssen,
SINTEF Unimed 
Tlf. 73 59 10 06
Projektveileder Professor Roar Johnsen,
Institutt for samfunnsmedisinske fag og allmennmedisin 
Tlf. 73 59 75 80
Samtykke-erklæring til kontrollgruppen Samtykke-erklæring til delstudien
 
 
 
Appendix 7 
 
Information brochure and informed consent (intervention cohort) in Norwegian 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B A R N E A L L E R G I S T U D I E N  I  T R O N D H E I M
P R E V E N T I O N  O F  A T O P Y  A M O N G  C H I L D R E N  I N  T R O N D H E I M .
Vil du hjelpe 
oss i arbeidet
med å forebygge   
barneallergi?
Til deg som er
GRAVID
SAMTYKKE-ERKLÆRING
I den vestlige del av verden har antallet barn
med allergiplager steget betydelig de siste 
30-40 årene. Årsaken til denne økningen er
ikke kjent, men mange fagfolk mener at miljø-
forurensing, endrede kost- og livsstilsvaner og
forandringer i virus og bakteriesammen-
setningen i miljøet vårt har betydning. I denne
undersøkelsen studerer vi virkningene av flere
forebyggende tiltak. Samtidig undersøker vi
samspillet mellom flere mulige årsaker til 
barneallergi.
Hvordan skal studien gjennomføres?
Hva ønsker vi å studere?
Vi inviterer deg til å delta i 
tiltaksgruppen som skal få ekstra
råd og veiledning i svangerskapet 
og barnets to første leveår. 
•• TIL  DEG SOM 
ER GRAVID
••
••
Vi vil studere effekten av å : 
•• Øke inntak av omega 3 fettsyrer (viktig 
bestandel i fet fisk og tran) i svanger-
skapet og barnets to første leveår.
•• Redusere eksponering for tobakksrøyk 
for barnet i fosterlivet og de første leveår.
•• Utbedre fuktproblem og fuktskader 
i boliger for å redusere eksponeringen 
for husstøvmidd og sopp.
Gjennomføringen av disse tiltakene starter ved
svangerskapskontrollene i Trondheim fra mai
2002 (tiltaksgruppen). For å måle effekten av
tiltakene vil tiltaksgruppen bli sammenliknet
med en kontrollgruppe. Kontrollgruppen har
siden høsten 2000 fulgt vanlig opplegg ved
legekontor og helsestasjoner.
ORIENTERING OM BARNE
Trondheim kommune, forskningsmiljøene ved 
SINTEF Unimed og Det Medisinske fakultet har startet en 
stor studie om barneallergi. Hovedhensikten er å forebygge 
allergiske sykdommer som astma, eksem og høysnue hos små barn. 
Best effekt oppnås hvis tiltakene iverksettes 
tidlig i svangerskapet.
Derfor henvender vi oss til deg som er gravid.
Hvis du har spørsmål nå eller seinere om studien og deltakelsen i den kan du kontakte:
Kommuneoverlege Helge Garåsen, Trondheim kommune Tlf. 73 54 87 47
Prosjektsekretær Anita Stølan, Sintef Unimed Tlf. 73 59 68 97
Stipendiat og prosjektkoordinator Jon A. Jenssen, SINTEF Unimed Tlf. 73 59 10 06
Projektveileder Professor Roar Johnsen, Institutt for samfunnsmedisinske fag og allmennmedisin Tlf. 73 59 75 80
Jon A. Jenssen Torbjørn Øien Ola Storrø Helge Garåsen
Stipendiat/siv.ing Stipendiat/lege Stipendiat/lege Kommuneoverlege
VEDLAGT FØLGER ET SKJEMA FOR SAMTYKKE 
TIL Å DELTA I TILTAKSGRUPPEN
Når du har skrevet under samtykkeerklæringen 
rives den av og leveres.
Å delta i tiltaksgruppen innebærer å svare på
spørreskjema om allergiske sykdommer i
familie/slekt, om livstil og boforhold (livstils-
skjema) og om barnets helse og sykdom (hel-
seskjema). 
Livsstilsskjemaet besvares av gravide, og
etter fødselen skal det fylles ut ved 6 ukers-
undersøkelsen og ved ett- og toårsunder-
søkelsene på helsestasjonene.
Helseskjemaet skal besvares ved to- 
og seksårsalderen.
Tiltakene
Alle vil få generell veiledning om kost, inne-
klima og røyking. I tillegg vil spørreskjemaet
bli brukt til å identifisere de som har behov
for tilpasset veiledning innenfor de tre tiltaks-
områdene. Det vil blant annet bli arrangert
matlagingskurs, røykeavvenningskurs og gitt
bistand til å avdekke fuktproblem i aktuelle
boliger. 
Hos noen av dere som deltar vil vi også
undersøke om innelufta i barnets hjem inne-
holder husstøvmidd, muggsopp og allergi-
framkallende stoffer fra husdyr, samt måle
nikotininnholdet i en liten hårprøve fra barnet.
Dette gjør vi for å få objektive mål på om de
nye tiltakene er effektive med hensyn til å
endre risikofaktorene for allergisk sykdom.
Noen foreldre med barn med allergisk 
sykdom eller allergiske plager, vil få tilbud
om vanlig klinisk undersøkelse av barnet hos 
barnelege med måling av lungefunksjon 
(pusteprøver) og allergiutredning (allergitest
og blodprøver). I tillegg vil et tilfeldig utvalg
av foreldre med friske barn få et tilbud om 
slik utredning av barnet. 
Vi ber om tillatelse til å innhente opplysninger
fra helsekort for gravide og barnets helsejour-
naler.
Hva innebærer det å være med i tiltaksgruppen? 
E ALLERGISTUDIEN I  TRONDHEIM
••
••
VEND!
SAMTYKKE-ERKLÆRING TIL 
TILTAKSGRUPPEN
Vi spør om tillatelse til å sammenholde opplysningene fra 
spørreskjema med opplysninger i:
Helsekort for gravide
Barnets helsekort
Barnets primærlegejournal
Barnets sykehusjournal
Studien er vurdert av Regional Komite for medisinsk forsknings-
etikk, Region Midt-Norge. Tillatelse til oppretting av forsknings-
register er gitt av Datatilsynet.
All personinformasjon vil bli behandlet strengt konfidensielt,
og all databearbeiding vil foregå på avidentifiserte datasett. 
Det betyr at forskeren ikke kan kan idenfisere enkeltpersoner 
på analysefilen.
Videre ber vi om at du skriftlig bekrefter at du vil delta i studien.
Deltakelse i studien er frivillig, og du kan når som helst trekke
deg fra studien uten nærmere begrunnelse. 
Deltakelsen medfører
•• å besvare spørreskjema om leve- og livsstilsfaktorer og om 
barnets helse med tanke på barneallergi
•• å motta veiledning om kosthold, røyking og inneklima
•• utredning av allergi hos barnelege med blodprøvetaking,
allergitesting og lungefunksjonsprøver
Jeg samtykker i å delta i Barneallergistudien
ja nei
…og at opplysningene sammen med resultatene 
fra tilleggsundersøkelser oppbevares til forskningsformål.
…og jeg tillater at opplysningene om barnets helse i spørre-
skjemaene sammenholdes med informasjon i helsekort for 
gravide, barnets helsekort, primærlegejournal og sykehusjournal.
ja nei
Trondheim den      /       /
…………………………….........……….………………...
Signatur
Hvis du har spørsmål om 
samtykkeerklæringen, 
vennligst kontakt:
Kommuneoverlege Helge Garåsen,
Trondheim kommune 
Tlf. 72 54 87 47
Prosjektsekretær Anita Stølan,
SINTEF Unimed 
Tlf. 73 59 68 97
Projektkoordinator Jon A Jenssen,
SINTEF Unimed 
Tlf. 73 59 10 06
Projektveileder Professor Roar Johnsen,
Institutt for samfunnsmedisinske fag og allmennmedisin 
Tlf. 73 59 75 80
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KOPI AV SAMTYKKE-ERKLÆRING 
TIL  TILTAKSGRUPPEN.
Vi spør om tillatelse til å sammenholde opplysningene fra 
spørreskjema med opplysninger i:
Helsekort for gravide
Barnets helsekort
Barnets primærlegejournal
Barnets sykehusjournal
Studien er vurdert av Regional Komite for medisinsk forsknings-
etikk, Region Midt-Norge. Tillatelse til oppretting av forsknings-
register er gitt av Datatilsynet.
All personinformasjon vil bli behandlet strengt konfidensielt,
og all databearbeiding vil foregå på avidentifiserte datasett. 
Det betyr at forskeren ikke kan kan idenfisere enkeltpersoner 
på analysefilen.
Videre ber vi om at du skriftlig bekrefter at du vil delta i studien.
Deltakelse i studien er frivillig, og du kan når som helst trekke
deg fra studien uten nærmere begrunnelse. 
Deltakelsen medfører
•• å besvare spørreskjema om leve- og livsstilsfaktorer og om 
barnets helse med tanke på barneallergi
•• å motta veiledning om kosthold, røyking og inneklima
•• utredning av allergi hos barnelege med blodprøvetaking,
allergitesting og lungefunksjonsprøver
Jeg samtykker i å delta i Barneallergistudien
ja nei
…og at opplysningene sammen med resultatene 
fra tilleggsundersøkelser oppbevares til forskningsformål.
…og jeg tillater at opplysningene om barnets helse i spørre-
skjemaene sammenholdes med informasjon i helsekort for 
gravide, barnets helsekort, primærlegejournal og sykehusjournal.
ja nei
Trondheim den      /       /
…………………………….........……….………………...
Signatur
 
 
 
Appendix 8 
 
Information brochure and advice to health worker regarding the intervention topics  
in Norwegian 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B A R N E A L L E R G I S T U D I E N  I  T R O N D H E I M
P R E V E N T I O N  O F  A T O P Y  A M O N G  C H I L D R E N  I N  T R O N D H E I M .
Om intervensjonen 
i Barneallergistudien 
i Trondheim
Veiledning for
LEGE  
JORDMOR
og
INTERVENSJONEN I  BARNE
•• RØYKE AVVENNING
••
••
••
Målsetting
Målet med røykeintervensjonen er å få flest mulig av de gravide som røyker og
ektefelle/samboer som røyker til å slutte å røyke og at kvinner som slutter å røyke
i svangerskapet forblir røykfrie etter fødselen.
••
Røykeavvenningsprogrammer
har vist å øke muligheten for
at gravide slutter å røyke
•• Oppmerksomhet mot problemet i svanger
skapsomsorgen har effekt i seg selv. 
•• Tilbud om røykeavvenning skal være obli-
gatorisk og rutinemessig i all svangerskaps-
omsorg slik som BT-kontroll, veiing, urin
kontroller osv…
Hvorfor røykende kvinner
ikke slutter å røyke når de 
er gravide
•• Negativ innvirkning på den gravide av 
røykeslutt, fordi røyking er en måte for 
henne å mestre stress på og å klare en 
strevsom hverdag.
•• En forestilling om at røykeslutt gir større 
babyer, mer slitsom og smertefull fødsel 
med risiko for keisersnitt.
•• Ukompliserte tidligere svangerskap med 
friske barn, og kjennskap til andre kvinner 
som har røkt i svangerskapet uten følger 
verken for svangerskap, fødsel eller for 
barna.
•• Det er en økende sosial ulikhet mellom 
røykere og ikkerøykere blant gravide.
Røykesluttprogrammer bør
tilpasses de lokale forhold
(kulturelle, sosiale, utdanningsmessige forhold osv.) 
•• Et røyeintervensjonsprogram som fungerer 
i et land/kultur/samfunn behøver ikke å 
fungere et annet sted. 
•• Brukermedvirkning i utformingen av det 
"lokale" programmet er viktig.
•• Helsearbeiderne bør ha innvirkning på 
programmet de skal bruke i sin daglige 
praksis.
•• Helsearbeiderne vil ha nytte av opplæring 
i røykeavvenning, selv om dette kun er 
dokumentert å gi øket aktivitet i røyke-
avvenningen, men ikke sikkert øket effekt
av denne.
Trondheim kommune tilbyr:
•• samarbeid med resursshelsestasjon for 
røykeavvenning.
•• strukturert røykeavvenigskurs over 
3 kvelder.
Litteratur røykeavvenning
Sowden AJ, Arblaster L. Mass media interventions for
preventing smoking in young people (Cochrane Review)
In The Cochrane Library, Issue 3, 1999.
Goldman LK, Glanz SA. Evaluation of antismoking
advertising campaigns. JAMA 1998 Mar 11; 
279(10): 772-7.
Sanner T, Dybing E Helseskader ved passiv røyking.
Tidsskr Nor Lægeforen. 1996; 11:3420-22.
Kendler KS, Neale MC Sullivan P et al. A population
based twin study in women of smoking initiation and
nicotine dependence. Psychol Med 1999; 29(2): 299-308.
Lamkin LP, Houston TP. Nicotine dependency and ado-
lescents: preventing and treating. Prim Care 1998; 
25(1): 123-35.
Raw M, McNeill A, West R. Smoking cessation: eviden-
ce based recommendations for the healthcare system.
BMJ 1999; 318: 182-5 
Lancaster T, Silagy C, Fowler G, Spiers I. Training
health professionals in smoking cessation (Cochrane
Review) In: The Cochrane Library, Issue 3, 1999.
Chapman S. (News) Scare tactics cut smoking rates in
Australia to all time low. BMJ 1999; 318:1508.
Silagy C, Mant D, Fowler G, Lancaster T. Nicotine
replacement therapy for smoking cessation (Cochrane
Review) In: The Cochrane Library, Issue 3, 1999.
White AR, Rampes H. Acupuncture for smoking cessati-
on (Cochrane Review) In: The Cochrane Library, Issue
3, 1999.
Abbot NC, Stead LF, White AR et al. Hypnotherapy for
smoking cessation (Cochrane Review) In: The Cochrane
Library, Issue 3, 1999.
Jorenby DE, Leischow SJ, Nides MA et al. A controlled
trial of sustained-release Bupropion, a nicotine patch, or
both for smoking cessation. N Engl J Med 1999;
340:685-91.
•• KOSTHOLD
••
ALLERGISTUDIEN I  TRONDHEIM
Målsetting
Målet med kostholdsintervensjonen er 
å øke inntaket av omega-3 fettsyrer, både
under svangerskapet og i barnets to første
leveår. I svangerskapet ønsker vi at alle 
gravide spiser minst to måltider i uken med
feit fisk som laks, ørret, sild, makrell, uer 
og kveite. I tillegg ønsker vi at den gravide
tar 5 ml tran under hele svangerskapet. 
Vi ønsker også at alle barn tar tran fra 4-6
ukers alder, og at feit fisk blir introdusert
som middagsmat og pålegg fra 6 måneders
alder, og at barnet spiser minst to slike 
måltider i uken fra 6 måneders alder. Unn-
tatt fra dette er barn som har høy risiko for
å utvikle atopisk sykdom. Et høyrisikobarn
kan defineres som et barn hvor både mor 
og far har betydelig allergisk sykdom, eller
mor og et søsken har betydelig allergisk 
sykdom. Anbefalingene som gis i interven-
sjonen bygger på anbefalinger gitt av
Statens råd for ernæring og fysisk 
aktivitet.(1) 
Bakgrunnen for kostholdsintervensjonen er en
australsk studie som viser at inntak av minst
ett måltid med fet fisk i uken reduserer fore-
komsten av astma hos barn i alderen 9-11 
år (2). Et høyt kostinntak av fett fra planter
(omega-6) i forhold til fett fra fisk (omega-3)
kan være en risikofaktor for å utvikle atopisk
sykdom (3). Forholdet mellom ulike lang-
kjedede flerumettede fettsyrer i blod viser seg 
og være annerledes hos mødre med atopi og
mødre som får barn med atopi. Dette tyder på
at atopi har en sammenheng med en forstyrret
fettsyremetbolisme (4,5). Den gravides kost-
hold kan derfor se ut til å ha betydning for
barnets sykdomsutvikling. I en velernært
populasjon er omega-3 fettsyre nivåene hos 
de nyfødte påvirket av nivåene hos moren (6).
Hvis mor tar tilskudd av omega-3-fettsyrer,
f.eks i form av tran, fører det til en høyere
konsentrasjon av disse fettsyrene både i blod 
og morsmelk (7,8). Kvinner som inkluderer
fisk i kostholdet, har høyere konsentrasjon av
omega-3fettsyrer i morsmelken enn kvinner
som lever på et vegetarisk kosthold (9).
Kosthold under graviditet
Det foreligger studier som tyder på at sensibi-
lisering med allergener kan skje allerede
mellom 15. og 22. svangerskapsuke. Hvilken
klinisk betydning denne sensibiliseringen har
for senere utvikling av allergi er uklart. Det er
foretatt klinisk prospektive studier hvor det er
gjort forsøk på å eliminere allergen fra mors
kost i svangerskapet, uten at dette har ført til
noen redusert forekomst av allergisykdom hos
barnet. En slik diett kan imidlertid ha negativ
innvirkning på ernæringstilstanden til mor og
foster, og gi lavere fødselsvekt.
Vi har derfor fra et allergisynspunkt ingen 
holdepunkter for å anbefale spesielle kostråd
til gravide, antigenunnvikelse under svanger-
skapet hos kvinner med høy risiko for atopisk
sykdom reduserer med liten sannsynlighet 
risikoen for at hun skal få et atopisk barn (1,10).
Kostholdsintervensjonen
under graviditet blir derfor
•• Minst to måltider med feit fisk ukentlig 
(laks, ørret, sild, makrell, uer og kveite).
•• Inntak av 5 ml tran daglig 
•• Ingen spesielle kostrestriksjoner under 
graviditet 
Dagsbehovet av omega-3 dekkes av: 50g laks,
115g (høst)/30g (vår) makrell, 30g makrell i
tomat, 25g sild, 500g torsk, 330g reke. 
••
••
Litteratur kosthold
1. Forebyggende kostråd - notat til helsepersonell.
Utviklet av Statens ernæringsråd i samarbeid med
Statens næringsmiddeltilsyn og Norges Astma- og
Allergiforbund og Folkehelsa, 1997.
2. Hodge L, Salome CM, Peat JK et al. Consumption of
oily fish and childhood asthma risk. Med J Australia.
1996;164:137-40.
3. Kankaanpaa P, Nurmela K, Erkkila A et al.
Polyunsaturated fatty acids in maternal diet, breast milk,
and serum lipid fatty acids of infants in relation to atopy.
Allergy 2001;56:633-8.
4. Yu G, Bjorksten B. Serum levels of phospholipid
fatty acids in mothers and their babies in relation to
allergic disease. Eur.J.Pediatr. 1998;157:298-303.
5. Duchen K, Yu G, Bjorksten B. Atopic sensitization
during the first year of life in relation to long chain
polyunsaturated fatty acid levels in human milk.
Pediatr.Res. 1998;44:478-84.
6. Matorras R, Perteagudo L, Sanjurjo P, Ruiz
JI. Intake of long chain w3 polyunsaturated
fatty acids during pregnancy and the influen-
ce of levels in the mother on newborn
levels. Eur.J.Obstet.Gynecol.Reprod.Biol.
1999;83:179-84.
7. Helland IB, Saarem K, Saugstad OD,
Drevon CA. Fatty acid composition in
maternal milk and plasma during supple-
mentation with cod liver oil.
Eur.J.Clin.Nutr. 1998;52:839-45.
8. Jensen CL, Maude M, Anderson RE,
Heird WC. Effect of docosahexaenoic acid
supplementation of lactating women on the
fatty acid composition of breast milk lipids
and maternal and infant.
9. Sanders TA. Essential fatty acid requirements
of vegetarians in pregnancy, lactation, and infancy.
Am.J.Clin.Nutr. 1999;70:555S-9S.
10. Kramer MS Meternal antigen avoidance during
pregnancy for preventing atopic disease in infants of
women at high risk. The Cochrane Library, Issue 3 1999.
•• INNEKLIMA
ALLERGISTUDIEN I  TRONDHEIM
Målsetting
Målsettingen er å få alle gravide til å gjøre
enkle tiltak som bidrar til bedre luftskifte 
og færre innendørs fuktkilder.
Bakgrunnen for intervensjonen er faktarappor-
ten om forebygging av astma (1) som konklu-
derer med at det er sterke holdepunkter for at
personer som bor i boliger med fuktproblem
har økt risiko for å utvikle allergi. Det er holde-
punkter for at barn som vokser opp i boliger
med fuktproblem løper en vesentlig større 
risiko for å utvikle allergisk sykdom, uavhengig
av atopisk disposisjon. Dette er spesielt allergi
knyttet til eksponering for husstøvmidd, dyre-
allergener og sopp (3,4 og 5).
En finsk undersøkelse har vist at langt de fles-
te fuktproblemene i boliger kan utbedres ved
enkle grep, bl.a. bedre ventilasjon, eliminere
fuktkilder og mindre bygningstekniske utbe-
dringstiltak (2).
I følge faktarapporten om forebygging av
astma hos barn (1) kan primærforebyggende
tiltak særlig rettes mot familier der det er ato-
pisk disposisjon. Følgende anbefalinger gis i
faktarapporten:
•• det bør etterstrebes å holde lavt nivå av 
husstøvmidd, særlig i sengemadrasser.
•• det anbefales bedre ventilering av boligen.
•• spesielt luftes soverom gjennom vindu.
•• hvis det er identifisert fuktskader eller 
boligen generelt er fuktig bør skaden 
saneres.
Ekstra målsetting
I Barneallergistudien tas det sikte på å etablere
et tilbud til de som kan ha mer omfattende
fuktproblemer. Tilbudet vil bestå i inspeksjon
og målinger for å avdekke fuktproblem og få
profesjonelle råd om utbedringstiltak som er
kvalitetsikret av Byggforsk.
Ved bruk av spørreskjema skal det identifise-
res ca 450 boliger med høy sannsynlighet for 
å ha fuktproblem eller fuktskader. Følgende
kriterier benyttes for å identifisere boliger med
høy sannsynlighet for å ha fuktskade på bad
eller i kjeller:
Avkryssing i spørreskjema for minimum 
2 fuktproblem som ikke var utbedret (identi-
fiserte 25% av kjellerne som hadde fuktskade
eller 19% av kjellerne hvor det ble funnet
sopp fuktindikator).
Dårlig ventilerte bad, dvs bad med som mangler
spalte under dør og hvor døren til vanlig er
lukket. (Ca 16% av boligene hadde denne til-
standen og på samtlige av disse badene ble det
funnet fuktskade.)
3. Avkrysset for at soverom er i kjeller eller i
sokkel og med minimum en yttervegg under
terreng (anses å være en høy riskofaktor for
fuktskade).
Punkt 1 og 3 avdekkes ved bruk av spørreskje-
ma bolig-/innemiljø mens punkt 2 avdekkes
ved samtale med den gravide. 
Ved oppfyllelse av 1 eller 2 eller 3 skal det gis
tilbud om inspeksjon av byggeteknisk sakkyn-
dig for å undersøke om bad, kjeller eller sove-
rom har fuktskader som må utbedres samt gi
råd om utbedringstiltak. Hver fjerde av disse
boligene vil i tillegg få tilbud om målinger.
Litteratur inneklima
1. Faktarapport til handlingsplan. Faktarapport om 
forebygging av astma, allergi og inneklimasykdommer.
Sosial- og Helsedepartementet. (I-0933 B)
2. Nevalainen A. et. al. Prevalence of moisture 
problems in Finnish houses. Indoor air - International
Journal of Indoor Air Quality and Climate, 1998;
Suppl. 4:44-49.
3. Sporik R., Chapman MD., Platts-Mills TAE. House
dust mite exposure as a cause of asthma. Clin. Exp.
Allergy. 1992; 22:897-906
4. Peat JK., Tovey E., Toelle BG. et al. House dust mite
allergens; a major risk factor for childhood asthma in
Australia. Am J. Respir. Crit. care Med. 1996; 
153:141-146.
5. Custovic A., Smith A., Woocock A.. Indoor allergens
are a primary cause of asthma. Eur. Resp. Rev. 1998;
53:155-158.
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•• PROSEDYRE I  SVANGERSKAPET
Inklusjonen bør skje så tidlig
som mulig i svangerskapet
•• Ved første konsultasjon hos lege (oftest 
8.-12.uke) eller hvis første konsultasjon 
er hos jordmor, bør prosjektet presenteres 
for den gravide i form av informasjons-
brosjyren “Til deg som er gravid” og 
“Samtykkeerklæring”. Samtidig informeres 
kort om Barneallergistudien.
•• Etter at samtykke er underskrevet deles 
spørreskjema ut, og fylles helst ut med 
det samme.
•• Den første informasjonen/intervensjonen 
gis i forbindelse med konsultasjonen hos 
legen, gjerne med støtte i utfylt spørre-
skjema hvis det er gjort. 
Brosjyremateriale deles ut 
og det sørges for
1. Kostinformasjon; med veiledning i øket 
inntak av fisk/omega-3-fettsyrer, gis til alle.
2. Boliginformasjon: Veiledning i daglige 
rutiner for å redusere fukteksposisjon/
fuktskader. Ved mistanke om fuktskader, 
henvises den gravide til Trondheim 
kommunes klimatelefon: 72 54 70 58
3. Røykeinformasjon: Hvis den gravide eller 
partner røyker: Informer om det tilbudet 
de får i prosjektet og motiver til røyke-
slutt. Hvis den gravide er motivert startes 
intervensjonen straks, evt. med tilbud om 
umiddelbart røykeavvenningskurs. Alterna-
tivt forsøkes det å lage en avtale om å komme
tilbake til temaet ved neste kontroll.
Senere kontroller
•• Dersom spørreskjema ikke ble utfylt ved 
første svangerskapskontroll tar den gravide 
skjemaet med ved neste kontroll. 
Gå gjennom spørreskjemaet med den 
gravide og fortsett intervensjonen på 
bakgrunn av de opplysninger spørre-
skjemaet gir om kost, inneklima og røyking.
•• Inngåtte avtaler følges opp, og det samtales 
om de endringer som har skjedd.
•• Skjema for registrering av røykeadferd for 
røykerne fylles ut, og tilbud om røyke-
avvenning for de som ikke har sluttet 
følges opp.
I hele svangerskapet
Sørg for at intervensjonark alltid følger 
helsekortet.
Ved spørsmål om intervensjonstemaene:
Røykeavvenning: kontakt Byåsen helsestasjon.
Tlf:
Fax:
e-post:
Kosthold: kontakt Charlottenlund helsestasjon.
Tlf:
Fax:
e-post:
Inneklima: kontakt Rosten helsestasjon.
Tlf:
Fax:
e-post:
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P R E V E N T I O N  O F  A T O P Y  A M O N G  C H I L D R E N  I N  T R O N D H E I M .
Til deg som er
GRAVID
•• Besøk vår Internettside:  
www.pact.ntnu.no
•• Røykeavvenning
www.helsenett.no
www.tobakk.no
•• Kost
www.sef.no
www.dinkost.no
www.helsenytt.no/artikler/gravideskost.htm
•• Inneklima
www.inneklima.com
www.innemiljo.net
Hvordan kan du 
styrke 
ditt
barns 
forsvar 
mot 
allergisk 
sykdom?
•• KILDE  T IL  MER 
INFORMASJON
Det meste av det du puster inn, når frem til
fosteret gjennom morkaken. Det gjelder både
nyttige og skadelige stoffer. Kullosen fra siga-
rettrøyken fortrenger oksygenet fra de røde
blodlegemene og gjør at fosteret hele tiden
lider av litt surstoffmangel. Nikotinet i tobak-
ken gjør at blodårene trekker seg sammen så
barnet får dårligere blodtilførsel. Disse, og
mange andre stoffer i røyken, gjør at barnet
ditt blir dårligere rustet til å tåle påkjenninger.
Det er flere tilfeller av abort og dødfødsler
blant røykere, og barna blir ofte litt mindre 
og har trangere luftveier. De er generelt litt
svakere og har oftere umodne lunger.
Flere undersøkelser  tyder på at barn av 
røykere kan henge litt etter i vekst. Risikoen
for kreft ser også ut til å øke litt hos dem som
har vært utsatt for stoffer fra røyk som foster. 
Det er også større fare for krybbedød hvis 
du røyker gjennom hele svangerskapet.
Hvordan påvirker røyking fosteret?
Hva kan skje med fosteret?
Kan barnet skades på lengre sikt 
hvis jeg har røykt under graviditeten?
Det er aldri for sent å slutte. Dersom du kutter
ut røyken helt før 4. måned, er det vanskelig å
finne alvorlige skader hos barnet senere. 
Til og med om du slutter bare noen uker eller 
dager før fødselen, så hjelper du barnet.
Er det for sent å slutte når jeg 
allerede har vært gravid en stund?
Light-sigaretter er like skadelige som vanlige
sigaretter, både fordi du røyker flere sigaretter
og inhalerer kraftigere for å oppnå samme
virkning.
Er det bedre å røyke light-sigaretter?
UNDER 
SVANGERSKAPET  
PÅVIRKER 
BARNET
!•• RØYKING •• 
•• 
•• 
•• 
•• 
•• 
•• 
••
•• 
•• 
Er det ikke nok å redusere 
røykingen – må jeg slutte helt?
Det er bedre å røyke lite enn å røyke mye. 
Bestem deg for en dag du skal slutte helt!
Hvordan kan mannen min hjelpe
meg til å stumpe røyken?
Hvis han er ikke-røyker, så be ham om å støtte 
og hjelpe deg uten å kritisere. Hvis han selv 
er røyker, er det bra om dere slutter samtidig. 
Da kan dere oppmuntre hverandre, og det blir
lettere for deg å slutte. Passiv røyking er heller
ikke bra for deg under graviditeten, og ikke for
barnet etter at det er født.
Hvordan kan røyking 
påvirke amming?
Røykere har vanskeligere for  å få i gang 
melkeproduksjonen enn ikke-røykere. De 
må derfor sette seg oftere med barnet til 
brystet. Som røyker får du nemlig mindre 
av hormonet prolaktin som regulerer melke-
mengden. Helseskadelige stoffer i tobakk 
overføres via melken til barnet. Tobakk 
reduserer melkeproduksjonen. 
Kan jeg  begynne å røyke igjen
når jeg er ferdig både med 
graviditet og amming?
Alle barn plages av tobakksrøyk i rommet. 
De blir oftere forkjølet og får lettere ørebeten-
nelse, lungebetennelse, bronkitt og astma. Barn
og røyking hører ikke sammen. Tenk også på
gevinsten for deg selv: Du får bedre helse,
penere hud, mindre rynker og god luktesans.
Dertil sparer du mange penger som kan brukes
til noe hyggelig.
Hvordan kan jeg få hjelp til 
å slutte med røykingen?
Be om hjelp og oppfølging hos lege eller 
jordmor. Du og din ektefelle/samboer kan 
melde dere på kurs for røykeavvenning. 
Be om hjelp og oppfølging av helsesøster 
etter fødselen.
Sats på et røykfritt hjem! 
Røyk ute, om du absolutt må røyke.
Ønsker dere å være med på 
røykeavvenningskurs?
Ring: 72 55 96 75
Vi vet at inntak av omega-3 fettsyrer fore-
bygger astma hos eldre barn.Vi tror at 
barnets risiko for å utvikle astma reduseres
om du som mor passer på å innta omega-3
fettsyrer under svangerskapet. Gjennom
Barneallergistudien i Trondheim skal vi finne
ut mer om dette. 
•• SP IS  FE IT  F ISK  MINST
TO GANGER UKENTLIG
NÅR DU ER  GRAVID
Vi anbefaler at du spiser minst to måltid med
feit fisk ukentlig  (laks, ørret, sild, makrell,
uer og  kveite). Dagsbehovet av omega-3
dekkes av: 50g laks, 115g (høst)/30g (vår)
makrell, 30g makrell i tomat, 25g sild, 500g
torsk, 330g reke. 
Statens næringsmiddeltilsyn fraråder gravide
og ammende å spise visse ferskvannsfisk
(gjedde, abbor over 25cm, ørret over 1 kg 
og røye over 1 kg) ut fra at de kan inneholde
kvikksølv. Oppdrettsfisk og sjøørret kan trygt
spises.
Ja, spis variert kost. Følg i tillegg legenes råd
om  ekstra tilskudd av folinsyre (tabletter) fra
før svangerskapet til 3. måned i svanger-
skapet. Dette for å forebygge ryggmargs-
brokk hos barnet.
Nei. En streng diett uten allergifremkallende
mat (egg, fisk, erter, nøtter, skalldyr) under
svangerskapet reduserer ikke risikoen for at
barnet utvikler allergi. Kostrestriksjoner i
svangerskapet er heller ikke nødvendig selv
om du eller barnefaren har allergi eller dere
tidligere har fått barn med allergisk sykdom.
Kan jeg forebygge allergisk sykdom hos barnet ved
å innta omega-3 fettsyrer under svangerskapet?
Hvilken mat inneholder omega-3 fettsyrer?
Bør jeg unngå et ensidig kosthold når jeg er gravid?
Er det noen typer mat jeg bør unngå for 
å forhindre at barnet utvikler allergier?
!
•• 
•• 
••
•• 
•• Tunfisksalat
1 boks tunfisk i olje, Litt rødløk
1 stor tomat, 1 ts sitronsaft, salt & pepepr
Godt brød, philadelfiaost, tunfisksalat over, 
med fersk, basilikum på toppen. Mmmmm.
•• Makrell i tomat
Makrell i tomat med majones og agurk
•• Laks, råstekte poteter 
og tomatsalat
500 g urtemarienert laksefilet
Mandelpoteter i båter m/skall legges 
i langpanne smurt med olivenolje
provencekrydder-tørket, salt/pepper
Laksefileten  legges i i folie m/ salt 
& pepper, Legg dette sammen med 
potetene.
Bakes i steikovnen ved 200 C, 25 min
•• Salat:
En kurv cherry tomater - del  tomatene i to
1 avokado i biter; litt feta ost
•• Dressing:
1 ts fransk sennep, 1 ts sukker, litt balsamico
eddikk, litt olivenolje, salt & pepper
I tillegg anbefales 5 ml (en spiseskje) tran daglig under hele svangerskapet
Sats på to måltider med fet fisk per uke og regelmessig tran!
•• OPPSKRIF TER
Ønsker dere å være med på  
matlagningskurs?
Ring: 
Har du  pørsmål om inneklima?
Ring Trondheim kommunes 
inneklimatelefon: 72 54 70 58
•• EN BOLIG UTEN 
FUKTPROBLEM 
GIR  BARNET EN 
GOD START
! Hvordan kan jeg unngå middproblemer på soverom?
•• Unngå heldekkende tepper, og overlesse 
rommet med leker og kosedyr, slik  at det 
blir enklere å rengjøre rommet. 
•• Veggventilene bør være åpne hele tiden.
•• Luft madrassen ved å ta til siden dynen 
om morgenen.
•• Unngå at damp fra dusj, koking, kles-
tørking og liknende når soverommet.
•• Skifte og vask av laken, putevar og dyne
trekk minst hver andre uke.
•• Støvsug madrass, overmadrass, seng og 
sengebunn minst hver andre måned.
Hvordan kan jeg unngå 
muggsopproblem i boligen?
•• Stans all uønsket fukttilgang.
•• Fjern alt fuktskadet materiale.
•• Hold det tørt og rent.
Ha godt avtrekk i rom med fuktkilder, 
gjerne elektrisk vifte i ventil i yttervegg 
eller sjakt på våtrom. 
Når bør barnets soverom være ferdig oppusset? 
Alle arbeider bør være ferdig minimum 
tre uker før rommet tas i bruk av barnet.
Rommet bør i denne perioden ha normal
”stuetemperatur” eller helst litt varmere slik
at avgassing fra maling og nye materialer 
kan skje raskere. Ny madrass bør også ligge
utpakket minst en uke før den tas i bruk av
barnet.
Hva betyr fuktproblem i
boligen for helsa?
Råte-, muggdannelse og lukt i huset kan opp-
stå når fukt trenger gjennom bygningsdeler
utenfra eller innenfra, eller når fukt fra byg-
gefasen ikke har fått tid til å tørke ut før kon-
struksjonen lukkes.
En bolig uten fuktproblem forebygger plager
som, hyppige forkjølelser, allergiske plager og
astma for deg og barnet.
Hvordan er boligkonstruksjonen
beskyttet mot fukt?
Over terrenget brukes plastfolie som fukt-
sikring i trekonstruksjoner på innsiden av
isolasjonen. Under terrenget skal det ikke
benyttes plastfolie fordi veggen skal ha
mulighet til å tørke ut innover. Utvendig 
tetning av vegger er som oftest luftet kled-
ning og en vindsperre. 
Hvor er boligen mest utsatt 
for fuktskader?
På bad i dusjhjørner og ved badekar hvor det
dusjes og det blir søl av vann på vegg og
gulv. Vannsøl direkte på flis er risikobetont.
Vann trenger inn i sprekker i flisfuger og inn
bak flisen. Ved feil på membran eller hvis
membran mangler helt, trenger vannet inn i
vegg eller gulv og det blir fuktskader.
I kjeller ved f.eks. svikt i drenering. Rundt
vindu og yttertak dersom det er utettheter
Hva kan skje dersom boligen 
har dårlig isolerte yttervegger? 
Det kan bli kondens på innvendige flater vin-
terstid pga. høy luftfuktighet og kalde inn-
vendige flater. Dette gjelder spesielt bak
gjenstander med stor flate eller skap plassert
mot yttervegg.
Hva kan jeg gjøre for 
å  unngå fuktskader? 
•• Se til at takrenner, nedløpsrør etc. ikke 
tettes av løv og mose.
•• Inspiser kryperom, kaldt loft og kjeller 
for synlige fuktskader og yttertak for 
synlige utettheter vår og høst.
•• Rens baderomssluk for hår og sand 
minst en gang pr. år.
•• Undersøk årsak til synlig muggvekst på 
innvendige flater og utbedre raskest 
mulig.
•• 
Høye konsentrasjoner av husstøvmidd og
muggsopp øker risikoen for at barn og 
voksne kan få allergiproblemer. 
Avføring fra midd og sporer fra muggsopp
innholder nemlig stoffer som kan framkalle
allergi. 
Midd trives i senger og teppegulv. Den lever
av flass fra huden.  Midd legger egg i
madrassen og på sengebunnen.
Muggsopp trives i boligen på steder med 
steder med kondens og fuktkilder. Den lever
av og på bygningsmaterialer og lager sporer
som spres i innelufta.
Hva er det ved innemiljøet som kan gi allergisk sykdom?
•• 
Hvordan bør jeg bruke boligen?
•• Hold lufttemperaturen i oppholdsrom på 20-22°C om vinteren.
•• Luft godt ved å åpne dører og vinduer i 3-5 minutter flere ganger daglig.
•• Slipp frisk uteluft inn gjennom ventilene i ytterveggene.
•• La den brukte, dårlige lufta få slippe ut gjennom ventiler i tak på bad, WC og andre våtrom.
•• 
•• 
•• 
•• 
•• 
•• 
 
 
 
Appendix 10 
 
Information brochure and advice to parents regarding the intervention topics 
in Norwegian 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Til
FORELDRE
Hvordan kan du styrke
ditt barns forsvar 
mot allergisk sykdom?
B A R N E A L L E R G I S T U D I E N  I  T R O N D H E I M
P R E V E N T I O N  O F  A T O P Y  A M O N G  C H I L D R E N  I N  T R O N D H E I M
RØYKING, KOSTHOLD OG INNEKLIMA
•• Besøk vår Internettside:  
www.pact.ntnu.no
•• Røykeavvenning
www.tobakk.no
www.helsenett.no
•• Kost
www.sef.no
www.dinkost.no
www.helsenytt.no/artikler/barneskost.htm
www.snt.no
•• Inneklima
www.inneklima.com
www.innemiljo.net
www.be.no/beweb/info/hh/hhinfo.html
•• KILDE  T IL  MER 
INFORMASJON
R
os
en
bo
rg
 G
ra
fis
k 
Ko
m
m
u
n
ik
as
jon
 A
S 
- R
21
38
6
Røyking under amming
Nå kan det vel ikke være så farlig om jeg 
begynner å røyke igjen, nå som barnet er født?
Prøv for all del å ikke begynne igjen. Røyking mens du ammer har lett 
for å gi dårligere melk og mindre melkemengde.
Hvorfor blir det mindre melk når jeg røyker?
En av grunnene kan være at røykere ofte produsere litt mindre av det hormonet som 
styrer melkemengden, prolaktin. Andre virkninger røyken har på din egen kropp er nok 
heller ikke bra for melkemengden. I tillegg ser det ut til at en del røykere bruker noe 
mindre tid på å amme pr. døgn, slik at brystene ikke blir godt nok stimulert.
Hvorfor blir melken dårligere hvis jeg røyker?
Mange av de rundt 4000 stoffene fra sigarettene, f.eks. kullos, blåsyre og tjære,
passerer over i melken. Nikotin er det som er best undersøkt. Nikotinet går spesielt 
lett over i melken, slik at konsentrasjonen i morens melk er høyere enn i blodet hennes.
Hvordan virker det på barnet mitt?
Barn av røykende kvinner som ammer har lettere for å få kolikk. De skriker gjerne mer,
er uroligere og legger ofte ikke på seg så mye som barna til kvinner som ikke røyker.
Da er det vel best at jeg ikke 
ammer barnet mitt siden jeg røyker?
Nei, ut fra det vi vet i dag mener ekspertene at morsmelken er så verdifull for 
barnet ditt at du bør fortsette å amme selv om du ikke klarer helt å slutte.
Jeg har nesten klart å kutte ut røyken. Når er det minst 
skadelig for barnet at jeg røyker?
Nikotinkonsentrasjonen er på topp i melken like etter at du har røykt. Derfor bør du 
først amme, så ta en røyk - eller helst bare en halv - hvis du ikke kan unnvære den,
og så ikke røyke noe mer før etter neste gang du har ammet.
Kan jeg bruke nikotintyggegummi når jeg ammer?
Du får jo nikotin i melken da også, derfor anbefales det vanligvis ikke til 
kvinner som ammer. Det er likevel bedre enn å røyke, fordi du unngår alle 
de andre stoffene som er i sigarettrøyk.
Det som raskt blir merkbart er at du unngår
vond lukt fra munnen og generelt blir friskere
og sunnere. Du får også mindre rynkete hud
som ikke-røyker. Det viktigste er likevel at
du reduserer risikoen både for akutte og
kroniske sykdommer som skyldes røyking.
Du får ikke så lett luftveisinfeksjoner som
forkjølelse, bihulebetennelse, bronkitt og
lungebetennelse, og forebygger KOLS
(Kronisk lungesykdom). På litt lengre sikt
reduserer du risikoen for hjerteinfarkt og slag,
samt flere farlige kreftformer. Og du sparer
store summer på å slutte å røyke: Dersom f.eks.
et par røyker 20 sigaretter hver om dagen
med litt ekstra i helgene, betyr røykeslutt
over 100 000 kroner spart i løpet av 3 år. 
Er det noen fordeler for meg selv ved å slutte å røyke?
Barn og passiv røyking 
Kilde: Overlege Dr. med. Gro Nylander, Rikshospitalet
Å røyke passivt vil si at man puster inn luft
som er forurenset av tobakksrøyk. Ved passiv
røyking utsettes man for de samme stoffene
som ved aktiv røyking, og kan få i seg like 
mye av de helseskadelige stoffene som om
man hadde røykt flere sigaretter selv. 
Passiv røyking er spesielt skadelig for små
barn. Tobakksrøyk gjør at lungene fungerer
dårligere, og at slimhinnene i luftveiene blir
mer mottakelige for infeksjoner. Barn som
vokser opp i et røykfylt innemiljø, får derfor
mer luftveisinfeksjoner som bronkitt og lunge-
betennelse, og gjentatte ørebetennelser. 
Langvarig passiv røyking øker i tillegg
risikoen for kroniske luftveissymptomer.
Barn som kommer fra hjem hvor foreldrene
røyker, har økt forekomst av astma. I tillegg 
vil passiv røyking øke hyppigheten og
alvorlighetsgraden av astmaanfall hos barn
som allerede har sykdommen.
PÅVIRKER 
BARNET !•• RØYKING
Sats på et røykfritt hjem! 
•• 
•• 
••
••
•• 
••
•• 
•• 
Ønsker dere å være 
med på røykesluttkurs?
Byåsen helsestasjon
Ring: 72 54 54 30 
!•• SPIS FEIT FISK MINST TO GANGER UKENTLIG
OG TA TRAN DAGLIG 
•• 
•• 
••
•• 
Eksempel på middagsmat (1dl)
1 potet, ca 30g grønnsaker (f.eks. 1/2 gulrot), vann til å koke i,
20–30g fet fisk (f.eks. laks), 1/2–3/4 dl kraft, kokavann eller mors-
melk til å mose maten i (eventuelt olje eller myk plantemargarin)
Tips:
• La poteter og grønnsaker koke til de er myke. 
• Fisken må være gjennomkokt.
• Bruk lite kokevann til potet/grønnsaker og bruk det til å mose maten i.
• Bruk rivjern på frossen laks. Dampkok laksen i folie,
bland den deretter med kokt, finmoset potet og grønnsaker.
• Middagsmaten kan mangedobles og fryses i posjoner.
Eksempel på pålegg
• Makrell i tomat og kaviarmix
Kan allergisk sykdom hos barnet forebygges ved at mor 
under ammeperioden inntar omega-3 fettsyrer?
Vi vet at mors inntak av omega-3 fettsyrer påvirker innholdet i morsmelk,
og at omega-3 fettsyrer forebygger astma hos barn. Dette skal vi undersøke i studien.
Går omega-3 fettsyrer over i morsmelken?
Mors inntak av omega-3 fettsyrer påvirker innholdet i morsmelk. Mor anbefales under
amming å ta 5ml tran daglig og spise fet fisk minst to ganger ukentlig som middagsmat
eller pålegg.
Hvilke matvarer inneholder omega-3 fettsyrer? 
De viktigste kildene til omega-fettsyrer er fet fisk og tran. Dagsbehovet for omega-3 fett-
syrer dekkes av: 25 g sild, 30g makrell i tomat, 50g laks, 200 g kveite. Oppdrettsfisk og 
sjøørret kan trygt spises. Ammende frarådes å spise visse ferskvannsfisk (gjedde, abbor 
over 25 cm, ørret og røye over 1 kg) ut fra at de kan inneholde kvikksølv. 
Når kan barnet gis tran og fet fisk?
Når barnet er fire uker kan det gis tran daglig. Start med noen dråper og øk til 5 ml - bruk
målebeger. Når barnet er 6 måneder gis det middagsmat eller pålegg to ganger ukentlig i 
tillegg til tran. Start med små porsjoner og øk gradvis.
Ønsker dere å være med 
på matlagningskurs?
Charlottenlund 
helsestasjon
Ring: 72 54 89 70
!••  EN BOLIG UTEN FUKTPROBLEM GIR BARNET EN 
GOD START
• Når du kommer inn i boligen oppleves
lufta innestengt?
Åpne veggventiler og takventiler. 
Sjekk at avtrekksvifter virker.
• Fjerner kjøkkenavtrekket matosen?
Vask filterrist, sjekk om spjeld stenger 
for avtrekket.
• Er det fortsatt mye dugg på vindu på 
bad 4 timer etter dusjing eller på 
soverom om morgenen?
Sjekk at ventilene er åpne. Lufting kan 
også bedres ved å åpne dører og vindu.
• Er det sprekker i flisfuger i dusjen?
Kan tyde på bevegelse pga fukt i vegg,
bør undersøkes nærmere.
• Renses sluk på våtrom 2 ganger 
i året?
Tett sluk kan gi vannskade i gulv.
• Er det tegn til muggsopp eller 
kondens på kalde ytterveggsflater
bak tunge møbler eller skap?
Tyder på dårlig isolert yttervegg, bør 
utredes. Unngå å plassere store 
gjenstander mot yttervegg.
• Kommer det fukt inn ved gulv/ytter
vegg i kjeller eller sokkel?
Tyder på mangelfull drenering,
bør utredes.
• Renses takrenner og nedløp både vår 
og høst?
Oppdemming eller gjentetting kan gi 
vannskader.
Egenkontroll av fuktproblem og ventilasjon i egen bolig?
Hvordan bør jeg bruke boligen
• Hold lufttemperaturen på 20-22°C om vinteren.
• Luft godt ved å åpne dører og vinduer 3-5 minutter flere ganger  daglig.
• Slipp frisk uteluft inn gjennom ventilene i ytterveggene.
• La den brukte, dårlige lufta få slippe ut gjennom ventiler i tak på bad. La bade-
romsdøren stå litt på gløtt etter dusjing for å få raskere utluftingen av badet.
Hvordan er det for barnet å bo i bolig med fuktproblem
Å bo i bolig med fuktproblem er forbundet med økt risiko for å få gjentatte luftveisplager
og astma. Hvis det er identifisert fuktskader eller boligen generelt er fuktig bør skaden
saneres og ventilasjonen bedres. med enkle grep er det mulig å forebygge fuktproblem.
• Hold lufttemperaturen på 15–18°C om vinteren.
• Hold det ryddig, ikke overless rommet med tekstiler,
kosedyr og leker. Dette letter også rengjøring av rommet.
• Barnets soverom bør ikke tas i bruk før minimum tre uker 
etter at malearbeidene var ferdig. Rommet bør ha minimum
stuetemperatur og luftes godt i disse 3 ukene.
• Ny madrass bør ligge utpakket en uke før den tas i bruk.
•• 
•• 
••
Har du  pørsmål om inneklima? Ring Trondheim
kommunes inneklimatelefon: 72 54 70 58
Høye konsentrasjoner av husstøvmidd og
muggsopp øker risikoen for at barn og 
voksne kan få allergisk sykdom. Avføring 
fra midd og sporer fra muggsopp innholder
stoffer som kan framkalle allergi. 
Midd og muggsopp er avhengig av fukt for 
å trives.
Midd trives i senger og teppegulv. Den
lever av flass fra huden. Midd legger egg 
i madrassen og på sengebunnen.
Muggsopp lager et trådlignende nettverk 
i og på bygningsmaterialer. Den danner 
sporer som spres i innelufta.
Hva er det ved innemiljøet som kan gi allergisk sykdom?
Barnets soverom
•• •• Hvordan kan jeg forebygge 
middproblem på soverom?
•• Unngå heldekkende tepper. 
•• Luft gjennom vinduet, ytterveggsventil 
og la soveromsdøren stå på gløtt.
•• Luft madrassen ved å ta til siden dynen 
hver morgenen.
•• Unngå at damp fra dusj, koking og 
klestørking når soverommet.
•• Skift og vask laken, putevar og dyne-
trekk minst hver andre uke.
•• Støvsug madrass, overmadrass, seng og 
sengebunn grunding minst hver andre 
måned, noe oftere sommer og høst.
Bruk sentralstøvsuger eller støvsuger 
med hepafilter.
Hvordan kan jeg forebygge 
muggsopproblem i boligen?
•• Hold det tørt og rent.
•• Oppstår uønsket fukttilgang, finn årsak 
og gjør utbedringstiltak snarest mulig.
•• Har boligen vært utsatt for fuktskade,
fjern alle fuktskadede, porøse materialer 
snarest mulig. 
•• Ha godt avtrekk i rom med fuktkilder,
gjerne elektrisk avtrekksvifte.
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